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(I) ABSTRACT IN ENGLISH 
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that affects 
15% of children worldwide. Pathophysiologically, skin lesions from these patients 
are characterized by infiltration of various inflammatory leukocytes and defective 
immune responses to microbial pathogens. Corticosteroids are the conventional 
method to control these immune dysregulations. Topical emollients and 
corticosteroids are the mainstay of treatments for these patients. However, none of 
the current therapeutic modalities are considered curative for this allergic disease. 
Due to an escalating prevalence and absence of definite cure for the disease, there 
has been an increasing interest in developing traditional Chinese herbal medicine 
(TCHM) as a treatment option for AD 
The present study aimed (1) to elucidate the clinical efficacy and tolerability 
of a newly concocted TCHM formula, the PentaHerbs formula (PHF), comprising 
Flos lonicerae (Jinyinhua), Herba menthae (Bohe), Cortex moutan (Danpi), Rhizoma 
atractylodis (Cangzhu) and Cortex phellodendri (Huangbaig) in children with AD; 
and (2) to evaluate whether the PHF possesses immunomodulatory activities in vitro. 
The PHF capsules were manufactured from the above ingredients according to the 
internationally-accepted Good Manufacturing Practice standards. 
i 
In our randomized, double-blind, placebo-controlled clinical trial, 86 children 
with moderate-to-severe AD were recruited from attendants of paediatric 
dermatology clinic in our Hospital. After a 2-week run-in period, patients either 
received 3 capsules of PHF or placebo twice daily for 12 weeks. The main outcomes 
of this study include: (1) AD severity as assessed by SCORing Atopic Dermatitis 
(SCORAD) index, (2) quality of life (QoL) by the validated and standardized CDLQI 
questionnaire, (3) the amount and frequency of using topical corticosteroid and 
antihistamine as recorded by patients and their parents using a medication diary. The 
profile of adverse effects was documented and hematological and biochemical 
parameters were monitored. 
The results showed that: (1) QoL in treatment group was significantly 
improved comparing with placebo group and also with the baseline value following 
the 12-week treatment, (2) total amount and frequency (days per month) of topical 
corticosteroid used in treatment group was significantly reduced as compared to that 
at baseline. It was not observed in placebo group. No significant difference obtained 
in SCORAD index and other outcomes measured between the two study groups. 
None of our subjects developed significant adverse event either clinically or on 
laboratory testing. 
For our in vitro study, TCHM was extracted from PHF by the hotwater 
extraction method. The degree of contamination of these PHF capsules by 
environmental endotoxin was quantified by the Limulus amebocyte lysate test. In 
order to delineate the immunomodulatory properties of PHF, we examined its (1) 
mitogenic activities on phytohemagglutinin (PHA)- and staphylococcal enterotoxin 
B (SEB)-activated peripheral blood mononuclear cells (PBMC) using radioactive 
tritiated-labelled thymidine uptake assay, (2) cytotoxicity on activated PBMC using 
ii 
the trypan blue exclusion assay, (3) effects on the expressions of inflammatory 
mediators including brain-derived neurotrophic factor (BDNF), epithelial neutrophil 
activating peptide (ENA-78), thymus and activation-regulated chemokine (TARC), 
tumor necrosis factor-alpha (TNF-a) and interferon-gamma (IFN-y) in PHA- and 
SEB-activated PBMC using enzyme-linked immunosorbent assay (ELISA) and 
reverse transcriptase-polymerase chain reaction (RT-PCR). 
As found in this study, the optimal concentrations of PHF for use in in vitro 
experiments were 10 |ig/ml and 100 |ig/ml, in which the above concentrations retains 
PBMC viability >80%. Endotoxin contamination was significant. Our results 
demonstrated that the PHF (1) exhibited in dose-dependent manner (1 fig/ml — 1000 
|ig/ml) significant inhibitions of the proliferation of PHA- and SEB-activated PBMC, 
(2) possessed dose-dependently significant cytotoxic effects on activated PBMC, (3) 
suppressed release of BDNF, IFN-y and TNF-a from PHA-stimulated PBMC; 
reduced secretion of BDNF and TARC, in response to SEB. At RNA level, PHF 
suppressed expression of TARC, IFN-y and TNF-a, in response to SEB stimulation. 
In contrast, PHF stimulated secretion of ENA-78 from PBMC, in response to PHA 
and SEB stimulation. 
In summary, PHF that we newly concocted possesses corticosteroid-sparing 
effect on our randomized controlled clinical trial. It is also efficacious in improving 
QoL in children with moderate-to-severe AD. Ingredients extracted from PHF are 
able to inhibit the proliferative activities, production of AD-related inflammatory 
mediators including BDNF, TARC, IFN-y and TNF-a and enhance the release of 
neutrophil-related ENA-78. These in vitro immunomodulatory properties may account 
for the clinical benefits in AD patients. 
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Section 1： GENERAL INTRODUCTION 
CHAPTER 1 
General Introduction of Atopic Dermatitis 
1.1. Definition of Atopic Dermatitis 
Atopic dermatitis (AD) (or atopic eczema) is a chronic, frequently relapsing, 
highly pruritic, inflammatory skin disease, which commonly presented in early stage 
of childhood. Two types of AD have been identified: (i) Extrinsic form, which 
affects 70-80% of patients, involves IgE-mediated sensitization towards 
environmental allergens; and (ii) Intrinsic, non-atopic form, which affects 20-30% of 
patients, does not involve allergen-sensitization and accompanies by low serum IgE 
level (Novak et al, 2003). Eosinophilia maybe presented in both forms of AD. 
According to the Nomenclature Task Force of the European Academy of 
Allergology and Clinical Immunology (EAACI) and World Allergy Organization 
(WAO), atopy is defined as "a personal and/ or familial tendency, usually in 
childhood or adolescence, to become sensitized and produce immunoglobin E (IgE) 
antibodies in response to ordinary exposure to allergens, usually proteins. As a 
consequence, such individuals can develop typical symptoms of asthma, 
rhinoconjunctivitis, or eczema". Dermatitis is defined as “a local inflammation of 
skin" (Johansson et at, 2001; Johansson et at, 2004). However, there is no 
universal agreement about the definition of AD until now. Some prefer to define its 
atopic nature using IgE-specific antibodies and peripheral eosinophilia, which will 
develop in response to allergen exposure (Bos, 2002; Boguniewicz and Leung, 2006); 
1 
while others suggest that AD should define a clinical state with specific distinctive 
criteria and features (Hanifin and Rajka, 1980; Williams et al, 1994), since 
IgE-associated mechanism is not a prerequisite in all AD patients. Hanifin and Rajka 
diagnostic criteria for AD are adopted in our study (Table 1.1). 
Table 1.1 Hanifin and Rajka Diagnostic Criteria for AD 
Major criteria: Must have three or more of: 
1. Pruritus 
2. Typical morphology and distribution 
• Flexural lichenification or linearity in adults 
• Facial and extensor involvement in infants and children 
3. Chronic or chronically-relapsing dermatitis 
4. Personal or family history of atopy (asthma, allergic rhinitis, atopic 
dermatitis) 
Minor criteria: Should have three or more of: 
1. Xerosis 
2. Ichthyosis, palmar hyperlinearity, or keratosis pilaris 
3. Immediate (type 1) skin-test reactivity 
4. Raised serum IgE 
5. Early age of onset 
6. Tendency toward cutaneous infections (especially staphylococcal 
aureus and herpes simplex) or impaired cell-mediated immunity 
7. Tendency toward non-specific hand or foot dermatitis 
8. Nipple eczema 
9. Cheilitis 
10. Recurrent conjunctivitis 
11. Dennie-Morgan infraorbital fold 
12. Keratoconus 
13. Anterior subcapsular cataracts 
14. Orbital darkening 
15. Facial pallor or facial erythema 
16. Pityriasis alba 
17. Anterior neck folds 
18. Itch when sweating 
19. Intolerance to wool and lipid solvents 
20. Perifollicular accentuation 
21. Food intolerance 
22. Course influenced by environmental or emotional factors 
23. White dermographism or delayed blanch 
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1.2. Epidemiology and Classification 
With lifetime prevalence of 10-20% in children and 1-3% in adults 
worldwide (Schultz-Larsesn and Hanifin, 2002), AD is one of the most common 
inflammatory skin disorders presenting in early infancy or childhood. However, the 
disease may persist or start in adulthood (Johansson and Bieber, 2002). 
The occurrence of AD has increased over the past three decades in 
industrialized and developed countries, but remains low in developing countries such 
as China and Eastern Europe (Leung et al，2004a). In western countries, AD affects 
2-3% of children before 1960 and it increases to 9-12% in those born after 1970 
(Larsen and Hanifin JM, 1992). The rapid increase of AD incidences and wide 
variations of prevalence observed in groups with similar genetic backgrounds within 
countries, suggest that other than susceptibility genes, phenotype of AD is also 
determined by environmental factors. 
In Hong Kong, prevalence of AD in schoolchildren is approximately 15-20% 
(Leung and Ho, 1994; Leung et al, 1997). This figure is similar to results collected in 
other developed countries: UK, Birmingham (19-5% among 3-11 year olds) (Kay et 
al, 1994), Denmark (22.9% among 7-year-old children) (Larsen et al, 1996), and 
Japan (19% among 7-9-year-old children) (Sugiura et al, 1998). It has been 
suggested that higher prevalence of AD is recorded in children with better parental 
education (Galassi et al, 2006)，in higher social class groups (Williams et al, 1994), 
and living in urban regions comparing with that in rural regions of developed 
countries (Taylor et al, 1984). The westernized lifestyle, high standard of living, and 
education may account for the high prevalence of AD in Hong Kong. 
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Several longitudinal studies suggest that AD patients are predisposed to the 
development of allergic rhinitis and asthma and together these three allergic 
disorders are habitually being recognized as “atopic triads", often with AD 
initializing the atopic march (Boguniewicz et al, 2003; Spergel, 2005). 
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1.3. Factors Provoking Flares of AD 
1.3.1. Genetics 
AD has a high familial occurrence, with a 2-fold increment in risk for a child 
to develop AD if one of the parents has AD; with a 3-fold increment if both parents 
are affected. In addition, the concordance of AD in monozygotic twins is 75-85%, 
but only 30% in dizygotic twins. Together with the observation of early age of onset, 
it is suggested that AD is a genetically complex disease (Novak et al, 2003). Various 
candidate genes have been identified by the studies of candidate genes or linkage 
gene analysis studies, including gene cluster lying in chromosome region lq21 
(Sugiura et al, 2005); locus 3q21 encoded for co-stimulating molecules CD80 and 
CD86 (Cookson, 1998); locus 5q31-33 encoded for interleukin (IL)-13 has been 
identified in linkage and association analysis studies (Tsunemi et al, 2002); gene 
locus 1 lq l3 encoding for the P-chain of the high-affinity receptor for IgE has also 
been linked to the AD phenotype (Cookson et al, 1992). Recent studies illustrated 
that AD, psoriasis, and asthma share loci on chromosome 17q25 (Cookson et al, 
2001; Ekelund et al, 2006). Various candidate genes from different regions of 
chromosomes have been identified, however, the significance and exact role of 
candidate genes in the pathogenesis of AD are still under investigation. 
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1.3.2. Allergens-Food Allergens, Aeroallergens and Autoallergens 
Exacerbation of AD by foods has been repeatedly reported. Food allergens 
induce skin rash in almost 40% of children with moderate-to-severe AD (Sampson, 
1999). Typically, children with food allergies have positive immediate skin tests or 
elevation of IgE levels towards specific foods, in most cases, egg, wheat, milk, soy, 
or peanut (Burks, 2003). However, due to difference in dietary practices and 
preferences of patients from countries to countries, a wide range of food allergen 
potency is shown among different races of paediatric patients (Hon et al, 2006e; Hon 
et al, 2007). 
Several studies have demonstrated the relevance of aeroallergens that elicit or 
worsen eczematous skin lesions and contribute to the flare-ups of AD in a subgroup 
of patients. Aeroallergen such as house dust mites (HDMs), weeds, pollens, animal 
dander and moulds, can lead to pruritus or skin exacerbation in patients. In a recent 
study, over 50% of adult AD patients showed positive eczematoid reactions to at 
least one test allergen in atopy patch test (APT) (Samochocki et al，2006). The 
degree of IgE sensitization towards aeroallergens is directly linked with the severity 
of AD in schoolchild (Schafer et al, 1999; Hon et al, 2007). 
IgE autoreactivity against human endogenous antigens is reported in patients 
with severe AD. Autoallergens seem to act as adjuvant to the immunologic 
mechanisms, especially in extrinsic form of AD; presence of autoantigens in 
IgE-immune complexes of AD sera was detected (Valenta et al, 1996). These 
findings suggest that immune response primarily initiated by environmental allergens 
can be maintained by autoallergens released from damaged tissue in chronic stage of 
AD. 
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1.3.3. Microbial Colonization: Staphylococcus Aureus (S. aureus) 
It is reported that S. aureus are presence in 90% of atopic dermatitis skin 
lesions, whereas in control or nonatopic population, only 5-30% are colonized 
(Leyden et al, 1974). Futhermore, other bacteria rarely colonized on the skin of AD 
patients (Hon et al, 2005a). Disease severity scoring of atopic dermatitis correlated 
with the density of S. aureus colonization fGuzik et al, 2005). A combination of 
treatment with both antibiotics and corticosteroids is more effective than 
corticosteroid (CS) therapy alone (Leyden and Kligman, 1977), suggesting the 
importance of such a bacterial infection. Innate immunity defects in skin from AD 
patients predispose them to S. aureus colonization, thus, S. aureus can act a 
persistence allergen stimulating IgE production, or as an irritant with inflammatory 
potency in chronic AD. Reasons of high susceptibility of S. aureus colonization in 
AD patients include: 
• Persistent scratching habit causes disturbed skin barrier and exposure of 
extracellular matrix adhesins (e.g. fibronectin, collagens, fibrinogens, elastin, or 
laminin) which favor binding of S. aureus (Leung, 2003); 
• S. aureus binds more readily to skin lesion undergoing 丁-helper 2 (丁h2) 
immune response which is dominated in acute AD lesions. Respective cytokine 
milieu in Th2 immune response leads to enhanced production of adhesion 
molecules and downregulation of antomicrobial peptides against bacterial 
growth. This specific condition helps S. aureus binding (Gallo et al, 2002; Ong 
et al, 2003); 
• Deficiency in production of antimicrobial peptides (AMPs) (e.g. human 
p-defensin-2: HBD-2; human p-defensin-3: HBD-3; cathelicidin: LL-37) 
7 
against bacteria, fungi, and virus, causes inadequate of host defense (McGirt 
and Beck, 2006). 
S. aureus is important to the pathogenesis of AD. The bacteria produce 
superantigens (SAgs) to stimulate T-cell and macrophage to become activated 
(Bunikowski et al, 2000; Hon et al, 2005a). In addition, superantigens from S. aureus 
cause non-responsive to drug treatment in AD patients. In vitro study showed SAgs 
could negate the effect of CS or cause CS resistance (Li et al, 2004), and decrease 
peripheral blood mononuclear cells (PBMC) sensitivity towards FK506 (Fukushima 
et al, 2006), in which these two drugs are the mainstay of anti-inflammatory therapy 
in AD. 
Other environmental factors including stress, damp and heat are suggested to 
associate with disease flare (Langan et al, 2006). To summarize, the clinical 
phenotype of AD involves a complex and intricate interaction between susceptibility 
genes, host's environment, pharmacological abnormalities, skin barrier defects, and 
immunological factors (Leung and Bieber, 2003) 
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CHAPTER 2 
Measurements of AD Severity and Quality of Life Impairment 
2.1. Scoring of Atopic Dermatitis severity and the SCORing Atopic 
Dermatitis (SCORAD) Index 
Despite the current ambiguities in understanding of AD, clinicians and 
researchers are seeking for the most valid, reliable, and relevant outcome measures to 
ensure the effectiveness of healthcare interventions (Charman et al, 2003). 
Due to the fact that AD is a syndrome of related clinical features arising in 
response to a number of endogenous and exogenous factors, there is not a sole 
definite marker to reflect definite severity of eczema. Therefore measurements are 
mainly based on a collection of clinical signs and symptoms (Finlay, 1996). A review 
of 93 randomized controlled AD-related clinical trials revealed that scoring of 
clinical signs was the most widely adapted outcome measure (in 91% of trials) 
(Charman et al, 2003). According to the review, the most widely used clinical 
scoring system was the SCORAD index (1993) (Figure 1.1), a score basing on a set 
of 24 major and minor clinical diagnostic criteria of AD proposed by Hanifin and 
Rajka (Hanifin and Rajka, 1980) (Table 1.). In SCORAD, 60% of the total score was 
based on clinical signs and 20% is based on disease extent, with only 20% weighting 
for patient reporting subjective symptoms of pruritus and sleep loss (Kunz et al, 1997; 
Gelmetti and Colonna, 2004). 
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2.2. Quality of life Measurement 
While a lot has been discussed on scoring of AD, quality of life (QoL) has 
always been neglected, with only 3% of reviewed clinical trials had proper 
measurements (Charman et al, 2003). The impact of life quality impairment of AD is 
a very important manifestation as it has both a high rate of prevalence and is often 
more severe and long-lasting than any other childhood skin disorders (Finlay and 
Burgdorf, 2004). It can cause severe psychological problems and can be 
overwhelming not only to the patients, but the entire family (Barnetson and Rogers, 
2002). Moreover, SCORAD has its own shortcomings. Although SCORAD is one 
the best-validated systems and is suited for clinical trials, it is too complicated and 
time consuming for routine clinical use (Gelmetti and Colonna, 2004). In patients' 
point of view, an objective clinical scoring system, like SCORAD, is also not 
necessary to provide a clinically all-rounded meaningful reflection of disease 
severity, with SCORAD focusing QoL impairment on pruritus and sleep loss only 
(Charman et al, 2005). Therefore patient-based symptom measures and QoL scoring 
systems have also been emphasized over the past decade for providence of additional 
information (Lindstrom and Kohler, 1991; Holm et al, 2006). 
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2.3. The Children�Dermatology Life Quality Index 
Among all, the Children's Dermatology Life Quality Index (CDLQI) is one of 
the most standardized and objective QoL measures (Lewis-Jones and Finlay, 1995) 
(Figure 1.2). It consists of 10 questions, designing for use in children ages 5-16 years. 
It is self-explanatory and can be filled in by the child with minimal help from the 
parent or caretaker. Questions in the index cover over the areas of symptoms and 
feelings, daily activities, leisure, impact during school or on holiday, personal 
relationships, and sleep and treatment compliance. The CDLQI has been validated and 
translated into Cantonese to suit local clinical and community epidemiology usage in 
Hong Kong (Chuh, 2003). 
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Figure 1.1 The SCORAD diagnosis worksheet for accessing AD severity for 
(a) children below 2 years; (b) children above 2 years (1993) 
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C H I L D R E N ' S D E R M A T O L O G Y LIFE Q U A L I T Y INDEX 
Hospital No 
Name: Diagnosis: CDLQI 
Age: SCORE: 
Address: Date: 
The aim of this questionnaire is to measure how much your skin problem has 
affected you O V E R T H E L A S T W E E K . Please tick 4 one box for each question. 
1. Over the last week, how i tchy, " s c r a t c h y " . Very much 口 
sore or p a i n f u l has your skin been' ' Quite a lot P 
Only a little 口 
Not at all 口 
2. Over the last week, how e m b a r r a s s e d Very much 口 
or self conscious, upset or sad have you Quite a lot P 
been because of your skin? Only a little 口 
Not at all 口 
3 Over the last week, how much has your Very much 口 
skin affected your friendships? Quite a lot 口 
Only a little 口 
Not at all 口 
4. Over the last week, how much have you changed Very much 口 
or worn different or special clothes/shoes Quite a lot 口 
because of your skin? Only a little 口 
Not at all 口 
5. Over the last week, how much has your Very much 口 
skin trouble affected going out , playing, Quite a lot 口 
or do ing hobbies? Only a little 口 
Not at all 口 
6. Over the last week, how much have you Very much 口 
avoided s w i m m i n g or o t h e r spor t s because Quite a lot P 
of your skin trouble'^ Only a little 口 
Not at all 口 
7. Last week’ If school time: Over the Prevented school 口 
was it last week, how much did Very much 口 
school t ime? your skin problem affect your Quite a lot 口 
school work9 Only a little 口 
O R Not at all 口 
was it If hol iday time: How much Very much 口 
hol iday t ime? | � o v e r the last week, has your Quite a lot 口 
skin problem interfered with Only a little 口 
your enjoyment of the hol iday? Not at all 口 
8. Over the last week, how much trouble Very much 口 
have you had because of your skin with Quite a lot 口 
other people call ing you names , teasing, Only a little 口 
bullying, asking questions or avoiding you9 Not at all 口 
9. Over the last week, how much has your sleep Very much 口 
been affected by your skin problem? Quite a lot 口 
Only a little 口 
Not at all 口 
10 Over the last week, how much of a Very much 口 
problem has the t r e a t m e n t for your Quite a lot 口 
skin been? Only a little 口 
Not at all 口 
Please check that you have answered EVERY question. Thank you. 
• M . S . Lewis-Jones, A.Y. Finlay, May 1993, This must not be copied without the permission of the authors. 
Figure 1.2 CDLQI (Lewis-Jones and Finlay, 1995) 
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CHAPTER 3 
Management of AD 
3.1. Current Management of AD and Their Drawbacks 
Symptomatic treatment includes frequent and regular topical application of 
moisturizer, e.g. aqueous cream, and oil baths. Avoidance of irritants is also advised. 
Topical anti-inflammatory treatment: Glucocorticoid (GC) is the mainstay of 
treatment for AD. GC performs function by binding to glucocorticoid receptor (GCR) 
in cytoplasm of target cells, being translocated to the nucleus through the nucleopore, 
hence suppresses leukocyte chemotaxis (Schleimer and Bochner, 1994), and prevents 
transcription of wide-range of pro-inflammatory mediators such as cytokines (e.g. 
IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-11 and IL-13), chemokines (IL-8; Regulated on 
activated normal T-cell expressed, and secreted: RANTES; macrophage 
inflammatory protein-1-alpha: MlP-la), and adhesion molecules (intercellular 
adhesion molecule-1: ICAM-1; vascular cell adhesion molecule-1: VCAM-1, and 
E-selectin) (Leung and Bieber, 2003). It is effective in controlling both acute and 
chronic skin inflammation. Yet prolonged use of GC may be associated with side 
effects (e.g. deranged metabolism, growth suppression and increased susceptibility to 
infection), and steroid fear in some AD patients (Hon et al, 2006b). In addition, GC 
non-responsiveness may occur in some patients, especially those with extensive S. 
aureus colonization. 
Topical calcineurin inhibitor (Tacrolimus: FK506 or pimecrolimus) (TCI) is 
another popular treatment option for AD. It binds to the macrophillin in target cells, 
and hence inhibits the nuclear factor of activated T cells (NF-AT) pathway. As a 
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result, activation of key effector cells involved in AD, including T-cells, mast cells, 
and keratinocytes, is inhibited (Novak et al, 2005). Unlike GC, TCI can be used in 
treatment of facial eczema safely. Nevertheless, it is possible that viral infections on 
skin may appear following long-term use of TCI. Warning from the Food and Drug 
Administration on potential relationship between TCI and lymphoma formation leads 
to concern in AD patients (Fonacier et al, 2006). 
Anti-infectious management: Systemic or topical anti-staphylococcal 
antibiotics are often used together with GC or TCI in treatment of patients with 
heavy colonization by S. aureus. 
Other management includes phototherapy, systemic antihistamines in control 
of pruritus, systemic GC or calcineurin inhibitor (cyclosporine A) for acute 
exacerbation. However, all of above treatments are not curative and with respective 
drawbacks. Therefore, there has been considerable interest in the use of traditional 
Chinese herbal medicine as a potential treatment for AD. 
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3.2. Traditional Chinese Herbal Medicine (TCHM) 
3.2.1. General Principle of TCHM 
TCHM is widely used in many Asian societies. The therapeutic strategy of 
TCHM emphasises holistic management of body, which is in particular appealing in 
modulating such chronic relapsing disease, as asthma, eczema, rheumatoid arthritis, 
and cancer (Lau et ai, 2001). Compared to a single, purified chemical utilized in 
western medicines, TCHM prescription is usually a cocktail of several herbs combined 
into formula. In a single formula, some herbs act as the main ingredients; some are 
essential to cancel out toxicity of other herbs; and some may act as catalyst of the 
formula. Balance and interaction between ingredients is more important than effect of 
individual ingredient in TCHM treatment (Koo and Arain, 1998). TCHM focuses on 
the importance of catering the therapy to suit the different needs of each individual 
(individualism), whereas most Western medication trials are standardized and stress 
on "average" efficacy in large, randomised controlled trial (RCT). This difference 
hinders TCHM research in both inpatient and outpatient settings (Koo and Desai, 
2003). 
In a UK study, 46% of AD children patients had used or were currently on 
complementary medicine (CM). The most commonly used CM was Chinese herbal 
medicine by 20 of 46 patients (43% of those who had used CM) (Johnston et al, 2003). 
In another study, two thirds of psoriasis patients recruited have attempted CM for 
psoriasis treatment during the study period or in the past. One-fifth of them have tried 
herbal medicine (Ben-Arye et al, 2003). According to our recent local study, over 
50% of AD children have ever tried traditional Chinese medicine (TCM), while only 
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one-filth of non-AD children have attempted TCM ever (Hon et al, 2006e). Due to 
dissatisfaction with their conventional treatment and no curative management 
available, patients with skin disease opte to use CM, in which TCHM is a popular 
choice. It urges a systematic and scientific investigation in use of TCHM for treatment 
of skin disease, especially in Asian countries. 
3.2.2. Side Effects of Using TCHM 
There is a general misconception about TCHM by the patients that TCHM 
has no side effect because TCHM is composed of "natural" substances, and TCHM 
is "milder" than western medicine (Koo and Desai, 2003). However, adverse effects 
of TCHM, including hypersensitive, hepatic toxicity, renal damage, and 
cardiotoxicity, have been reported (Huang and Tao, 1989; Wang and Lu, 1992; Li, 
1995). 
3.2.3. Literature Reviews of TCHM Use in Treating AD 
Currently there are only a few well-documented studies on the application of 
Chinese herbal therapy in AD. In an open study involving 30 AD patients, BSASM 
(a mixture of compounds which are found in several plants) demonstrated a 
reduction in AD severity as measured by eczema area severity index, degree of 
pruritus, and transepidermal water loss (TEWL). Besides, BSASM had no irritative 
or allergic effects (Lee et al, 2004). 
The best-known double-blind placebo-controlled trial of TCHM in adult 
(Sheehan et al, 1992; Sheehan et al, 1995) and children (Sheehan and Atherton, 1994) 
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AD patients was carried out in UK in early 90’s. In this placebo-controlled crossover 
trial of Zemaphyte (a standardized formulation containing ten Chinese herbs), the 
area of erythema and the extent of surface involvement were significantly decreased 
with active herbs compared to placebo group. No adverse effect on liver, renal 
function was observed during the study period. In the 1 -year follow-up, patients 
continued to use TCHM showed persistent benefit but deterioration observed in 
patients chose to stop. However, the same decoction of TCHM was not beneficial to 
patients in subsequent double-blind placebo-controlled crossover study carried out in 
Hong Kong (Fung et al, 1999). Yet, there is no other well-documented RCT on the 
utilizing of TCHM in treatment of AD since the above trial. 
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CHAPTER 4 
The Pentaherbs Formula for AD Treatment 
4.1. Pilot study: Pentaherbs Capsule as Treatment Option of AD Children 
A twice-daily concoction containing five herbal extracts (PentaHerbs formula: 
PHF) has been found to be beneficial in an open pilot study (Hon et al, 2004b). A 
total of nine pediatrics patients participated in the study. There was significant 
improvement in AD disease severity and the distressing symptoms of itch and sleep 
loss after the 3-mouth treatment with PHF. The median (range) overall SCORAD 
score before and at the end of 3 months was 60.3 (20.0-82.6) and 40.0 (11.4-56.5), 
respectively (P=0.008). Significant improvement was also noted in the components 
of the SCORAD index. No clinical and biochemical evidence of any adverse effect 
was observed during the study period. 
The five herbs in the concoction are Flos lonicerae (Jinyinhua), Herba 
menthae (Bohe), Cortex moutan (Danpi), Rhizoma atractylodis (Cangzhu) and 
Cortex phellodendri (Huangbai), and this formulation is based on a widely used 
ancestral Chinese concoction (Hon et al, 2004b). 
As the therapeutic efficacy of many TCHM preparations has been previously 
attributed to CS-containing ingredients (Graham-Brown et al, 1994; Perharic et al, 
1995) and there has been much fear and misunderstanding concerning CS use among 
parents (Hon et al, 2006b), it would be rational to develop safe, 
non-steroid-containing immunomodulating formulations that are efficacious in 
treatment of AD. Using thin-layer chromatography, infrared spectrophotometry, we 
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demonstrated that there was no CS or CS related compound in this formulation (Hon 
et al, 2006d). 
The pilot study was limited by the small sample size, because of unexpected 
Severe Acute respiratory Syndrome outbreak in Hong Kong. Despite this limitation, 
the clinical effects of the PHF for AD appear impressive and no any harmful effect 
observed. Therefore, the next step in this study aimed at evaluating the efficacy and 
tolerability of PHF in pediatrics AD patient by a double blind RCT in a scientific and 
systemic regime. Possible adverse events of our TCM on haematologic, hepatic and 
renal functions, if any, were also recorded to ensure safety of the medications. 
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4.2. Literature Review: Nature of Five Herbs 
4.2.1. PHF as Treatment Option of AD under TCHM Concepts 
In Chinese Medicine, "wind", "dampness", and ‘‘heat’，are considered to be 
the main pathogenic factors of AD. The five herbs in the PHF used in the study are 
proposed to work as follow: Jinyinhua and Bohe clear wind-heat from the exterior; 
Danpi clears heat and cools blood; Huangbai gets rid of damp-heat; and Cangzhu 
clears wind-heat from interior. These herbs have been used extensively in China for 
treatment of allergic disease including eczema, asthma, and allergic rhinitis; and 
bacterial infection. (Hon et al, 2004b; Chu, 2007). 
4.2.2. PHF as Treatment Option of AD from Modern Research Literature 
As previous mentioned, anti-eczematic drug such as CS, though effective, 
might be associated with adverse side effects. The search of alternative or 
complementary anti-eczematic is therefore desirable. Atopic dermatitis is a type of 
allergic disease attributable an altered THl/TH2-balance and/or reduced T cell 
regulation of the immune response. Patients with AD Patients display defects in innate 
immune responses resulting in a heightened susceptibility to bacterial, fungal and viral 
infections, most notably colonization by S. aureus. It is hypothesized that herbs 
possessing immunomodulatory, anti-microbial or anti-fungi properties may be an 
effective anti-eczematic agent. 
A review of the five herbal components in PHF was performed using PubMed, 
the literature database of National Centre for Biotechnology Information. Results were 
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mainly focus on studies performed on single herb preparation and shown in table 
below (Table 1.2). From literature reviews, the five herbal components in PHF 
possessed potential immunomodulatory, anti-microbial, and anti-fungi properties 
respectively in various in vitro, in vivo, ex vivo, and clinical trial studies. The five 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Pathobiology of Atopic Dermatitis 
5.1. Nature of Complexity of Pathogenesis 
Although characteristic phenotypes make AD diagnosis to be simple and 
clear-cut (Barneton and Rogers, 2002), its underlying pathophysiology mechanisms 
are very complex and debatable, and still not completely understood. Various cell 
types (e.g. Lymphocytes, Langerhans cells, eosinophils, keratinocytes), factors (e.g. 
cytokines, chemokines and immunoglobulins, particularly IgE) have been identified 
(Friedmann, 2002). 
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5.2. Skin barrier-impairment of epidermal barrier 
The distorted lipid composition of stratum corneum is fundamental defect of 
AD, which is responsible for the xerotic aspect of the skin and results in a higher 
permeability to allergen entry (Fartasch, 1997). Dry skin and increased TEWL are 
presented in both lesional and non-lesional skin of AD patients (Leung et al, 2004a). 
In particular, a reduced expression of ceramides, which serves as major 
water-retaining molecules in the extra-cellular space of the comified envelope, was 
reported in AD patients (De Nardo et al, 1998). A recent publication suggested that 
an elevated production of stratum corneum chymotryptic enzyme, which promoted 
breakdown of corneodesmosomes, was observed in AD due to genetic defect (Cork 
et al, 2006). Additional damage to skin was proposed to be caused by exogenous 
protease from increased colonization of S. aureus or HDMs (Deleuran et al, 1998; 
Miedzobrodzki et al, 2002). 
Impaired skin barrier function predisposing to allergen entry, together with 
the inflammation-induced skin damage, increase the susceptibility to irritants in AD 
patients (Novak et al, 2003). And it in turns results in cutaneous hypersensitivity to 
environmental triggers. 
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5.3. Biphasic T cell response in skin of AD 
A commonly accepted immunological pathway leading to AD is the TH1/TH2 
paradigm model (Abramovits, 2005). It begins from differentiation of CD4+ T-helper 
lymphocytes (THO) to THI and TH2 cells. In AD, the hygiene hypothesis 
(Yazdanbakhsh, 2002; Flohr et al, 2005; Baker, 2006) (Figure 1.3) suggests that due 
to a reduction of infection or exposure to endotoxin in early years of life, 
differentiation of THO towards TH2 over IFN-丫-dominated THI profile is enhanced. It 
is believed that genetically susceptible individual influences from the environment in 
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Figure 1.3: Two possible mechanisms for the increased prevalence of allergy 
as a result of decreased exposure to microbial antigens (Baker, 2006) 
The first mechanism suggests that reduced exposure to pathogens or recognize 
pathogen-associated molecular patterns (PAMPs) associated with microorganisms 
leads to decrease in production of IL-12, THI development is not favored, while it 
makes TH2 development dominant. The second mechanism proposed that there may 
be defects in stimulating dendritic cells by the nonpathogenic microorganisms in 
gut-associated lymphoid tissue and it leads to reduced in making of IL-10-producing 
regulatory T cells (Tr). It in turns results in unbalanced expression of TH WTH2-type 
immune response (Baker, 2006). 
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Overproduction of IL-4, IL-5 and IL-13 from TH2 cells, and diminished 
expression of THI cytokines favor production of IgE from B cells and activation of 
eosinophils and mast cells for releasing histamines, the key pruritus-causing suspects 
(Abramovits, 2005). Consequently, type-1 hypersensitivity reactions are promoted in 
acute phase of AD (Jelinek, 2000; Friedmann 2002). THI lymphocytes produce IL-2 
and IFN-y, provoking delayed hypersensitivity reactions (Knoell and Greer, 1999). 
The two T-cells are mutually affected in the way that cytokines produced by Th2 
suppress THI activities (Abramovits, 2005), whereas IFN-y produced by THI 
suppressed TH2 (Grew et al, 1998) (Figure 1.4), 
Figure 1.4: Differentiation of T-helper (TH) lymphocytes (Friedmann, 2002) 
In chronic lichenified skin lesion, local production of IL-12 from infiltrating 
eosinophils and inflammatory dendritic epithelial cells (IDECs), stimulates 
differentiation of THO towards THI cells. Productions of IL-4 and IL-13 in chronic 
skin lesions are significantly less than that in acute ones，but levels of IL-5, 
granulocyte-macrophage colony stimulating factor (GM-CSF), IL-12, and IFN-y are 
higher in chronic lesions (Leung et al, 2004a). 
Nevertheless, along the whole course of AD development from acute to 
chronic phase, the patients exhibit a biphasic T-cell pattern in which TH2 immune 
response predominance will switch to a more ThI-like profile respectively (Leung et 
al, 2004a). It may be vital for initiation of intercellular adhesion molecule-1 
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(ICAM-1) expression from keratinocytes and successive accumulation of 
inflammatory cells in lesional skin (Grewe et al, 1994). 
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5.4. Nature of Immunoglobulin-E and its Role in Atopic Dermatitis 
Basing on the above-proposed model, the majority of AD patients will 
therefore exhibit a hyper-production of immunoglobulin E as a result of the enhanced 
production of TH2 cytokines, particularly during the onset or the acute lesional phase 
(Abramovits, 2005). Another source of IgE production is due to presence of S. 
aureus antigens (Nordvall et al, 1992) and other SAgs (Marrack et al, 1990). It has 
been documented for long that IgE is the key mediator of AD and related 
hypersensitivities towards environmental allergens (Church et al, 1976), and a 
hallmark of atopic diseases (Burrows et al, 1989). Recent studies continue to prove 
that total serum IgE levels have significant epidemiological associations with early 
AD incidence, its subsequent prognosis (Perkin et al, 2004) and its severity (Laske 
and Niggemann, 2004). Nevertheless, it has to be reminded that the above definition 
did not apply to the group of patients with intrinsic AD, who exhibit normal values 
of total or specific IgE (Dotterud et al, 1995). 
IgE in peripheral blood forms crosslinks with antigens and triggers type I 
hypersensitivity reaction by inducing mast cells and basophils to release mediators, 
including histamines, which are the main pruritus-causing suspects (Abramovits, 
2005). IgE also poses its significance on antigen-presenting cells (APCs) 
(Langeveld-Wildschut et al, 2000). The number of IgE-bearing Langerhans cells and 
IDECs expressing FcsRI also increases (Novak et al, 2001). Langerhans cells 
provide a positive feedback loop by increasing the pool of TH2 cells, while FcsRI 
capture and internalize incoming antigens before they are processed to T lymphocyte 
in atopic skins (Santamaria-Babi, 2006). 
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5.5. Innate Immunity Defect in AD 
Nearly 90% of AD patients are colonized with S. aureus on their skin, 
whereas in control or non-atopic subjects, only 5-30% are colonized (Leung et al, 
2003). Degree of colonization of S. aureus positively correlates with the disease 
severity of AD (Zollner et al, 2000). Increased susceptibility to cutaneous infection is 
partially due to failing in innate immunity as first-line defense against microbes. 
The barrier function of stratum corneum (SC) is disturbed as mentioned 
above, due to reduced in lipid levels (ceramide and sphingosine) leading to TEWL 
and ultimately resulting in dry; abnormal keratinazation; and mechanical breakdown 
of skin barrier caused by extensive scratching in AD patients. Augmented water loss 
and pathogen entry are as consequence of exposed and disturbed SC. 
Response of keratinocytes, one of the key effector cells in AD development, 
to microbial infection is aberrant, which may partly be elucidated by polymorphism 
in Toll-like receptor 2 (TLR2) and CD 14. There is a recent report suggesting that 
missense mutation in the TLR2 gene correlated with disease severity, higher serum 
IgE level, and increased in susceptibility of S. aureus infection in AD (Werfel et al, 
2004). Reduced level of soluble CD 14 (receptor for LPS and other bacterial cell wall) 
is also observed in AD children (Zdolsek and Jenmalm, 2004). It is speculated that 
mutant TLR2 does not respond to its antigen appropriately, hence downstream 
immunological cascade against microbial infection may be diminished. 
The production of AMPs (LL-37, HBD-2, HBD-3, and dermcidin) is reduced 
by the skin of AD patients compared to both psoriasis patients and normal control 
subjects (Ong et al, 2002; Howell et al, 2005). Lastly, impairment of 
polymorphonuclear neutrophils (PMN) in chemotaxis (Rogge and Hanifin, 1976), 
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phagocytosis (Michaelsson, 1973) and superoxide generation (Mrowietz et al, 1988) 
are demonstrated in various studies. It is obvious that there is a mixture of defects in 
the innate immune system, ranging from skin barrier dysfunction to reduced 
production of AMPs, that all defects play an important role in development and 
severity of AD. 
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5.6. Role of Superantigen in Pathogenesis of AD 
Defective skin barrier function, increased S. aureus adherence to AD skin, 
and reduced innate immune responses generate an environment well suited to S. 
aureus growth and survival on AD skin. S. aureus-"^xoducmg SAgs, including 
Staphylococcal enterotoxin (SE) A, B, C (SEA, SEB, SEC) and toxic shock 
syndrome toxin-1 (TSST-1), are toxic proteins secreted from S. aureus that involved 
in various inflammatory and autoimmune diseases. More than 50% of patients with 
AD produce specific IgE antibodies directed against SAgs found in their skin (Leung 
et al, 2004a; Nissen et al, 1997). The production superantigen-specific IgE arms 
release of histamine and degranulation from mast cells and basophils. Thus, it 
contributes to scratch-itch cycle in AD patients (Yarwood et al, 2000). 
SAgs bind directly to major histcompatibility complex (MHC) class II 
molecule on APCs, such as macrophages and the (3 variable region of T cell receptor 
(TCR) without antigen processing by APC. Thus, SAgs can act as potent mitogens 
that stimulate a large population of T cells in a short time and low dose (Cardona et 
al, 2006) (Figure 1.5). 
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Figure 1.5 Activation of T cells by (a) conventional antigen; (b) 
superantigens (SAgs) 
(a) Antigen processing by APC is required; antigen is then presented by APC 
through MHC class II. The complex is attracted and binded to variable chain of TCR 
specific to antigen presented, (b) The SAgs bind directly outside the MHC class II 
and crosslink it to the variable chain of TCR. This event initiates non-specific 
polyclonal T cell activation (Le Loir et al, 2002). 
T cell activation is further promoted in AD patients by a subversive effect on 
the immunosuppressive activity of circulating CD4+CD25+ regulatory T cell activity 
by SEB (Ou et al, 2004). In addition to T cells, SAgs also perform mediate effects 
on other cell types taking part in the pathogenesis of AD, including eosinophils, 
langerhans cells (LC), and macrophages. SE promotes expression of surface 
activation antigens and cytokine-activated oxidative burst on eosinophils (Wedi et al, 
2002); and stimulates production of IL-1, TNF-a, and IL-12 from LC and 
macrophages (Baker, 2006). Other than cellular activation, apoptosis of various 
effector cells (eosinophil, monocytes, and macrophages) in the pathogenesis of AD 
are inhibited by SAgs (Wedi et al, 2002; Bratton et al, 1999). 
With continual S. aureus colonization and infection, SAgs secreted cause 
activation of numerous cell types, decrease in apoptosis and IgE production. It leads 
to degranulation and histamine release and therefore, persistent inflammation with 
vicious cycle of scratch-itch maintained on AD skin. 
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5.7. Cytokines, Chemokines and Inflammatory Mediators in Pathogenesis of 
Atopic Dermatitis 
It is generally accepted that cytokines and some chemoattractants play 
important roles in pathogenesis of AD. A new family of small, cytokine-like proteins, 
the chemokines, which regulates infiltration and migration of inflammatory 
lymphocytes into tissue through G-protein coupled 7-transmembrane domains 
(Hijnen et al, 2004), is also a new focus in AD research. 
5.7.1. Proinflammatory Cytokines 
Pruritus characterizes a prominent symptom of AD. Mechanical trauma due 
to intense scratching together with existing skin barrier disruption, results in 
production of primary proinflammatory cytokines (IL-1, IL-18, TNF-a, and 
GM-CSF). These proinflammatory cytokines are important for inducing release of 
adhesion molecules, chemoattractants, supporting the recruitment, proliferation, and 
survival of leukocytes at cutaneous sites (Homey et al, 2006). 
5.7.2. TH1/TH2 Cytokines 
As mentioned, overall, atopic disease is associated with a TH2 immune 
response with obsessive production of IL-4, IL-5, and IL-13; blood eosinophilia, and 
elevated blood IgE level. However, the scenario is shown only in acute eczematous 
lesion. In chronic lesions, either coexistence of THI and TH2 cells or THI immune 
response dominance is reported (Grewe et al, 1994; Grewe et al’ 1998). As in 
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chronic phase, expression of cytokines (e.g. IFN-y and IL-2) is essential for the 
induction of adhesion molecules, such as ICAM-1, production from keratinocytes 
and hence the accumulation of inflammatory cells in lesional skin (Grewe et al, 
1994). 
5.7.3. Chemokines 
Various chemokines have been shown to be associated with AD phenotypes, 
including CCLl-5, CCLl l , CCL13, CCL17, CCL18, CCL20, CCL26, and CCL27 
(Homey et al, 2006). Among all chemokines, the thymus and activation-regulated 
chemokine (TARC/ CCL17) shows strong correlation with disease severity of AD 
and allergic asthma (Leung et al, 2003). Cutaneous T-cell attracting chemokine 
(CTACK/ CCL27) is suspected to be pivotal in AD pathogenesis and shown to be 
specific for AD, which increase with AD severity and decrease with successful 
treatment (Hijnen et al, 2004; Hon et al, 2004a). Proinflammatory cytokines (IL-1 
and TNF-a) stimulate production of CTACK and TARC from keratinocytes and 
endothelial cells. TARC preferentially attracts CCR4+ T cells recognized to be 
primarily of TH2 subtype whereas CTACK attracts skin-homing T cells of both THI 
and TH2 subtype expressing CCRIO (Vestergaard et al, 2004). TARC and CTACK 
cooperate to recruit CCR10+CCR4+ skin-homing CLA+memory T cells into the skin, 
where they are then activated through allergens or SAgs (Reiss et al, 2001). It results 
in releasing of effector cytokines (e.g. IL-4, IL-13, and IFN-y) for maintenance and 
amplifying the production of chemokines within inflammatory sites. 
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5.7.4. Pruritus Mediators 
Pruritus is an essential feature of AD, which significantly impairs quality of 
life of patients (Hundley et al, 2006). Among all mediators, histamines have long 
been believed as the major peripheral mediator in pruritus since the very beginning 
of skin research (Lewis, 1927). In addition to histamine, other mediators, such as 
proteases, cytokines, and neuropeptides can also induce pruritus (Schmelz, 2002). 
Recent studies demonstrated that cytokine IL-31 induced severe pruritus and 
dermatitis in mice (Dillon et al, 2004). IL-31 is preferentially produced by TH2 cells 
and induced by staphylococcal superantigens (Sonkoly et al, 2006). Following 
production of IL-31, expression of a set of atopy-related chemokines, including 
CCLl, CCL17, and CCL22 will be stimulated (Dillon et al, 2004). In short, after S. 
aureus infection, recruitment of T-cells is promoted by chemokines, and pruritus is 
induced. It is linked together by cytokine IL-31 and other inflammatory mediators. 
Another important pruritogenic mediator that is under heavy investigation is 
brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family 
(Leibrock et al, 1989) abundantly found in the neurons (Lewin and Barde, 1996). It 
is reported that serum BDNF was higher in patients with AD as compared to 
non-atopic control (Namura et al, 2007) and that a positive correlation exists between 
BDNF and the severity of AD (Raap et al, 2006). In addition, neurotrophins were 
found to have mediatory effects upon inflammatory conditions (Toyoda et al, 2002), 
and were also suspected in regulating important immune cells of AD, including 
T-cells (Kerschensteiner et al, 1999) and eosinophils (Raap et al, 2005). Moreover, 
BDNF secretion is induced by proinflammatory cytokines TNF-a and IL-6, which 
are produced during monocyte/ macrophage activation (Schulte-Herbruggen et al, 
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2005). In addition, it is reported that plasma levels of BDNF correlates with 
nocturnal scratching activities, as documented by a movement recorder, in AD 
children (r=0.9) (submitted manuscript, Hon et al). Its multifactorial effect suggests 
its possible important roles in pathogenesis of AD. 
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Section 2: CLINICAL TRIAL OF PENTAHERBS 
CHAPTER 1 
Objective 
The PHF capsules were well-tolerated by children and apparent clinical 
benefits were noted from the pilot, open-labeled study. 
The present study is aimed to determine the efficacy and tolerability of the 
Pentaherbs concoction in children with moderate-to-severe AD in a larger 




Materials and Methods (RCT) 
2.1. Materials 
2.1.1. SCORAD worksheet 
The SCORAD (1993) is a validated scoring system, which has been used in 
many clinical trials on AD, which involves assessment of objective parameters (area 
and intensity signs) and subjective symptoms (pruritus and sleep loss). Patients with 
objective SCORAD >15 are defined as suffering from moderate-to-severe AD. 
2.1.2. CDLQI questionnaire 
The CDLQI is a questionnaire used for assessing the subjects' life quality 
impairment (Lewis-Jones and Finlay, 1995) over the preceding seven days. It 
consists of 10 questions which covers the following areas: (i) symptoms and feelings, 
(ii) daily activities, (iii) leisure, (iv) work and school, (v) personal relationships, and 
(vi) treatment, with each question scoring from 0 ("not at all") to 3 ("very much"). 
The maximum possible score of the whole questionnaire is 30 and the minimum 
score is 0. The higher the score is, the more the quality of life (QoL) is impaired. To 
facilitate a better understanding of the questionnaire to the subjects, a 
Cantonese-translated version was used (Chuh, 2003) (Figure 2.1). 
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2.1.3. Allergic Rhinitis Score (ARS) 
ARS evaluates the severity of symptoms (i.e. sneezing, watery rhinorrhoea, 
itching nose, itching eyes and eye watering) from coexisting allergic rhinitis (Premier 
et al, 1996). For each item, the scores range from 0-4, which represents nil to severe 
symptoms. 
2.1.4. ELISA Assay Kits 
ELISA kits for measuring the concentrations of TARC and BDNF were 
purchased from R & D Systems (Minneapolis, MN, USA). The respective minimum 
detectable limits were 7 pg/ml and 20 pg/ml. 
2.1.5. EDTA blood collection tubes 






呢？ • 口 
些少 • 
無 • 
2.喉過去一個星期裏面’你因爲皮庙問題而產生抵拉、太注意自己、 非常嚴重 • 
唔開心或者傷心概程度點樣呢？ 厳重 • 
些少 • 
無 • 
3.縣過去一個星期裏面，你概皮丨苗問題對你同朋友之間概關係影響有 非常嚴重 • 
幾大？ 嚴重 • 
些少 • 
無 • 
4.嗨過去一個星期裏面’你槪皮庙問題令你換衫/鞋或者着特別喷衫 非常多 • 
/鞋多唔多呢？ 多 • 
些少 • 
無 • 
5.縣過去一個星期裏面’你概皮庙問題對你出街、玩或者做你鐘意傲 非常嚴重 • 
概嚼槪影幾大？ 嚴重 • 
些少 • 
無 • 
6..過去一個星期裏面，你因爲皮庙問題而要避免游水或者傲其他運 非常多 口 
動哦情況多唔多？ 多 • 
, 些 少 • 
^ • 
7 .上星期， 如果係返學時間：嗎過去一個星期裏 不能上課 • 
係唔係 面’你概皮庙問題對你概學業有幾大影 非常厳重 • 
返學時間 麥？ •嚴重 • 
些少 • 
或者 無 • 
係唔係 如果係假期：略過去一個星期裏面，你 非常嚴重 • 
假期 DiMr問礙你享受假期有幾厳重？ mm • 
些少 • 
無 • 
8.喉過去翻裏面•你因爲颇問題而俾人叫花名、笑、 非常多 • 
「瑕J、問問題或者避開你，D甘银麻煩多唔多呢？ 多 • 
些少 • 
無 • 









®M.S. Lewis-Jones, A.Y. Finlay, May 1993 




The study was a single-centre, randomized, double-blind, placebo-controlled 
and parallel-group clinical trial. 
2.2.2. Intervention 
Following a 2-week run-in period, patients were randomized into two groups 
to receive 12-week treatment with three capsules twice daily of either PHF or 
placebo. 
2.2.3. Treatment 
2.2.3.l.The Pentaherbs Formula 
PHF was formulated under the supervision of Institute of Chinese Medicine 
(ICM) of the Chinese University of Hong Kong. The capsule was manufactured, 
packaged and labeled by the Chinese Medicine Industry Development Centre of the 
Hong Kong Institute of Vocation Education, according to the Good Manufacturing 
Practice (GMP) standard. The optimal composition of each herb included was 
standardized prior to manufacturing. The powder was formulated into uniform dose 
capsules under the supervision of the Clinical Trials Section, ICM according to 
established procedures. Before this clinical trial, ICM tested these capsules for the 
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presence of heavy metals, microbial contamination and residual pesticides to ensure 
their quality and safety. 
The original formula was composed of 2 grams Flos lonicerae (Jinyinhua), 1 
gram Herba menthae (Bohe), 2 grams Cortex moutan (Danpi), 2 grams Rhizoma 
atractylodis (Cangzhu) and 2 grams Cortex phellodendri (Huangbai), and the 
extraction rate from these raw herbs ranged between 18% and 20%, which was made 
6 to 7 capsules. The dose calculation was based on the assumption that patients were 
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Figure 2.2 The Pentaherbs (PHF) capsules 










PHF or placebo treatment was randomly assigned to consented patients 
according to computer-generated sequence provided by ICM. A research assistant 
used computer software to generate this randomization schedule in blocks of 10 in 
order to ensure similar number of subjects in the two treatment arms. The allocation 
sequence was concealed throughout the study period. The investigators were not 
allowed to break the blinding for any patient until the trial and all data analysis were 
completed. Capsules were supplied in containers labeled with the randomization 
numbers, and which were dispensed to patients in strict numerical sequence. PHF 
and placebo treatments were matched in external appearance, and placebo capsules 
contained starch and food additives to match up texture, colour and taste. Each 
patient received three capsules twice daily. The placebo capsules were unlikely to 
exert any beneficial or adverse effect on AD. 
2.2.3.3.Concomitant Treatment in Study Period 
Patients were allowed to use their usual AD treatments throughout this study. 
Concomitant treatments were allowed for two weeks before or during the study, but 
the strengths and dosages had to be the same except the quantity and frequency of 
topical steroid and oral antihistamine. These latter drugs were used as-needed 
according to the severity of their disease. Permitted concomitant medications 
included emollient cream, bath oils, soap substitutes, and topical steroids classified in 
the British National Formulary as "mild," "moderately potent," or "potent" (but not 
"very potent" topical steroids). "Potent" topical steroids were prohibited in our 
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children. Systemic antihistamines were allowed, but no other systemic treatment or 
ultraviolet light treatment was permitted. For standardization purpose, most patients 
were changed to momentasone furoate as their primary topical corticosteroid and 
chlorpheniramine as their primary oral antihistamine unless they experienced adverse 
reactions to these medications or were stable on alternative medication (such as 
hydroxyzine). A minimum four-week washout period was needed for patients who 
had received systemic steroids or other oral immunosuppressive treatment. 
2.2.4. Participants 
Chinese children aged 5-21 years with moderate-to-severe AD (objective 
SCORAD >15) managed at the paediatric dermatology outpatient service of a 
university teaching hospital were invited to participate. AD diagnosis was made 
according to the criteria by Hanifin and Rajka. Patients were excluded from this 
study if they suffered from other inflammatory dermatitides (such as psoriasis, 
seborrhoeic dermatitis, ichthyosis) or clinically overt asthma (i.e. interval symptoms 
of cough, wheeze, shortness of breath or exercise-induced symptoms). Patients were 
required to discontinue any systemic corticosteroid, immunomodulating drug, or 
TCHM for at least four weeks before entering the study. The Clinical Research 
Ethics Committee of the Chinese University of Hong Kong approved this study. All 
parents and older patients (considered by the investigators and their parents to be old 
enough to understand the issues) provided written informed consent to participate in 
this study. 
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2.2.5. Outcome Measures 
Participants were seen at baseline (visit 1) and at 4 (visit 2), 8 (visit 3), 12 
(visit 4) and 16 (visit 5) weeks. AD severity was assessed by SCORAD index at each 
visit by the same principal investigator (Hon) and QoL with the CDQLI 
questionnaire. Symptoms of coexisting allergic rhinitis were also scored with the 
ARS. 
At each visit, the need for topical steroid and/or antihistamines was 
documented. The unused antihistamines were also counted and weight of remaining 
topical steroid recorded. Unused study medications were counted at each visit for the 
monitoring of drug compliance. The principal investigator was unaware of such 
information. 
Blood tests including complete blood count, eosinophil count, serum total 
IgE level, liver and renal functions and thyroid function were performed at visits 1 
and 4. Blood samples (EDTA-plasma) for measuring levels of TARC and BDNF 
were collected at baseline (visit 1), and the end of treatment (visit 4). Plasma was 
obtained by centrifugation at 1000 x g for 10 minutes at 4°C within 2 hours of blood 
collection, and immediately stored at -80°C for further use. Plasma levels of TARC 
and BDNF were quantified by ELISA according to manufacturer's instructions. 
2.2.6. Statistical Analysis 
SCORAD, QoL scores, topical steroid use, antihistamine use, and laboratory 
parameters in paired samples before and after treatment were compared using the 
paired t test or Wilcoxon signed-rank test. Comparisons of outcomes between PHF 
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and placebo groups were performed by Student t test or Mann-Whitney U-test. 
Statistical analysis was performed using SPSS 13.0 (Chicago, IL, USA). All 






Ninety participants were screened between February 2004 and July 2005. 
Three were excluded for mild disease (i.e. SCORAD < 15). Two participates refused 
to join the RCT because of concerns on TCM use in the study. 
Eighty-five consented participants (Treatment: 42; placebo: 43) started the 
trial. The patient sample was believed to be the representative of the population of 
patients with AD treated at our department as compared with our other published 
report (Hon et al, 2006a). 
Demographics of treatment and placebo groups at baseline were comparable 
as shown in Table 4.1. Disease severity as assessed by SCORAD was comparable in 
the two groups at baseline. Seventy-one of the 85 AD patients had co-existing 
allergic rhinitis. The patients had been treated with various combinations of 
emollients, moderately potent topical CS (80% on momentasone furcate on an 
as-need basis) and oral antihistamines on an as-needed basis. The mean (standard 
deviation [SD]) age was 11.7 (3.6) years, and there were 39 female and 46 male 
patients in this trial. The patients were randomized to receive active treatment or 
placebo. Table 2.1 summarizes the flow of patients through the study. 
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Table 2.1 Subject baseline characteristics 
Results showed in mean (SD), comparisons between treatment and placebo group 
were performed by Student t test. 
Treatment Placebo P value 
Subjects enrolled 42 43 
Age (year) 11.7(3.8) 11.7(3.5) 0.932 
Gender 0.920 
Female 19 20 
Male 23 23 
SCORAD score 58.3 (15.6) 55.8 (18.5) 0.515 
CDLQI 11.0 (5.1) 9.9 (5.3) 0.346 
Body weight (kg) 38.8 (14.8) 40.4 (17.1) 0.649 
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Figure 2.3 Patients flow chart 
54 
3.2. Drug Compliance 
Non-compliance was defined as using less than 75% of prescribed medication 
during the study. Four participants (two in treatment group and two in placebo group) 
were non-compliant. Two participants from placebo group withdrew during the trial. 
A teenager girl refused PHF and instead used Tacrolimus previously prescribed by 
another practitioner, and another boy developed non-specific abdominal discomfort. 
Both agreed to return monthly for outcome evaluation under our intention-to-treat 
assessment. The overall compliance rate was 92%, in which treatment group was 




Comparing within each group, the mean (SD) SCORAD significantly 
decreased from 58.3 (15.6) to 49.7 (20.0) in treatment group (P二0.003), and 55.8 
(18.5) to 46.9 (22.0) in placebo group (PK).001). However, there was no significant 
difference in SCORAD between the two groups at the end of treatment (visit 4) 
(P=0.543). The result was shown in Fig. 2.4 and Table 2.2. Similarly, there was no 
difference between treatment group and placebo group in the components of 
SCORAD. 
3.3.2. Quality of Life Score 
In contrast, comparing within each group, the mean (SD) QoL score 
significantly decreased from 11.0 (5.1) to 7.6 (5.2) in treatment group (P=0.001), but 
no improvement of QoL score was observed in placebo group. There was significant 
difference in QoL score between treatment and placebo groups at the end of 
treatment (visit 4) (P 二 0.031). The result was shown in Fig. 2.5 and Table 2.3. 
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Table 2.2 SCORAD index comparison at each visit 
There were no differences in SCORAD scores between the two groups at each visit. 
However when compared with baseline, both groups were improved after treatment 
(p<0.05). 
Treatment (n二42) Placebo (n=43) p . _ a ^ 
而 Mean (SD) Mean (SD) 
Visit 1 (Baseline) 58.3 (15.6) 55.8 (18.5) 0.515 
Visit 2 49.2 (17.0) 49.2(19.8) 0.996 
Visit 3 50.7 (20.7) 45.5 (18.7) 0.227 
Visit 4 (end of treatment) 49.7 (20.0) 46.9 (22.0) 0.543 
P value b 0.003 0.001 
Visit 5 (end of study) 50.0 (20.8) 46.6 (22.0) 0.475 
a Compared with placebo by Student t test 
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Figure 2.4 Mean SCORAD index (standard error of mean: SEM) of 
treatment and placebo groups at each visit 
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Table 2.3 Quality of life (QoL) score comparison at each visit 
The scores of quality of life in treatment group were significantly lower than placebo 
group at visit 4 (P=0.031). When compared with baseline, the score at visit 4 was 
significantly decreased in treatment group (P=0.001), no such change was observed 
in placebo group (P=0.796). 
TCM (n=42) Placebo (n=43) p a 
Mean (SD) Mean (SD) 蘭 e 
Visit 1 (Baseline) 11.0 (5.1) 9.9 (5.3) 0.346 
Visit 2 8.5 (4.9) 9.0(5.5) 0.614 
Visit 3 8.9 (4.8) 8.7 (5.2) 0.832 
Visit 4 (end of treatment) 7.6(5.2) 10.1 (5.5) 0.031 
P value b 0.001 0.796 
Visit 5 (end of study) 7.4(5.4) 8.7(5.0) 0.248 
a Compared with placebo by Student t test 
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Figure 2.5 Mean QoL score (SEM) of treatment and placebo groups at each 
visit 
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3.3.3. Duration and Amount of CS Usage 
The duration of primary topical CS usage (as measured by days of CS use per 
month) was significantly reduced by an average of four days in treatment group 
(P=0.042) but not in placebo group (P=0.287) (Table 2.4). However, there was no 
significant difference in duration of CS usage between two groups at the end of 
treatment. 
Of 79 patients using 1% mometasone furoate as the primary topical CS, the 
amount of CS usage (as measured by grams of 1% mometasone furoate use per 
month) was significantly decreased by 3.7g per month in treatment group (P=0.020) 
but not in placebo group (P=0.678) (Table 2.5). However, there was no significant 
difference observed in amount of CS usage between treatment and placebo group. 
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Table 2.4 Primary steroid (days) usage comparison at each visit 
After treatment, the duration (day) of using steroid in treatment group was 
remarkably reduced by average four days when compared with baseline (p=0.042). 
In placebo group only reduced 1 day (P=0.289). 
^ ！ 二 a - = = 4 3 ) ^ ^ p 她 e a 
Mean (SD) Mean (SD) 
V' month 19(11) 17(12) 0.550 
2nd month 16(12) 16(12) 0.888 
3rd month 16(12) 16(12) 0.869 
4th month 15(12) 16(13) 0.747 
P value b 0.042 0.289 
a Compared with placebo by Mann-Whitney U-test 
b Compared with baseline by Wilcoxon signed-rank test 
Table 2.5 Primary topical steroid: 1% mometasone furoate (g) usage 
comparison at each visit 
In treatment group the usage of primary topical steroid (1% mometasone furoate) 
was significant decreased after 4 months treatment (P=0.020) when compared with 
baseline. No such change was seen in placebo group (P=0.678). 
TCM (n=39) Placebo (n=40) a 
顺 Mean (SD) Mean (SD) [ vame 
ist month 11.03 (12.91) 11.98 (15.14) 0.765 
month 8.17 (10.42) 8.94 (10.95) 0.750 
3rd month 8.51 (9.68) 11.21 (14.97) 0.346 
4th month 7.32 (8.13) 11.57 (14.81) 0.120 
P value b 0.020 0.678 
a Compared with placebo by Student t test 
b Compared with baseline by paired t test 
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3.3.4. Amount of Antihistamine Usage 
No significant difference was observed in amount of antihistamine usage 
within treatment or placebo group as compared with baseline and between the 
treatment and placebo groups. The result was shown in Table 2.6. 
Table 2.6 Primary antihistamine (piriton or equivalent) usage (days/ month) 
There was no difference in the duration of antihistamines usage between the two 
groups. 
TCM (n=37) Placebo (n=40) ^ 
憶 Mean (SD) Mean (SD) ^ 
ist month 9.3(11.9) 13.3(14.5) 0.200 
month 10.6(11.8) 12.0(14.4) 0.584 
3rd month 12.3 (12.6) 13.6(16.4) 0.621 
4th month 10.2(12.3) 11.3(15.1) 0.703 
P value b 0.395 0.386 
a Compared with placebo by Mann-Whitney U-test 
b Compared with baseline by Wilcoxon signed-rank test 
3.3.5. Allergic Rhinitis Score 
Thirty-five participants in treatment group and 36 participants in placebo 
group had allergic rhinitis symptoms. Significant difference in overall ARS and 
components of ARS was observed for sneezing score but not the other components. 
Sneezing symptom significantly improved in treatment group from a mean (SD) of 
1.51 (0.92) to 1.06 (1.11) (P=0.003), but not in placebo group (P=0.213). However, 
significant difference in sneezing score was not observed between the two groups 
(Table 2.7 and 2.8). 
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Table 2.7 Overall allergic rhinitis score comparison at each visit 
There were no differences in overall ARS between the two groups at each visit. 
Treatment (n=35) Placebo (n=36) , 
Mean (SD) Mean (SD) 誦 e 
Visit 1 (Baseline) 1.63 (0.91) 1.86 (0.93) 0.291 
Visit 2 1.46 (0.92) 1.69 (0.75) 0.236 
Visit 3 1.46 (0.92) 1.67 (0.83) 0.316 
Visit 4 (end of treatment) 1.49 (0.92) 1.67 (0.76) 0.368 
P value b 0.377 0.228 
Visit 5 (end of study) 1.66 (0.84) 1.58(0.91) 
a Compared with placebo by Student t test 
b Compared with baseline by paired t test 
Table 2.8 Sneezing scores comparison at each visit 
Sneezing symptom score in treatment group was remarkably improved after treatment 
at visit4. No such changes were observed in placebo group. 
Treatment (n=35) Placebo (n=36) a 
Mean (SD) Mean (SD) 厂 vaiue 
Visit 1 (Baseline) 1.51 (0.92) 1.61 (0.77) 0.631 
Visit 2 1.14 (0.94) 1.36 (0.99) 0.345 
Visit 3 1.11 (0.90) 1.25 (0.91) 0.529 
Visit 4 (end of treatment) 1.06 (1.11) 1.42 (1.03) 0.160 
P value b 0.003 
Visit 5 (end of study) 1.40(1.01) 1.22 (0.90) 
a Compared with placebo, by Student t Test 
b Compared with baseline, by paired t Test 
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3.3.6. Blood chemistry and Haematology 
There were no significant difference in white cell count, eosinophil count and 
serum IgE levels between the two groups before and after treatment. Results were 
summarized in Table 2.9. 
Table 2.9 White cell count, eosinophil count and serum IgE level 
comparison at visit 1 and visit 4 
There were no differences in the white cell count, eosinophil count, and serum IgE 
level between the two groups pre- and post-treatment. 
Study visit Treatment Placebo P value ^ 
Mean (SD) Mean (SD) 
White cell c o u n t V i s i t 1 7.41 (1.98) 8.04 (2.07) 0 . 1 3 0 ^ 
(XIOVL) Visit 4 7 .48 (2 .45) 7 .62 (1 .91 ) 0 . 466 
Eosinophil count Visit 1 0.73 (0.42) 0.78 (0.49) 0.966 
(X109/L) Visit 4 0.72 (0.50) 0.73 (0.41) 0.764 
IgE Visit 1 6321.57 (7604.86) 8167.76 (15944.20) 0.471 
Visit 4 8177.81 (12185.44) 7952.53 (13297.16) 0.209 
a Compared with placebo by Mann-Whitney U-Test 
3.3.7. Plasma TARC and BDNF levels 
The mean (SEM) plasma levels of TARC and BDNF are shown in the table 
below (Table 2.10), and there was no statistical difference in plasma levels of these 
two inflammatory mediators within each group and between the two treatment 
groups before or after treatment. 
Plasma TARC levels showed significant correlations with SCORAD (r=0.678, 
P<0.001) and QoL score (r=0.272, P=0.013), while BDNF levels correlated with 
SCORAD (r=0.257, P=0.021). There was also a significant positive correlation 
between plasma levels of TARC and BDNF (r-0.502, P<0.001). 
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Table 2.10 Plasma levels of TARC and BDNF: comparison at visit 1 and visit 
4 
Plasma concentrations of TACR and BDNF are expressed in mean (SEM) (pg/ml). 
No difference in level of TARC and BDNF was found within or across groups after 
the 3-month trial. 
Inflammatory Study visit Treatment Placebo P value a 
mediator 
TARC Visit 1 1179.38 ( 3 2 4 . 9 0 ) 1 0 2 1 . 2 8 ( 2 4 0 . 3 6 ) 0 . 7 5 0 
Visit 4 1089.94 (301.10) 941.48 (227.67) 0.386 
P value^ 0.124 0.397 
BDNF Visit 1 3171.43 (410.32) 3853.94 (447.23) 0.237 
Visit 4 3655.29 (523.91) 3935.67 (559.46) 0.620 
Pvalueb 0.221 0.687 
a Compared with placebo by Mann-Whitney U-Test 
b Compared with baseline by Wilcoxon Signed Ranks Test 
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3.4. Tolerability 
The PHF was generally well tolerated. Table 2.11 lists all adverse events as 
reported by more than one patient. No significant difference in frequency of adverse 
events was noted between treatment and placebo groups. Analysis of biochemical 
data also showed no significant change in any biochemical parameter (electrolytes, 
renal, and liver functions) (Table 2.12). All patients had normal renal and liver 
functions following PHF treatment. 
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Table 2.11 Adverse events reported by more than one participant (number of 
participants reporting) 
^ i Treatment Placebo i c Events , , … P value 
(11=42) (n =43) 
Upper respiratory tract infection 8 9 0.828 
Diarrhea 3 0 0.074 
Abdominal pain 4 2 0.381 
Episodes of asthma 6 3 0.274 
New rash 8 5 0.342 
Miscellaneous ^ 6 4 0.476 
Hospitalization 2 2 0.981 
GP visits b 21 11 0.020 
Antibiotic for >3 days 12 6 0.099 
Topical / Oral Steroid 5 1 0.085 
Away from Hong Kong 7 4 0.312 
a For treatment group: pustules, dizziness, bronchitis, ringworm, pompholyx, and 
pneumonia. For placebo group: pustules, appendicetomy, menstrual disturbance, 
haematuria 
b GP visits may include prescription of various antihistamines, topical steroids, and 
oral antibiotics. Two patients in the treatment group and one patient in the placebo 
group had been prescribed brief course of oral corticosteroids. 
e Compared with placebo by Mann-Whitney U-Test 
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Table 2.12 Blood chemistry monitored at visit 1 and visit 4 
There were no statistical difference in blood chemistry between the two groups pre-
and post-treatment. 
Study visit Treatment Placebo P value ^ 
Mean (SD) Mean (SD) 
Sodium Visit 1 139.05 (1.68) 139.60 (1.61) 0.122 
Visit 4 139.46 (2.13) 139.24 (1.74) 0.617 
Potassium Visit 1 3.96 (0.31) 4.11 (0.60) 0.167 
Visit 4 4.07 (0.61) 3.96 (0.30) 0.316 
Phosphorus Visit 1 1.44 (0.26) 1.51 (0.17) 0.402 
Visit 4 1.91 (1.43) 1.43 (0.19) 0.333 
Calcium Visit 1 2.48 (0.08) 2.47 (0.10) 0.721 
Visit 4 2.47 (0.13) 2.44(0.13) 0.675 
Adjusted Visit 1 2.37 (0.10) 2.36 (0.11) 0.868 
Calcium Visit 4 2.34 (0.12) 2.36 (0.11) 0.751 
Urea Visit 1 4.40 (0.98) 4.43 (0.98) 0.896 
Visit 4 4.33 (0.97) 4.44 (0.82) 0.574 
Creatinine Visit 1 53.76 (11.54) 55.26 (13.96) 0.593 
Visit 4 56.38 (14.56) 54.29 (14.06) 0.515 
Total Protein Visit 1 77.02 (5.23) 76.42 (4.92) 0.584 
Visit 4 75.82 (5.73) 75.83 (4.15) 0.994 
Albumin Visit 1 44.05 (2.46) 43.95 (2.65) 0.866 
Visit 4 44.08 (3.54) 43.51 (2.77) 0.428 
Total Bilirubin Visit 1 8.14 (4.24) 7.23 (3.35) 0.280 
Visit 4 7.66 (2.75) 7.10 (3.11) 0.410 
Alkaline Visit 1 207.07 (105.99) 189.09 (82.67) 0.385 
phosphate Visit 4 199.57 (97.74) 200.08 (72.87) 0.979 
ALT/GPT Visit 1 19.36 (6.60) 20.34 (10.06) 0.609 
Visit 4 19.91 (5.98) 21.03 (11.86) 0.619 
a Compared with placebo by Student t test 
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Sec t ion 3： IN VITRO STUDY OF PENTAHERBS 
CHAPTER 1 
Objectives and Study Design 
The pharmacological mechanisms of PHF concoction remain unknown. We 
hypothesized that it possesses immunomodulatory properties that accounts for the 
clinical efficacy in treating AD. To delineate its immunomodulatory effects, an in 
vitro study was proposed. The study included: (i) Limulus Amebocyte Lysate test for 
quantifying the degree of endotoxin contamination in the PHF preparation; (ii) 
Trypan blue exclusion assay for evaluating the cytotoxic effects on human peripheral 
blood mononuclear cells (PBMC); (iii) Tritiated-thymidine incorporation assay for 
estimating mitogenicity on PBMC; (iv) Enzyme-linked immunosorbent assay 
(ELISA) and reverse transcription-polymerase chain reaction (RT-PCR) for 
quantifying at protein and RNA levels the inflammatory mediators released cultured 
PBMC. 
The PBMC were stimulated by mitogen (phytohaemagglutinin: PHA) or 
superantigen (SEB) prior to all the assays to mimic the allergen-stimulating 
environment in AD. Five inflammatory mediators (TNF-a: proinflammatory 
cytokine; IFN-y: THI cytokine, Epithelial-derived neutrophil-activating protein 78 
(ENA-78): neutrophilic chemokine; BDNF: neurotrophin, and TARC: chemokine), 
all of which being closely related to the pathogenesis of AD, were chosen for the 
study. The immunomodulatory effects of PHF on above inflammatory mediators in 
vitro were investigated. 
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CHAPTER 2 
Materials and Methods (In vitro Study) 
2.1. Materials for in vitro study 
2.1.1. Preparation of the Water Extracts of PHF Capsules 
• Phosphate-buffered saline (PBS) 
It was from Gibco™ Invitrogen Corp (Carlsbad, CA, USA). 
• 0.2 |Lim polyethersulfone filter 
It was from Coming Inc Life Sciences (Acton, MA, USA). 
2.1.2. Endotoxin Assay 
• QCL-1000® Chromogenic Limulus Amebocyte Lysate (LAL) kit 
It was from BioWhittaker Inc (Walkersville，MD, USA). 
• Water for injections B.P. (WFI) 
The non-pyrogenic WFI was from B. Braun Medical Industries S/B (Penang, 
Malaysia). 
• Stop solution 
It was prepared by dissolving sodium dodecylsulfate (SDS) powder (Sigma Chemicals, 
St. Louis, MO, USA) in pyrogen-free water to a final concentration of 10% (w/v). 
• Ninety-six-well immunolon plate 
It was from Nalge Nunc International (Rochester, NY, USA). 
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2.1.3. Cell isolation and culture of PBMC 
2.1.3.1.Cell Isolation from Human Peripheral Blood 
• Ficoll-pague™ plus solution 
It was from Amersham Pharmacia (Uppsala, Sweden). 
• COULTER® AC.T Diff™ 
It was from Beckman Coulter Inc (Fullerton, CA, USA). 
2.1.3.2.Culture of Peripheral Blood Mononuclear Cells (PBMC) 
• RPMI media 1640: with L-glutamine 
It was from Gibco™ Invitrogen Corp (Carlsbad, CA, USA). 
• Fetal bovine serum (FBS) 
It was from Gibco™ Invitrogen Corp (Carlsbad, CA, USA). FBS was added to the 
RPMI medium to a final concentration of 10 % (v/v). 
• Penicillin-streptomycin antibiotic mixture (P/S) 
It was from Gibco™ Invitrogen Corp (Carlsbad, CA, USA) as lOOX stock solution, 
which contains 10000 units/ml penicillin G sodium and 10000 |Lig/ml streptomycin 
sulfate in 0.85 % saline. The antibiotic mixture was added to the RPMI medium to a 




It was from Gibco^^ Invitrogen Corp (Carlsbad, CA, USA) as lOOX stock solution, 
which contains 29.2 mg/ml L-glutamine in 0.85% saline. The L-glutamine solution 
was added to the RPMI medium to a final concentration of 1 % (v/v). 
• Polymyxin B (PMB) 
It was from Sigma Chemicals (St. Louis, MO, USA). The stock solution was prepared 
by dissolving PMB powder in PBS at concentration 50 mg/ml and stored at -20°C. The 
stock PMB solution was added to the RPMI medium to a final concentration of 10 
|ig/ml. 
• Phytohaemagglutinin 
It was from Sigma Chemicals (St. Louis, MO, USA). The stock solution was prepared 
by dissolving PHA powder in PBS at a concentration of 100 |ig/ml and stored at -20°C. 
The stock PHA solution was added to the RPMI medium to a final concentration of 10 
|ig/ml. 
• Staphylococcal enterotoxin B 
It was from Sigma Chemicals (St. Louis, MO, USA). The stock solution was prepared 
by dissolving SEB powder in PBS at concentration 10 |ig/ml and stored at -20°C. The 
stock SEB solution was added to the RPMI medium to a final concentration of 100 
ng/ml. 
• Dexamethasone (DEX) 
It was from Sigma Chemicals (St. Louis, MO, USA). The stock solution was prepared 
by dissolving DEX powder in PBS at concentration 50 |iM and stored at 4°C. 
• Cell culture wares 
The 6-well plates, 96-well plates, centrifuge tubes, and 10 ml serological pipets were 
from Becton Dickinson Labware (Franklin Lakes, NJ, USA). 
71 
2.1.4. Trypan Blue Exclusion Assay 
• Trypan blue dye 
Trypan blue powder was from Sigma Chemicals (St. Louis, MO, USA). 0.4% (w/v) 
stock trypan blue dye was prepared by dissolving trypan blue powder in PBS at 
concentration 4 mg/ml. 
• Haemocytometer 
Cell number was determined by direct cell count using haemocytometer from Sigma 
(St. Louis, MO, USA). 
2.1.5. f3Hl-Thvmidine Incorporation Assay 
• -thymidine 
It was from Amersham Biosciences (Piscataway, NJ, USA) at a concentration of 1 
mCi/ml. The working solution was prepared by 20-fold dilution of stock solution by 
RPMI 1640 medium and stored at 4°C. 
• Beta-scintillation counter 
It was from Microbeta TriLux; EG & G Wallac (Turku, Finland). 
2.1.6. Supernatant Collection and ELISA 
• ELISA Assay Kits 
ELISA kits for quantifying the concentrations of brain-derived neurotrophic factor 
(BDNF), epithelial neutrophil activating peptide (ENA-78), and thymus activation 
regulated cytokine (TARC) were purchased from R & D Systems (Minneapolis, MN， 
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USA). The minimum detectable limits in pg/ml were 20, 15 and 7, respectively. 
ELISA kits for quantifying the concentrations interferon-gamma (IFN-y) and tumor 
necrosis factor-alpha (TNF-a) were purchased from BioSource (Camarillo, CA, USA). 
The minimum detectable limits in pg/ml were 2 and 1.7, respectively. 
2.1.7. RNA Extraction and RT-PCR 
2.1.7.1.Reagents for RNA Extraction 
• TRIzol 
It was from Invitrogen Life Technologies (Carlsbad, CA, USA). 
• Bromo-3-chloropropane (BCP) 
It was from Sigma Chemicals (St. Louis, MO, USA). 
2.1.7.2.Reagents for Reverse Transcription 
• 01igo(dT)18 
It was synthesized by Invitrogen, Life Technologies (Carlsbad, CA, USA). The 
lyophilized powder was reconstituted in autoclaved double distilled water to 100 |LIM. 
• lOmM dNTP mix 
It was from Amersham Biosciences (Piscataway, NJ, USA). 
• Reverse transcriptase and reaction buffer 
The M-MLV reverse transcriptase (200 units/|il) and the 5x reaction buffer were 
from USB Corp (Cleveland, OH, USA). The 5x reaction buffer contains 250mM 
Tris-HCl (pH 8.3), 395mM KCl, 15mM MgCli, 50mM DTT. 
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• Ribonuclease inhibitor 
RNAGuard ribonuclease inhibitor (30 U/|LI1) isolated from human placenta was from 
Amersham Biosciences, (Piscataway, NJ, USA). It was supplied in buffer containing 
20 mM HEPES-KOH, pH 7.6, 50 mM KCl, 5 mM DTT, and 50% (v/v) glycerol. 
2.1.7.3.Reagents for Polymerase Chain Reaction 
• DNA primers 
They were synthesized by Invitrogen, Life Technologies (Carlsbad, CA, USA). The 
lyophilized powder was reconstituted in autoclaved double distilled water to 100 jiM 
and stored in -20°C.10 jiM as working primers were prepared by 10-fold dilution of 
the 100|LIM stock solution with autoclaved double distilled water. 
• Taq DNA polymerase and reaction buffer 
Taq DNA Polymerase (5 U/|LI1) and lOx reaction buffer were from Roche Diagnostics 
Corp (Indianapolis, IN, USA). The lOx reaction buffer contained 100 mM Tris-HCl, 
15 mM MgCl2, and 500 mM KCl. 
參 Thermal cycler 
The thermal cycler (MJ Research PTC-200 Thermal Cycler) was from Bio-Rad 
Laboratories (Hercules, CA, USA). 
2.1.7.4.Reagents for Gel Electrophoresis 
• Agarose 
It was from USB Corp (Cleveland, OH, USA). All DNA fragments were separated 
on 2 % (w/v) agarose gel. 
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• lOX Tris-acetate-EDTA (TAE) electrophoresis buffer 
Stock lOX TAE buffer was prepared by dissolving 48.4 g of tris base (Amersham 
Biosciences, Buckinghamshire, UK), 11.42 ml of glacial acetic acid (Sigma, St Louis, 
MO, USA) and 20 ml of 0.5 M EDTA, pH 8.0 (Sigma, St Louis, MO, USA) in 1-liter 
double distilled water. The IX working solution was prepared by 10-fold dilution of 
the stock TAE. 
• lOX loading dye solution 
It was prepared by mixing 0.25 % (w/v) bromophenol blue (Amersham Biosciences, 
Piscataway, NJ, USA), 0.25 % (w/v) xylene cyanol FF (ICN BioMedicals Inc, Irvine, 
CA, USA), and 67 % (v/v) glycerol (Amersham Biosciences, Piscataway, NJ, USA), 
in autoclaved double distilled water. 
• DNA ladder marker 
The lOO-lOOObp DNA ruler was from Bio-Rad Laboratories (Hercules, CA, USA). 
The working solution was prepared by mixing the stock DNA markers, 1 OX loading 
dye and autoclaved double distilled water in a ratio of 2:7:1. For each agarose gel, 6 
1^1 of working DNA ladder marker was loaded. 
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2.2. Methods 
2.2.1. Isolation and Culture PBMC 
2.2.1.1.Isolatioii of PBMC 
PBMC were isolated from fresh human buffy coat supplied by the Hong Kong 
Red Cross Blood Transfusion Service. Buffy coat was diluted 5-fold with PBS. The 
diluted samples (8 ml) were carefully layered on Ficoll-pague^"^ plus (4 ml) density 
gradient in 14 ml tubes. They were centrifuged at 900 x g for 45 minutes at 18°C 
without brake. PBMC collected at the interphase was washed with 5 ml PBS for three 
times (400 x g for 10 minutes; 300 x g for 8 minutes; 250 x g for 6 minutes). Cell count 
and differentiation was performed by COULTER® A^.T Diff™, and the typical results 
for PBMC purity of PBMC > 99.5% were achieved. The cell viability were > 98.5% 
by trypan blue exclusion assay. 
2.2.1.2.Culture of Isolated PBMC 
Isolated PBMC were resuspended at 1 x 10^ cells/ml in RPMI 1640 medium 
supplemented with 10% FBS, 1% P/S, 100 昭/ml L-glutamine and 10 |ig/ml PMB. 
Cells were seeded in either 96-well plate (trypan blue exclusion assay or thymidine 
incorporation assay) or 6-well plate (for collection of supernatant or RNA). 
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2.2.1.3.PHA/SEB Treatment 
Isolated PBMC were primed with either 10 |ag/ml PHA or 100 ng/ml SEB. It 
was incubated at 31�C chamber in a humidified atmosphere of 5% CO2 for 2 hours 
before addition of DEX or PHF extracts. 
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2.2.2. Preparation of PHF Water Extracts and Endotoxin Level 
2.2.1.1.Hot Water Extraction 
The water-soluble active ingredients pooled from four PHF capsules were 
isolated by heating the powder in pyrogen-free WFI (volume ratio 1:30) at 80°C for 4 
h. Supernatant was collected by centrifugation at 5,000 x g for 10 minutes at 4°C to 
remove any insolubles. The extract was filtered through 0.22 |Lim polyethersulfone 
filter twice, lyophilized for 48 hours, reconstituted in PBS at 20 mg/ml, and finally 
stored at -20°C. The extraction efficiency of hot water extraction was calculated by the 
following formula: 
( Weight of lyophilised content � ^ lOO�/ 
�Weight of staring powder from PHF capsules) 
2.2.1.2.Limulus Amebocyte Lysate Assay 
Endotoxin standards (0.125, 0.25, 0.5, 1.0 EU/ml) were prepared by 2-fold 
serial dilutions using pyrogen-free water. Standards, samples (PHF water extracts), 
96-well immunolon plate, LAL, and substrate were pre-equilibrated at 37°C for 10 
minutes. 50 |il of standard, sample or blank (pyrogen-free WFI) was dispensed into 
appropriate immunolon plate well in duplicates. 50 |il of LAL was dispensed into each 
well by a multi-channel pipettor. The immunolon plate was covered and incubated at 
37°C for 10 minutes. 100 [d of substrate was dispensed into each well in the same 
order as dispensing the LAL. The immunolon plate was covered and incubated at 37°C 
78 
for 6 minutes. The reaction was then terminated by the addition of 100 \x\ stop reagent. 
Absorbance was read immediately at 405 nm with reference wavelength at 490 nm. 
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2.2.3. Study on the Cytotoxic and Mitogenic Effects of PHF on PBMC 
PBMC (1x106 cells/ml, 200 |il/well) were seeded into 96-well plate for 
cytotoxicity and mitogenic assays. Cells were primed with PHA or SEB for 2 hours. 
2.2.3.1.Trypan Blue Exclusion Assay 
Cells were treated with various concentrations of DEX as internal positive 
control and PHF extracts at 37°C for another 24 hours. Cell pellets were collected by 
centrifugation at 3,000 rpm for 10 minutes. The pellets were then resuspended in 40 fil 
0.2 0/0 trypan blue dye (Stock 0.4 % trypan blue dye diluted by equal volume of PBS 
and incubated for 15 minutes. Cell count was performed by haemocytometer. Dead 
cells were identified by the intake of trypan blue while viable cells remained 
translucent. The percentage of cell viability was calculated by the following 
formula: 
f Total number of unstained cells ) , ^ … 
X 100% 
V Total number of cells 7 
2.2.3.2.[3H]-Thymidine Incorporation Assay 
The mitogenic activities of PHF on PBMC were assessed by [^H]-thymidine 
incorporation assay as previously described (Leung et al, 2004b). Assay was 
performed in triplicates. PHA- or SEB-primed cells were treated with various 
concentrations of DEX and PHF extracts in at 37°C for 18 hours. They were then 
pulsed with 1 |iCi [^H]-thymidine per well and incubated at 37°C for another 6 hours. 
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Cells were harvested and lysed by an automated cell harvester onto a filter paper. 
The radioactivity (counts per minute, CPM) was measured by the beta-scintillation 
counter, and expressed as percentage of maximum proliferation in the wells with 
only PHA or SEB as the background. 
‘ A v e r a g e CPM of wells with DEX or PHF ^ 乂 聊 , 。 
�Average CPM of wells with PHA or SEB only J 
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2.2.4. Study on the Effect of PHF on PBMC Inflammatory Mediator Production 
PBMC (1x106 cells/ml, 2 ml/well) were seeded into 6-well plate for the 
collection of supernatant and RNA. Following priming with PHA or SEB for 2 hours, 
the cells were treated with 100 nM DEX as internal positive control, and 10 |ig/ml or 
100 昭/ml PHF extracts at 37�C for another 24 hours. 
2.2.4.1.Measurement of Inflammatory Mediators in Culture Supernatant by 
ELISA 
a) Collection of Supernatant 
Culture supernatant was centrifuged at 3,000 rpm for 10 minutes at 4°C to 
remove any cell debris before quantification of inflammatory mediators by ELISA. It 
was stored at -20°C before use. 
b) ELISA 
Expression levels of inflammatory mediators were quantified by 
sandwich-type ELISA. Assay was performed in duplicates according to the 
manufacturers' instructions. 
In brief, assay diluent was added to each well. Standards or samples (with 
appropriate dilution) were dispensed to wells coated with primary antibody against 
respective inflammatory cytokine. The plate was covered and incubated for 1-2 hours 
at room temperature. The plate was washed three times with wash buffer. Secondary 
antibody (conjugated with horseradish peroxidase) against respective inflammatory 
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mediator was dispensed to each well. The plate was covered and incubated for 1-2 
hours. The plate was washed with wash buffer three times. Substrate (Stabilized 
hydrogen peroxide and tetramethylbenzidine) was added and incubated in the dark for 
30 minutes. The reaction was stopped by the addition of sulfuric acid. Absorbance was 
read at 450 nm with X correlation at 570 nm. 
The results were expressed as percentage changes of these inflammatory 
mediators according to the following formula: 
‘[Inflammatory mediator with DEX or PHF]- ’ 
[Inflammatory mediator with PHA or SEB only] 
X 100% 
[Inflammatory mediator with PHA or SEB only] 
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2.2.4.2.Semi-quantification of Inflammatory Mediator mRNA Levels by 
RT-PCR 
a) Isolation of Total RNA 
PBMC was homogenized in 1 ml TRIzol and harvested by scrapping. The 
lysate was incubated at room temperature for 5 minutes and then mixed vigorously 
with 0.1 ml BCP. The aqueous phase was collected after centrifugation at 12,000 x g 
for 15 minutes at 4°C. RNA was precipitated with 0.75 ml isopropanol overnight at 
-20°C. RNA pellets were collected by centrifugation at 12,000 x g for 15 minutes at 
4°C and washed with 75% ethanol. Ethanol was removed by centrifugation at 7,500 x 
g for 5 minutes at 4°C. The RNA pellets were air-dried at room temperature, dissolved 
in 20 [i\ RNase-free water, and finally stored at -80°C until analysis. 
RNA concentration was quantified at 260 nm. The purity was estimated by the 
ratio of A260/A280 and only samples with values greater than 1.7 were used for further 
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experiments. The integrity of isolated RNA was checked by gel electrophoresis on 1% 
agarose gel and two predominant bands of 18S (~2 kb) and 28S ( � 5 kb) ribosomal 
RNA in a ratio of 1:2 should be visualized. 
b) Reverse Transcription (RT) 
Two micrograms of total cellular RNA was used as template for RT. In brief, 
total RNA was first incubated with 0.1 ^mole oligo(dT)i8 at 75°C for 5 minutes for 
denaturing of RNA. 0.5 fil (15 units) of ribonuclease inhibitor, 0.5 f^ l (100 units) of 
reverse transcriptase, 1.25 i^l of dNTP mix, 5 i^l of 5x reaction buffer, and appropriate 
amount of RNase-free water were added to the mixture to give a final volume of 25 fil. 
The reaction mixture was incubated at 42°C for 1 hour for cDNA synthesis and 
heat-inactivated at 75°C for 10 minutes. cDNA product was diluted to 125 |il by 
autoclaved double distilled water and stored at -20°C for further use. 
c) Polymerase Chain Reaction 
5 |Lil of diluted cDNA was used as template per 25 |LI1 PGR reaction. The 
components, primer sequences and conditions for PGR are shown in Table 3.1, 3.2 and 
3.3) below: 
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Table 3.1 Components in the PCR amplification 
Component Volume _ 
1 OX reaction buffer 2.5 
10 mM dNTP mix 0.5 
10 [iM Forward primer 0.5 
10 \aM Reverse primer 0.5 
Diluted cDNA 5 
Autoclaved H2O 15.8 
Tag DNA polymerase ^ 
Total: 25 
Table 3.2 Primer sequences specific for different genes 
Gene Primer set 
^ B D N F F: 5,-AAA CAT CCG AGG ACA AGG TG-3, 
R: 5'-TGG CCT TTT GAT ACA GGG AC-3' 
ENA-78 F: 5,-CGT TGC GTT TGT TTA CAG ACC-3' 
R: 5'-GTT TTC CTT GTT TCC ACC GTC-3' 
TARC F: 5,-TGC AGC ACA TCC ACG CAG CTC-3' 
R: 5'-ACT TTA ATC TGG GCC CTT TGT GCC-3' 
IFN-y F: 5'-GGA CCC ATA TGT AAA AGA AGC AGA-3, 
R: 5,-TGT CAC TCT CCT CTT TCC AAT TCT-3' 
TNF-a F: 5'-AGA GGG AAG AGT TCC CCA GGG-3' 
R: 5’-ATA GAT GGG CTC ATA CCA GGG CTT-3' 
GAPDH F: 5,-CAT CAC CAT CTT CCA GGA GC-3' 
R: 5,-TGG CAT GGA CTG TGG TCA TG-3, 
Table 3.3 PCR cycling conditions specific for different genes 
Annealing temperature Number of cycles Product size 
56�C 38 456bp 
56�C 35 201 bp 
62�C 30 424bp 
56�C 38 121bp 
62�C 27 410bp 
56�C ^ 283bp 
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d) Gel Electrophoresis and Quantification 
PCR products were separated in 2% agarose gel. The band intensity on agarose 
gel was quantified by Image J software (Research Services Branch, National Institute 
of Mental Health, Bethesda, MD, USA). The band intensities of target inflammatory 
mediators were expressed as a fraction to the band intensity of GAPDH. Results were 
expressed in changes in RT-PCR signals with reference to the samples treated with 
PHA or SEB only. 
2.2.5. Statistical Analysis 
Continuous variables between baseline and PHA- or SEB-stimulated 
subgroups were compared by Kruskal-Wallis test or Mann-Whitney U test as 
appropriate. All comparisons were made two-tailed using SPSS 13.0 (Chicago, IL, 
USA). Bonferroni correction was performed on the results, and the level of 
significance set at 5% except for inflammatory mediator measurements, which was 
set at 1% to adjust for multiple statistical comparisons. 
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CH APTER 3 
Results {In vitro Study) 
3.1. Preparation of PHF Water Extracts and Endotoxin Level 
Each PHF capsule contained 0.25-0.30 mg yellowish-brown powder. The 
powder was only partially soluble in PBS after heated for 4 hours in 80°C water bath. 
The filtered water extract of PHF was clear yellowish-brown. Powder from four PHF 
capsules was pooled together for one single hot water extraction. The extraction 
efficiency of the water-soluble ingredients in PHF was 71.8%. The endotoxin 
contamination of our PHF extract was 9.68 EU/mg of PHF powder. The possible 
effects of this endotoxin contamination on our subsequent in vitro studies were 
minimized by the addition of 10 |ig/ml PMB in all assays (Lee et al, 2006; Fu et al, 
2006). 
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3.2. Cytotoxicity Effect of PHF on PBMC 
The cytotoxicity of PHF on PBMC was assessed in order to establish the 
optimal doses of PHF for our in vitro experiments. Figure 3.1 illustrates that the PHF 
concentrations (up to 1 mg/ml) was inversely associated with the cell viability. The 
higher the concentration of PHF used, the higher was its toxicity on PBMC. PBMC 
viability was retained >80% at PHF concentration <100 |ig/ml following either PHA 
or SEB stimulation. Figure 3.2 shows the effect of different doses (1 nM to 5000 nM) 
of DEX on PHA- or SEB-stimulated PBMC. The viability of PBMC retained >80% 
under all test doses of DEX. DEX up to 5mM was non-toxic to cells in our system. 
Two dosages (10 |ig/ml and 100 |ig/ml) of PHF extract were chosen for 
subsequent assays to study the effects on PHF, and 100 nM of DEX was used as 
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Figure 3.1a Effects of different PHF extract concentrations on PBMC 
cytotoxicity in response to PHA stimulation 
PHA-primed PBMC (1 x 10^ cells/ml) were treated with different concentrations of 
PHF extracts for 24 hours incubated at 37°C. Cells were then harvested and trypan 
blue exclusion assay was performed. PHF showed dose-dependent cytotoxic effect 
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Figure 3.1b Effects of different PHF extract concentrations on PBMC 
cytotoxicity in response to SEB stimulation 
SEB-primed PBMC (1 x 10^ cells/ml) were treated with different concentrations of 
PHF extracts for 24 hours incubated at 37°C. Cells were then harvested and trypan 
blue exclusion assay was performed. PHF showed dose-dependent cytotoxic effect 
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Figure 3.2a Effects of different DEX concentrations on PBMC cytotoxicity in 
response to PHA stimulation 
PHA-primed PBMC (1 x 10^ cells/ml) were treated with different concentrations of 
DEX for 24 hours incubated at 37°C. Cells were then harvested and trypan blue 
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Figure 3.2b Effects of different DEX concentrations on PBMC cytotoxicity in 
response to SEB stimulation 
SEB-primed PBMC (1 x 10^ cells/ml) were treated with different concentrations of 
DEX for 24 hours incubated at 37°C. Cells were then harvested and trypan blue 
exclusion assay was performed. Results are presented in mean土SEM of six 
independent experiments. 
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3.3. Mitogenicity Effect of PHF on PBMC 
The in vitro effects of PHF and DEX on the proliferation of PHA- and 
SEB-stimulated PBMC were shown in Figure 3.3 and 3.4. 
PHF (up to 1 mg/ml) showed dose-dependent inhibition on PBMC 
proliferation following either PHA or SEB stimulation. The higher the concentration 
of PHF used, the greater was the suppression of cell proliferation. The IC50 (defined 
as the drug concentration causing half of the maximal cell proliferation) of PHF on 
PHA- and SEB-stimulated PBMC was 198.2 ^g/ml and 237.1 |Lig/ml respectively. 
The extent of suppression on PBMC proliferation also increased with 
increasing DEX concentrations. 
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Figure 3.3a Effects of different PHF extract concentrations on PBMC 
proliferation in response to PHA stimulation 
PHA-primed PBMC (1 x 10^ cells/ml) were treated with different concentrations of 
PHF extracts for 18 hours incubated at 37°C. Each well was then pulsed with 1 jiCi 
[^H]-thymidine and incubated for another 6 hours. Cells were then harvested and 
radioactivity was counted. PHF showed dose-dependent inhibition on 
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Figure 3.3b Effects of different PHF extract concentrations on PBMC 
proliferation in response to SEB stimulation 
SEB-primed PBMC (1 x 10^ cells/ml) were treated with different concentrations of 
PHF extracts for 18 hours incubated at 37°C. Each well was then pulsed with 1 |iCi 
[^H]-thymidine and incubated for another 6 hours. Cells were then harvested and 
radioactivity was counted. PHF showed dose-dependent inhibition on 
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Figure 3.4a Effects of different concentrations of DEX on PBMC proliferation 
in response to PHA stimulation 
PHA-primed PBMC (1 x 10^ cells/ml) were treated with different concentrations of 
DEX for 18 hours incubated at 37°C. Each well was then pulsed with 1 |iCi 
[^H]-thymidine and incubated for another 6 hours. Cells were then harvested and 
radioactivity was counted. DEX showed dose-dependent inhibition on 
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Figure 3.4b Effects of different concentrations of DEX on PBMC proliferation 
in response to SEB stimulation 
SEB-primed PBMC (1 x 10^ cells/ml) were treated with different concentrations of 
DEX for 18 hours incubated at 37°C. Each well was then pulsed with 1 |LiCi 
[^H]-thymidine and incubated for another 6 hours. Cells were then harvested and 
radioactivity was counted. DEX showed dose-dependent inhibition on 
SEB-stimulated PBMC proliferation. Results are presented in mean士SEM of 12 
independent experiments. 
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3.4. Effects of PHF on Expression of Inflammatory Mediators from PBMC 
Following Mitogen (PHA) Stimulation 
To elucidate the immunomodulatory role of PHF, we measured the 
expression of five inflammatory mediates (BDNF, ENA-78, TARC, IFN-y, and 
TNF-a) in PHA-stimulated PBMC under the influences of PHF and DEX. 
3.4.1. Effects of PHF on mRNA Expression of Inflammatory Mediators from 
PHA-stimulated PBMC 
The effects of PHF on mRNA expression of inflammatory mediators were 
evaluated by semi-quantitative RT-PCR. Table 3.4 illustrates the effects of PHF 
and DEX on inflammatory mediator mRNA expression in PBMC following PHA 
stimulation. Figure 3.5 shows the representative mRNA gel photo of individual 
inflammatory mediator in PBMC following PHA stimulation. In response to PHA 
stimulation, only IFN-y and TARC were suppressed by DEX treatment. 
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Table 3.4 Changes in RT-PCR signal intensities for five inflammatory 
mediators in PHA-stimulated PBMC in response to PHF and DEX treatments 
Isolated PBMC was primed with PHA for 2 hours followed by incubation with PBS 
(Baseline), 100 nM DEX, 10 |ig/mL PHF or 100 |ig/mL PHF for 24 hours at 37�C. 
Cells were then harvested and total cellular RNA was isolated. Two \ig of total 
RNA was subjected to reverse transcription and the inflammatory mediator genes 
were then amplified from the cDNA using specific primers. The PCR products were 
resolved by 2% agarose gel. Band intensities were quantified by ImageJ programme, 
and results were expressed as changes in band intensity relative to baseline. Data 
represent the mean 士 SEM of six independent experiments. Statistical significant 
difference compared to baseline by Mann-Whitney U test. Bonferroni correction was 
performed on the results, and level of significance set at 1% to adjust for multiple 
statistical comparisons. NS: no significant difference. 
DEX 100 nM PHF 10 |Lig/mL PHF 100 |ng/mL 
Mean 士 SEM p value Mean 士 SEM p value Mean 士 SEM p value 
BDNF -24.60+ 16.42 NS -5.98 ± 7.33 NS -24.79 + 21.10 NS 
ENA-78 -15.37 ±7.92 NS 7.50 ±10.52 NS 8.72 ± 8.89 NS 
IFN-y - 1 8 . 2 0 土 4.23 0 . 0 0 1 * -13.90 土 6.34 NS -11.78 ±7.51 NS 
TARC - 2 3 . 6 0 土 4.20 0 . 0 0 1 * -8.80 ±4.53 NS -8.14 土 4.73 NS 
TNF-a -29.73 ±12.23 NS -9.06 ±4.89 NS -2.41 ± 7.76 NS 
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Figure 3.5 Representative mRNA expressions as shown in gel photo of 
individual inflammatory mediator in PBMC following PHA stimulation 
Isolated PBMC was primed with PHA for 2 hours followed by incubation with PBS 
(baseline), 100 nM DEX (DEX), 10 |Lig/mL PHF (PHF 10) or 100 ^ig/mL PHF 
(PHF 100) for 24 hours at 37�C. Cells were then harvested and total cellular RNA 
was isolated. Two fig of total RNA was subjected to reverse transcription and the 
inflammatory mediator genes were then amplified from the cDNA using specific 
primers. The PCR products were resolved by 2% agarose gel. 
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3.4.2. Effects of PHF on Secretion of Inflammatory Mediators from 
PHA-stimulated PBMC 
Table 3.5 summarizes the effects of PHF on release of inflammatory 
mediators from PHA-stimulated PBMC. Data was expressed as changes in the 
concentrations of inflammatory mediators as compared with the baseline. 
Figure 3.6 illustrates the effects of PHF and DEX on inflammatory mediator 
concentrations in PBMC culture supernatants following PHA stimulation. In general, 
DEX suppressed inflammatory mediators released from PBMC whereas the effects 
associated with PHF extract were more specific. The addition of higher PHF (100 
|ig/ml PHF) to PBMC reduced supernatant concentrations of BDNF, IFN-y and 
TNF-a in response to PHA. Lower dose of PHF (10 |ig/ml PHF) was unable to 
suppress the secretion of inflammatory mediators from PHA-stimulated PBMC. A 
higher dose of PHF induced the release of ENA-78. 
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Table 3.5 Changes in concentrations for five inflammatory mediators in 
PHA-stimulated PBMC in response to PHF and DEX treatments 
Isolated PBMC was primed with PHA for 2 hours followed by incubation with PBS 
(baseline), 100 nM DEX, 10 |ig/mL PHF or 100 |ag/mL PHF for 24 hours at 37�C. 
Supernatants were collected and ELISA was performed to quantify the secretory 
levels of the mediator. Results were expressed as changes in concentration of 
mediator relative to baseline. Data represent the mean 士 SEM of 10 independent 
experiments. *: Statistical significant difference compared to baseline by 
Mann-Whitney U test. Bonferroni correction was performed on the results, and level 
of significance set at 1% to adjust for multiple comparisons. NS: no significant 
difference. 
DEX 100 nM PHF 10 |ig/mL PHF 100 [ig/mL 
Mean 士 SEM p value Mean ± SEM p value Mean 土 SEM p value 
BDNF -14.34 ±3.16~0.002* -2.29 ±3.28 ^ -8.69 ± 1.81 0.002* 
ENA-78 - 6 2 . 9 8 士 11.60 0 . 0 0 2 * -14.53 ±6.66 NS 4 7 . 5 6 土 12.38 0.007* 
IFN-y - 9 2 . 6 5 士 1.86 <0.00P 14.93 士 11.23 NS -22.27 土 4.15 < 0 . 0 0 1 * 
TARC - 6 8 . 9 2 土 8.84 < 0 . 0 0 1 * 1.79 ±7.10 NS 4.06 ± 9.75 NS 
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Figure 3.6 Effects of addition of 100 nM DEX (DEX) and PHF extracts at 10 
Hg/ml (PHFIO) and 100 jig/ml (PHFIOO) on percentage changes of supernatant 
concentrations of five inflammatory mediators [(i) BDNF，(ii) ENA-78, (iii) 
IFN-y, (iv) TARC, and (v) TNF-a] following PHA stimulation 
Data represent the mean 土 SEM of 10 independent experiments. Statistical 
significant difference compared to baseline by Mann-Whitney U test. Bonferroni 
correction was performed on the results, and the level of significance set at 1% to 
adjust for multiple statistical comparisons. 
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3.4.2. Effects of PHF on S e c r e t i o n of Inflammatory Mediators from 
SEB-stimuIated PBMC 
To elucidate the immunomodulatory role of PHF under the influence of SAgs, 
we measured the expression of five inflammatory mediates (BDNF, ENA-78, IFN-y, 
TARC, and TNF-a) in SEB-stimulated PBMC under the influences of PHF and 
DEX, 
3.5.1. Effects of PHF on mRNA Expression of Inflammatory Mediators from 
SEB-stimulated PBMC 
The effects on mRNA expression of inflammatory mediators by PHF were 
evaluated by semi-quantitative RT-PCR. 
Table 3.6 illustrates the effects of PHF and DEX on inflammatory mediator 
mRNA expression in PBMC following SEB stimulation. Figure 3.7 shows the 
representative mRNA expression (gel photo) of individual inflammatory mediator in 
PBMC following SEB stimulation. In response to SEB stimulation, secretions of 
all mediators except BDNF were suppressed by DEX treatment. 10 |Lig/mL PHF 
could suppress expression of IFN-y significantly. High dose of PHF significantly 
inhibited the expression of TARC and TNF-a. 
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Table 3.6 Changes in RT-PCR signal intensities for five inflammatory 
mediators in SEB-stimulated PBMC in response to PHF and DEX treatments 
Isolated PBMC was primed with SEB for 2 hours followed by incubation with PBS 
(baseline), 100 nM DEX, 10 |Lig/mL PHF or 100 |Lig/mL PHF for 24 hours at 37�C. 
Cells were then harvested and total cellular RNA was isolated. Two |Lig of total 
RNA was subjected to reverse transcription and the inflammatory mediator genes 
were then amplified from the cDNA using specific primers. The PCR products were 
resolved by 2% agarose gel. Band intensities were quantified by ImageJ programme, 
results were expressed as changes in band intensity relative to baseline. Data 
represent the mean 士 SEM of six independent experiments. *: Statistical significant 
difference compared to baseline by Mann-Whitney U test. Bonferroni correction was 
performed on the results, and the level of significance set at 1% to adjust for multiple 
comparisons. NS: no significant difference. 
DEX 100 nM PHF 10|ig/mL PHF 100 |ig/mL 
Mean 土 SEM p value Mean 土 SEM p value Mean 土 SEM p value 
B D N F -15.55 ± 13.09 NS -10.78 ± 4 . 6 1 ^ -16.57 ± 9 . 7 2 NS 
ENA-78 - 4 0 . 1 5 土 6.72 0.001* -6.18±3.41 NS -6.91 ± 3.48 NS 
IFN-y -15.17 ± 5.91 0.026 -16.09 ±3.89 0.001* -16.96 ±6.61 NS 
TARC - 3 0 . 3 5 ± 8 . 3 7 0 . 0 0 1 * -10.30 ±9.61 NS - 2 1 . 3 1 土 7.60 0 . 0 0 1 * 
TNF-a - 3 1 . 1 7 土 5.26 O.OOl* -13.71 ±5.66 NS - 1 8 . 8 2 土 5 . 5 3 0 . 0 0 1 * 
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Figure 3.7 Representative mRNA expression (gel photo) of individual 
inflammatory mediator in PBMC following SEB stimulation 
Isolated PBMC was primed with SEB for 2 hours followed by incubation with PBS 
(baseline), 100 nM DEX (DEX), 10 ng/mL PHF (PHF 10) or 100 [ig/mL PHF 
(PHF 100) for 24 hours at 37°C. Cells were then harvested and total cellular RNA 
was isolated. Two |ig of total RNA was subjected to reverse transcription and the 
inflammatory mediator genes were then amplified from the cDNA using specific 
primers. The PCR products were resolved by 2% agarose gel. 
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3.4.2. Effects of PHF on Secretion of Inflammatory Mediators from 
SEB-stimulated PBMC 
Table 3.7 summarizes the effects of PHF on secretion of inflammatory 
mediators from SEB-stimulated PBMC. Data was expressed as changes in the 
concentrations of inflammatory mediators compared with baseline. 
Figure 3.8 illustrates the effects of PHF and DEX on inflammatory mediator 
concentrations in PBMC culture supernatants following SEB stimulation. In general, 
DEX suppressed inflammatory mediator released from PBMC whereas the effects 
associated with PHF extract were more specific. The addition of higher PHF (100 
|ig/ml PHF) to PBMC reduced supernatant concentrations of BDNF, and TARC in 
response to SEB. A lower dose of PHF (10 |ig/ml PHF) was unable to suppress the 
release of inflammatory mediators from SEB-stimulated PBMC. A higher dose of 
PHF induced the release of ENA-78. 
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Table 3.7 Changes in concentrations for five inflammatory mediators in 
SEB-stimulated PBMC in response to PHF and DEX treatments 
Isolated PBMC was primed with SEB for 2 hours followed by incubation with PBS 
(baseline), 100 nM DEX, 10 ^ig/mL PHF or 100 |ig/mL PHF for 24 hours at 37°C. 
Supernatants were collected and ELISA was performed to quantify the secretory 
levels of the mediator. Results were expressed in changes in concentration of 
mediator relative to baseline. Data represent the mean土SEM of 10 independent 
experiments. *: Statistical significant difference compared to baseline by 
Mann-Whitney U test. Bonferroni correction was performed on the results, and level 
of significance set at 1% to adjust for multiple comparisons. NS: No significant 
difference. 
DEX 100 nM PHF 10 ^ig/mL PHF 100 |ag/mL 
Mean士SEM p value Mean±SEM p value Mean+SEM p value 
BDNF - 1 7 . 6 1 ± 2 . 7 6 < 0 . 0 0 1 * - 9 . 0 9 ± 6 . 2 1 N^ -8.34 土 1 2 . 6 3 0 . 0 0 2 * 
ENA-78 -56.71 土20.84 NS 20.25±16.56 NS 1 8 1 . 7 9 ± 6 9 . 8 7 <0.001* 
IFN-y - 7 2 . 2 3 ± 3 . 5 9 < 0 . 0 0 1 * 8.84±13.19 NS -4.58±8.96 NS 
TARC - 2 6 . 8 9 ± 6 . 3 7 0 . 0 0 2 * -15.93±5.05 NS - 3 1 . 6 5 土 5.09 < 0 . 0 0 1 * 
TNF-a - 6 6 . 8 5 ± 8 . 0 9 <0.001+ -0.87±5.79 NS 3.57±8.35 NS 
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Figure 3.8 Effects of addition of 100 nM DEX (DEX) and PHF extracts at 10 
jig/ml (PHFIO) and 100 jig/ml (PHFIOO) on percentage changes of supernatant 
concentrations of five inflammatory mediators [(i) BDNF, (ii) ENA-78, (iii) 
IFN-y, (iv) TARC, and (v) TNF-a] following SEB stimulation 
Data represent the mean 士 SEM of 10 independent experiments. Statistical 
significant difference compared to baseline by Mann-Whitney U test. Bonferroni 
correction was performed on the results, and level of significance set at 1% to adjust 
for multiple comparisons. 
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3.6. Summarization of Effects of PHF on Expression of Inflammatory 
Mediators from PHA- and SEB-stimulated PBMC 
3.6.1. Mitogen (PHA) Stimulation 
Significant results were only obtained at protein but not RNA level. In general, 
DEX suppressed the release of multiple inflammatory mediators in PBMC culture 
supernatants. The addition of PHF reduced concentrations of BDNF, IFN-y, and 
TNF-a, but increased ENA-78 level in the culture supernatants. 
3.6.2. Superantigen (SEB) Stimulation 
In general, DEX suppressed the expression of multiple inflammatory 
mediators at both protein and RNA levels. The RNA expression levels of TARC, 
IFN-y and TNF-a were suppressed by PHF. PHF suppressed the expression of BDNF 
and TARC, while it induced the expression of ENA-78 at protein level. 
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Section 4: DISCUSSIONS 
CHAPTER 1 
Discussions on RCT of PHF 
1.1. Clinical Efficacy and Tolerability of PHF for Treatment of Children AD: 
a RCT study 
The current treatment of AD has largely been dependent on the usage of CS, 
which is generally effective, relatively rapid in onset of action and cheap when 
compared with alternative therapies. However, side effects of systemic CS have been 
reported, which include acneiform eruption, thinning of skin, telangiectases, striae, 
rosacea, contact dermatitis, and side effects secondary to systemic absorption. These 
side effects can be harassing if CS are applied incorrectly or longer than suggested 
(Callis and Krueger, 2003). Furthermore, long-term safety of TCIs, being the newer 
topical armamentarium, on especially on any theoretical risk of cancer has not been 
established. Despite the application of systemic steroid or TCI, a considerable 
proportion of AD patients remain symptomatic. 
Conversely, there is a growing interest on the application of complementary 
medicine, especially herbal medicine, for treatment of allergic diseases (e.g. asthma, 
hay fever and AD) (Koo and Arain, 1998; Bielory L and Lupoli K, 1999; Ziment and 
Tashkin, 2000). TCHM use is particularly popular among Asian children with AD. 
Our previous study showed that one-third of children with AD had tried TCHM as a 
supplementary treatment in the preceding 12 months (Hon et al, 2005b). 
The remarkable therapeutic value of a TCHM concoction (Zemaphyte®) as a 
treatment option for AD was reported in both children (Sheehan and Atherton, 1992) 
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and adults (Sheehan et al, 1992) using double-blind, placebo-controlled trials and 
follow-up studies (Sheehan and Atherton, 1994; Sheehan et al, 1995). The benefits of 
this concoction, however, could not be reproduced in a RCT carried out in Hong Kong 
(Fung et al’ 1999). No other placebo-controlled study involving TCHM for AD 
treatment AD was published in the English medical literature. Furthermore, 
Zemaphyte® is no longer produced (Zhang et al, 2004). Given the impressive clinical 
effects of PHF demonstrated in our open-label pilot study (Hon et al, 2004b), it would 
be rational to initiate the present RCT to elucidate the clinical efficacy and safety of 
PHF for treatment of AD. 
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1.2. Efficacy of PHF for Treatment of Children with AD 
This is the first report to demonstrate that a novel TCHM concoction, PHF, 
could improve the QoL in children suffering from moderate-to-severe AD. The QoL 
score significantly decreased from 11.0 (very large effect on patient's life) to 7.6 
(moderate effect on patient's life) after study in the treatment group but remained 
unchanged in the placebo group (Finlay and Khan, 1994; Hongbo, 2005). Total 
SCORAD scores, extent of disease, intensity of lesions and subjective symptoms in 
both the treatment and placebo groups were significantly reduced during the study 
period, but no significant difference was observed between the two groups. There was 
a discrepancy between the two scoring systems, SCORAD and quality of life 
measurement. Our recent study suggested that these two tools were two different 
assessment dimensions, and AD patients should be evaluated by both tools separately 
(Hon et al, 2006a). 
Nevertheless, the duration and amount of primary CS (1% mometasone furoate) 
use in treatment group significantly decreased from 19 days per month and 11 g per 
month at the beginning of study, to 15 days per month and 7g per month by the end of 
the study in the PHF group. This effect was not observed in the placebo group. The 
study suggests a steroid-sparing effect of PHF, and which should not be due to the 
presence of CS or CS-related precursors in the formula (Hon et al, 2006d). 
There was no change in the amount or duration of antihistamine use, blood 
chemistry including white blood cell count, eosinophil count, serum IgE levels, and 
plasma levels of the two AD-associated inflammatory mediators TARC and BDNF. 
Over 80% of our patients with AD had concomitant symptoms of allergic 
rhinitis (AR). As both AR and AD are atopic diseases, it would be important to assess 
if our PHF concoction could also relief the symptoms of AR. In our RCT, only 
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sneezing symptom was significantly improved in the treatment group and other AR 
symptoms or ARS remained unchanged. 
There is discrepancy between the SCORAD scores and the QoL score found 
in the present study. It is reported that total score of CDLQI was only weakly 
correlated with total SCORAD (p=0.23, p<0.05); while no significant correlation was 
found between the objective SCORAD and the total score of CDLQI (Hon et al, 
2006a). It is suggested that the objective indicators (IgE and objective SCORAD), 
self-reported scores (subjective SCORAD) and CDLQI were separate domains in the 
assessment of AD severity in children. Thus, both SCORAD and the CDLQI were 
employed in our study to evaluate the clinical efficacy of the PHF. 
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1.3. Safety and Tolerability of PHF Use in Children with AD 
The selection of herbs for PHF had been very careful, as the adverse effects of 
hepatic and renal derangements due to TCHM were frequently reported 
(Perharic-Walton L, Murray, 1992; Ferguson et al, 1997; Fung et al, 1999). For 
instance, the use of Clematis armandi in Sheehan and Atherton's studies 
(Zemaphyte®) was associated with a diuretic effect. Its long-term use necessitates 
potassium supplementation to avoid hypokalaemia. This herb was, therefore, not 
included in our PHF concoction. 
Many herbal remedies were shown to have medical effects. Due to poor 
standardization and quality control of these preparations, it would be important for us 
to collect sufficient efficacy and safety data on any TCHM before using it for patient 
treatment (Vender, 2002). 
In our RCT, the composition of each herb in the formulation was standardized 
prior to the manufacturing of concoction. The TCHM capsules were manufactured 
according to GMP standard, and they were also tested to ensure the absence of any 
heavy metal or residual pesticide. The whole batch of medicine required for this 
study was prepared and encapsulated at one time in order to guarantee the 
homogeneity of capsule ingredients. Many Chinese parents believe that herbs possess 
therapeutic properties and without any long-term harmful effect. Therefore, it was 
important to develop a safe and effective concoction for AD. 
The adverse effects during patients' visits were reviewed. They were relatively 
uncommon and were generally mild and self-limiting. There was no difference in 
haematological or biochemical parameters at baseline and following TCHM use. 
Despite the theoretical worry about hepatic and renal toxicity, our TCHM was not 
associated with any derangement of liver or renal functions throughout the whole 
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study period. PHF was found to be safe from our results. Unlike many bitter TCHM 
remedies, our recruited children in this study found PHF capsules to be palatable and 
also easy to swallow. 
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1.4. Rounding up 
A general trend of improvement in outcome measures during the study period 
was observed in both groups, irrespective of whether they received active PHF or 
placebo capsules. These findings might be explained by the placebo effect, which was 
commonly reported in TCHM studies. During this study, patients were regularly 
reviewed by the same investigator every 4 weeks, which were much more frequent 
than what it should be under the prevailing clinical practice. This factor would result 
in better drug compliance and reduced psychological stress during the RCT, which 
probably accounted for the improvement seen in the placebo group. The improvement 
among AD patients might also be related to the nature of AD manifestations in which 
both stresses and environmental factors might provoke disease exacerbations. These 
reasons explained the placebo effect frequently observed in drug trials for AD (Fung 
et al, 1999). However, our data suggested that the improvement of clinical AD score 
might be related to the higher consumption of topical CS among patients in the 
placebo group. 
There were two unique features in our PHF study. First, not only the SCORAD 
score, which was commonly employed in other studies, was used to assess the clinical 
benefits of therapeutic interventions but also QoL score which was an important end 
point for AD. This combination of assessment tools provides valuable information on 
how our study medication might help these AD patients from the children and 
parents' perspective. Secondly, use of systemic CS and antihistamine was recorded 
over the entire study period. It was difficult to quantify the amount and frequency of 
using these medications, but this parameter formed an important facet of outcome 
measurement in this study. The amount and frequency of antihistamine use was 
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recorded in a diary by the patients, whereas the quantity of topical CS use was 
measured by weighing the CS preparations in each 4-weekly visit. 
The PHF concoction used in our trial might be too mild, which might explain 
the mild and gradual improvement observed in our patients during the study period. 
Yet, PHF should be a useful supplement in the treatment of AD patients. 
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CHAPTER 2 
Discussions on In vitro Immunomodulatory Activities of PHF 
2.1. General Effects of PHF on PBMC 
The present in vitro study provides evidences that PHF possesses 
immunomodulatory properties that may explain the clinical efficacy observed in our 
RCT for AD children. Specifically, PHF suppresses the proliferation of PBMC in a 
dose-dependent manner. The addition of PHF to PHA-stimulated PBMC suppresses 
the release of BDNF, IFN-y and TNF-a. PHF reduces secretion of BDNF and TARC 
in response to SEB. At the RNA level, PHF suppresses the expression of BDNF, 
TARC, IFN-y and TNF-a, in response to SEB stimulation. In contrast, PHF stimulates 
the release of ENA-78 from PBMC in response to PHA and SEB stimulation. 
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2.2. Effects of PHF on Inflammatory Mediators Expression in PBMC 
PHF significantly reduced the expression of TARC from SEB-stimulated 
PBMC at both RNA and protein levels. TARC (CCL17) is an important Th2 
chemokine. Together with macrophage-derived chemokine (MDC; CCL22), they 
selectively attracted Th2 type memory T cells through interaction with CCR4. The 
plasma levels of TARC and MDC were elevated in patients with AD, and which also 
showed strong correlations with disease severity (Kakinuma et al, 2001; Song et al, 
2006). Our group has previously reported that serum concentrations of TACR were 
significantly associated with AD severity in local infants and young children (Leung et 
al, 2003). In addition, the plasma levels of this chemokine were correlated with 
nocturnal wrist movements in children with AD (Hon et al, 2006c). In short, these 
results demonstrated an important role for TARC in AD pathogenesis. 
CTACK, which attracts CCR10+ lymphocytes to skin, is a skin-specific 
chemokine biomarker for AD (Hon et al, 2004a). Vestergaard et al reported that 
TARC augmented TNF-a-induced CTACK production in primary keratinocytes 
(Vestergaard et al, 2004). They suggested that TARC-induced TH2-dominated 
inflammation by the selective recruitment of Th2 type memory /effector T cells to skin 
lesions (Yoshie et al, 2001). By inducing CTACK expression, this was followed by 
local skin-specific inflammatory reaction. Apart from AD, TARC was an important 
inflammatory mediator for childhood asthma (Leung et al, 2002; Leung et al, 2004c). 
Hence, the suppression of TARC expression in cultured PBMC provides a strong 
evidence of PHF-mediated immunomodulation for AD and other allergic diseases. 
It has been demonstrated that a wide range of immune cells, including mast 
cells (Wedi et al 1997; Wedi et al, 1998), lymphocytes (Sanico et al, 2000), 
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keratinocytes (Marconi et al, 2003) and eosinophils (Bonini et al, 1996), is capable of 
producing neurotrophins and expressing neurotrophin receptors (Nassenstein et al, 
2003). There is a growing interest in the potential roles of neurotrophins in our 
immune system, especially in the research of allergic diseases such as asthma and AD 
in which the pathophysiology is characterized by allergic inflammation. 
It is recently reported that the plasma levels of BDNF were markedly increased 
in patients with AD when compared with non-atopic controls, and which showed 
strong correlation with AD severity (Namura et al, 2006; Raap et al, 2006). Our results 
from the RCT also suggested this biomarker to be significantly and positively 
associated with AD severity as measured by the SCORAD index. Raap et al examined 
the functional roles of BDNF in AD pathogenesis, and found that BDNF significantly 
inhibited eosinophil apoptosis and induced chemotaxis of eosinophils from patients 
with AD, whereas these results were not shown in eosinophils from non-atopic 
controls (Raap et al, 2005). In addition, the expression of BDNF receptors (p75NTR 
and trk B) on eosinophils from AD patients was higher as compared with non-atopic 
controls (Raap et al, 2005). These results suggested that AD patients might be more 
susceptible to BDNF-stimulated downstream immune cascade. A Japanese group 
demonstrated a positive correlation of BDNF with eosinophil counts and percentage of 
Th2 cells in AD patients (Namura et al, 2006). PHF significantly reduced the 
expression of BDNF RNA expression and in vitro release from PBMC, which 
supports an immunomodulatory effect of PHF on the neurogenic mechanism of AD. 
Apart from AD, elevated levels of BDNF in blood and bronchoalveolar fluid in 
asthma patients were observed (Noga et al, 2001; Lommatzsch et al, 2005). BDNF 
also plays critical roles in the pathogenesis of airway hyperresponsiveness and 
inflammation in allergic asthma (Kerzel et al, 2003). 
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The present study observed a significant increase in ENA-78 concentrations in 
cultured PBMC following the stimulation with PHA or SEB, and this change was in 
opposite direction to the decreased levels of both BDNF and TARC. ENA-78 (CXCL5) 
belongs to the family of chemotactic chemokines (a family of proinflammatory 
peptides that attracts and activates leucocytes through binding to G protein-coupled 
receptors on the cell surface) known as CXC chemokines. The major effect of ENA-78 
is activation and chemotaxis of neutrophils, in which ENA-78 is as potent as 
interleukin-8 (IL-8), a classical strong chemotactic chemokine, in inducing neutrophil 
chemotaxis (Walz et al, 1991). ENA-78 shares structural homology with IL-8 
(CXCL8), growth-related protein-alpha (Walz et al, 1991), and alveolar 
macrophage-derived neutrophil chemotactic factor (Goodman et al, 1992). ENA-78 is 
secreted concomitantly with IL-8 in response to stimulation with either IL-1 or TNF-a. 
Thus, there is a close functional and structural relationship between ENA-78 and IL-8 
(Walz et al 1991). 
The role of ENA-78 in allergic asthma has recently been studied. It is reported 
that epithelial expressions of neutrophilic chemokines including ENA-78 and IL-8 
were elevated in atopic asthmatics after exposed to ozone (Bosson et al, 2003), which 
is a common air pollutant that induces inflammation and airway neutrophilia in asthma 
(Koren et al, 1989; Schelegle et al, 1991). Ghildyal et al demonstrated that the 
production of ENA-78 and vascular endothelial growth factor (VEGF) by human 
airway fibroblasts was induced after rhinovirus (RV) infection (Ghildyal et al, 2005). 
By RT-PCR and ELISA, the expressions of ENA-78 at mRNA and protein levels were 
significantly increased in bronchial epithelium in response to RV16 infection. Also, 
nasal expression of ENA-78 was significantly elevated following RV16 infection in 
asthmatic patients. Together with other chemokines, ENA-78 might be an important 
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initiator of neutrophilic airway inflammation (Donninger et al, 2003). Another study 
suggested that the recruitment and activation of CXC receptor 2-bearing cells, such as 
neutrophils, at the site of inflammation by eosinophils was also mediated through 
ENA-78 expression (Persson et al, 2003). Neutrophil chemotaxis is a crucial facet in 
the immune defence against S. aureus, which is an important risk factor for AD 
severity in Chinese children (Hon et al, 2005a). 
However, previous studies have shown various polymorphonuclear 
neutrophils (PMN) defects in patients with AD (McGirt and Beck, 2006), and these 
included an impaired response towards the chemotactic chemokine IL-8 (Zheng et al, 
1996). In addition, the expression of IL-8 was found to be decreased in skin biopsies of 
AD patients as compared with those of psoriasis and normal control (Nomura et al, 
2003). Because PMN is the initiator of innate immune response towards infection, 
patients with AD are, therefore, susceptible to microbial infection. Although ENA-78 
has not been studied in AD, this study suggested the PHF augmented ENA-78 release 
from PBMC. This effect may in turn stimulate neutrophil-mediated immunity against 
S. aureus infection. Further studies are needed to elucidate this immunomodulatory 
role of PHF. 
Our findings suggest that PHF suppressed the release of IFN-y from PBMC 
stimulated by PHA but not SEB. Due to a complex genetic predisposition, the 
differentiation of TH2-type immunological characteristics such as eosinophilia, 
enhanced IgE level and increased number ofTH2-type cells is favoured in AD patients. 
However, it was proposed that both ThI- and TH2-type cytokines played significant 
roles in development of AD, but at different stages (Figure 4) (Grewe et al, 1998). In 
this model, the activation of TH2-type cells is critical at the initial stage of 
inflammation. However, with the infiltration of macrophages and eosinophils, the 
127 
production of IL-12 is elevated which drove the local immunity towards THI-type 
cells to maintain the inflammatory response. This hypothesis was supported by the 
finding that fewer IL-4 and IL-13 mRNA-expressing cells, but more IFN-y 
mRNA-expressing cells, were present in chronic AD lesions when compared with 
acute AD lesions (Leung et al, 2004a). 
(a) (b) (c) 
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Figure 4 A model for pathogenesis of atopic dermatitis (Grewe et al, 1998) 
(a) In the initiation phase of AD, production of Th2 cytokines is induced by 
environmental allergens; (b) Skin invading inflammatory cells, including eosinophils 
and macrophages, are activated and attracted to the site of inflammation by Th2 
cytokines. They release IL-12, which in turns stimulates and activates the 
allergen-specific and non-specific THI and THO cells; (c) THI cytokine milieu 
associated with increased level of IFN-y is predominant. It is responsible for the 
chronicity of AD lesions and determines the severity of disease. Abbreviations: Ag, 
antigen; APC, antigen-presenting cell; IFN-y, interferon y; IL-4, interleukin 4; MHC, 
major histocompatibility complex; TCR, T-cell receptor. 
When compared with controls, mRNA expression of IFN-y, being a key 
ThI-type cytokine, was significantly increased in skin lesions from AD patients. 
Following successful treatment of AD, this elevated level of IFN-y was reduced 
(Grewe et al, 1994). This data indicated that IFN-y was linked to the clinical course of 
AD. It was also reported that the expression of adhesion molecule ICAM-1 was 
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strongly induced by IFN-y (Krutmann, 1994). Purwar et al recently reported that the 
production of MDC, a Th2 chemokine which attracts CCR4+ T-cells, from human 
primary keratinocytes was stimulated by IFN-y (Purwar et al, 2006). Induction of both 
MDC and TARC in mouse skin following IFN- y injection was observed (Horikawa et 
al, 2002). An IFN-y knockout murine AD model revealed a reduction in dermal 
thickening (Spergel et al, 1999). These findings suggested that the predominance of 
ThI-type cytokines such as IFN-y in chronic phase of AD might contribute to the 
attraction, accumulation and maintenance of inflammatory cells in lesional skin. This 
biphasic switch in immune response is characterized by epidermal hyperplasia, 
lichenification and dermal fibrosis (Leung, 2000). 
The present study reported that PHF suppressed PHA-stimulated IFN-y 
secretion from PBMC. The results suggested that PHF might alter the persistence of 
skin inflammation caused by the release of Th 1 -type cytokines. Further studies are 
needed to verify whether this immunomodulatory property of PHF on Th 1 -type 
cytokines could be replicated on cells isolated from AD patients. It is logical that the 
effect of PHF was not observed in PMBC stimulated with SEB. As SEB-stimulation 
mimic effect of infection by S. aureus, in which cell-mediated immune responses were 
required (Baker, 2006). Therefore, expression of ThI-type cytokines should not be 
suppressed. 
PHF treatment of PHA-stimulated PBMC down-regulated the synthesis of 
TNF-a. This pro-inflammatory cytokine activates a well-known transcription factor, 
NF-KB, that plays important roles in the transcriptional regulation of a variety of 
genes (Sebban, H. & Courtois, 2006). Many of these genes are linked to inflammatory 
responses (Aggarwal et al, 2003). Elevated level of TNF-a was observed in cutaneous 
lymphocyte antigen positive (CLA+) T cells (the T-cell subtype with skin tropism that 
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preferentially response to the stimulation by cutaneous allergen) in AD patients with 
acute lesions (Antunez et al, 2004). However, the effect of TNF-a was more 
prominent in the chronic stage of AD. TNF-a was initially released from infiltrating 
mast cells, and later also from invading T-helper lymphocytes and keratinocytes. It 
stimulated the release of pro-inflammatory cytokines (e.g. IL-1, IL-6 and IL-8) and 
expression of adhesion molecules (e.g. ICAM-1 and VCAM-1) on keratinocytes and 
vascular endothelial cells, whereby facilitating the adhesion and migration of immune 
cells to sites of inflammation and further amplifying inflammation in chronic skin 
lesions (Jacobi, 2005; Numerof and Asadullah). Thus, TNF-a is a very potent mediator 
in immune and inflammatory responses. 
Various studies reported that patients with AD had significantly higher serum 
and tissue concentrations of TNF-a (Ackermann and Harvima, 1998; Junghans et al, 
1998). Overproduction of TNF-a had also been reported in asthma patients, which 
increased airway responsiveness and sputum neutrophils. In addition, TNF-a potently 
stimulated airway epithelial cells to generate RANTES, IL-8 and GM-CSF (Stirling 
and Chung, 2000). Consequently, the suppression of TNF-a in cultured PBMC 




Limitations of the Present Study 
There are a number of limitations for this study. Although our randomized 
clinical trial showed PHF to be able to reduce topical CS use and improve QoL in AD 
patients, this treatment did not result in significant reductions in AD severity or plasma 
levels of the two inflammatory biomarkers TARC and BDNF. We hypothesized that 
the dosage of PHF in this RCT might not be adequate. Equally, we did not have strong 
data on what PHF extract concentration to use in our in vitro assays. The current 
formulation of PHF extract was a crude one that was pooled from four PHF capsules 
using hot water extraction. Thus, it would be difficult for us to estimate the appropriate 
dosage of PHF in clinical trial using data from the in vitro experiments. 
Secondly, we found that the PHF extract contained a measurable amount of 
endotoxin. The immunostimulatory effects from this endotoxin contamination were 
minimized by using pyrogen-free water and plastic-wares in the hot water extraction 
process and by adding PMB in PBMC culture (Lee et al, 2006). However, it is unlikely 
that the small amount of endotoxin present may cause the significant findings obtained 
in our study. 
Thirdly, as mentioned in the introduction, herbs are rarely used alone in 
Chinese medicine. TCHM is habitually heterogeneous in nature and composed of a 
complex mixture at a specified ratio. Since PHF is a multi-herbal preparation, it would 
be difficult to identify which active compound(s) from the herbal mixture play roles in 
mediating the immunomodulatory effects. This issue is a common limitation of 
TCHM studies. Further investigation will be necessary to identify the specific 
compounds for PHF-related immunomodulatory activities. However, it should be 
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emphasized that the biological activity of herbal extracts might vary from its isolated 
purified components. In fact, the complex combination of compounds present in the 
various herbal extracts was likely to be accountable for their biological activities, 
including both additive and synergistic effects (Liu, 2003; Kim et al, 2005). 
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Section 5： CONCLUSIONS AND FUTURE PROSPECTS 
CHAPTER 1 
Conclusions 
Our RCT of the PHF concoction in AD patients demonstrates that PHF is 
efficacious in improving QoL and sparing topical CS use in children with 
moderate-to-severe AD. There is no derangement in hematological or biochemical 
parameters after PHF treatment. This PHF formulation can possibly be used for 
supplementary treatment for children with refractory AD. 
The PHF formulation suppresses the in vitro production of AD-related 
inflammatory mediators including BDNF, TARC, IFN-y and TNF-a, and enhances the 
release of neutrophil-related ENA-78. These findings provide useful biochemical 




The PHF formulation can be modified to enhance its effectiveness. Chinese 
herbs such as Cortex Moutan Radix, Radix Paeoniae Abla, Potentilla Chinensis Ser 
and Radix glycyrrhizae, which are commonly used in eczematous conditions, can be 
included to form a new concoction (Zhang 1990). Moreover, the dosage taken by 
patients can also be calculated according to their body weights. This would minimize 
the problem of insufficient dosage of PHF in patients who are older or heavier (Chang 
et al, 2006). It would be an advantage to prepare a similar formulation in the syrup 
form for younger children who are not able to swallow capsules. 
PHF extracts used in the in vitro study was hot water extracts. It is reported that 
volatile extracts from plants also exhibited some biological activities (Muhlbauer et al, 
2003). We suggest that immunomodulatory properties of both water extracts and 
organic solvent extracts of PHF should be studied and compared. Hence, we can select 
the more potent part of this extract in any future study. Experiments may also be 
performed to delineate the signaling pathway(s) that mediate the PHF-induced 
immunomodulatory properties. 
As mentioned, the allergen/antigen-stimulated response in AD patients is 
different from that seen in normal non-atopic subjects due to genetic predisposition 
(Smart and Kemp, 2002). To further investigate the effects of PHF in vitro, we may 
use PBMC or other immune cells isolated from peripheral blood of AD patients 
instead of from buffy coat. Though it may be difficult to obtain an adequate amount 
of samples, this approach would enable us to obtain a more accurate picture on how 
PHF works. Otherwise, we may also perform similar using various in vivo 
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pharmacological disease models such as NC/Nga mouse, hairless guinea pigs with 
superantigen-induced dermatitis and genetically engineered AD-like disease models 
(e.g. transgenic interleukin-31 mice) (Petersen, 2006). 
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Abstract 
Background: Topical glucocorticoids (GCs) are the mainstay of treatment for eczema, but G C phobia and fears are very 
common among the parents of paediatric patients. Aim: To survey the nature and extent of "fears" of G C use, and to 
evaluate if disease severity is associated with such fears. Methods: Patients with eczema managed in the paediatric 
dermatology outpatient clinic of a university hospital were recruited in this survey. Disease severity and various aspects of 
belief and practices of G C use were assessed with the Nott ingham Eczema Severity Score and a questionnaire. Results: G C 
"fears" were present in two fifths of informants with non-eczematous skin disease and mild eczema, but three fifths in 
moderate-to-severe disease. Requests for steroid-sparing medications (such as tacrolimus or pimecrolimus) had been made 
in nearly 50% of cases with moderate-to-severe eczema, and many parents would wait until eczema had worsened or apply 
G C only as a last resort to avoid potential side effects. "Fears" were predominantly interpersonal and rarely iatrogenic in 
nature. Skin problems (in particular skin thinning) and adverse effects on growth were the side effects of G C of most 
concern. However, fewer than half of the informants had discussed their concerns with doctors. 
C o n c l u s i o n : Our results suggest the importance of understanding the nature and extent to which G C fears, regardless of 
eczema severity, are prevalent so that sound advice can be offered in a timely manner to parents and patients. 
K e y W o r d s : Children, eczema, glucocorticoid fears, NESS 
I n t r o d u c t i o n W e set o u t to survey the n a t u r e a n d e x t e n t o f G C fears 
^ , .. in our e c z e m a pat i ent s , a n d eva luate if d i sease severity 
E c z e m a is a c o m m o n c h r o n i c re laps ing d i sease in , , , ^ 
1 J T , 1 J 1 , , ^o/ r IS corre la ted w i t h s u c h fears, 
chi ldren. It has b e e n e s t i m a t e d that a b o u t 15% of 
ch i ldren suf fer f r o m this d i s e a s e [ 1 - 3 ] . Top ica l 
g l u c o c o r t i c o i d s ( G C s ) are t h e m a i n s t a y o f t r e a t m e n t , M e t h o d s 
b u t their e x c e s s i v e u s e m a y b e a s s o c i a t e d w i t h d e -
r a n g e d m e t a b o l i s m , g r o w t h s u p p r e s s i o n , increased Inclusion criteria 
suscept ib i l i ty to i n f e c t i o n s a n d s u p p r e s s i o n o f the Pat ients o f 1 m o to 2 0 y of age a n d wi th e c z e m a 
h y p o t h a l a m i c - p i t u i t a r y - a d r e n a l axis [4] , T h e m e d i a m a n a g e d in the paed ia tr i c d e r m a t o l o g y outpat i en t 
have r e p o r t e d adverse ly o n v a r i o u s a s p e c t s c o n c e r n i n g c l inic o f a univers i ty hosp i ta l in H o n g K o n g were 
G C use . S imi lar t o o t h e r inves t igators , our e x p e r i e n c e c o n s e c u t i v e l y recru i t ed in this survey. E c z e m a was 
at the paediatr ic d e r m a t o l o g y c l in ic reveals that m a n y d i a g n o s e d a c c o r d i n g to criteria p r o p o s e d by H a n i f i n 
of the parents h a v e h a d s o m e d e g r e e o f " p h o b i a " or and Rajka [8] . E c z e m a severity in the p r e c e d i n g 12 
"fear" o f G C u s e [ 5 - 7 ] . Fa l lacy a n d m i s l e d i n f o r m a - m o w a s a s s e s s e d cl inical ly by the N o t t i n g h a m E c z e m a 
t ion m a y be d e t r i m e n t a l t o the d i s ease contro l o f Sever i ty S c o r e ( N E S S ) [ 9 , 1 0 ] . W e prev ious ly f o u n d 
chi ldren. It is there fore i m p o r t a n t to u n d e r s t a n d the that the N E S S is a val id score for the rapid a s s e s s m e n t 
ex ten t to w h i c h G C fears are preva lent so that s o u n d of e c z e m a severity, a n d is easy to p e r f o r m by parents 
a n d correct adv ice c a n b e o f f e r e d in a t ime ly m a n n e r , or n o n - s p e c i a l i s t staff [10 ] . In order to reduce 
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inter- and intra-observer variability, various aspects of patients were 11.2，11.6 and 10.6 y, respectively. All 
beliefs and practices of G C use were assessed by a patients were of ethnic Chinese origin. T h e mothers 
research assistant ( W Y C K ) in accordance with a were the informants in 7 0 % of these patients. 
questionnaire based partly on previous research Topical G C s had b e e n prescribed in 38% of non-
[6,7]. G C fear was classif ied into six categories, eczema controls (for alopecia, hypopigmentat ion, nail 
namely, interpersonal, iatrogenic, bibliophilic, doctor dystrophy, etc . ) , 8 2 % of mi ld eczema but 94% 
induced, media i n d u c e d or misce l laneous . Specif!- moderate or severe eczema, and were regularly used 
cally, we def ined interpersonal fear as a fear of G C use (def ined as use for more than 2 d per week) in the 
consequent to negative c o m m e n t s about G C s by moderate- to-severe eczema group (OR 2 .38 , 95% CI 
friends, relatives or n o n - m e d i c a l personnel; iatrogenic 0 . 9 9 - 5 . 8 6 , p = 0 . 0 5 3 compared to controls). Apart 
as fear of G C use fo l lowing side effects previously from ant i - inf lammatory actions, many informants 
experienced by the informant or the patient; biblio- believed that G C s killed germs and reduced itch. 
philic as fear of steroid use due to knowledge from G C fear or phobia, broadly def ined as concerns or 
books, magazines , or drug formulary; and doctors, fears expressed by informants about steroid use, was 
media or misce l laneous as fear of G C use as a result of present in 4 0 % of informants with non-eczematous 
c o m m e n t s from medica l personnel , media (television, skin disease and mild eczema, compared with 60% in 
radio, newspaper) or misce l laneous sources, respec- moderate or severe disease. In patients with moder-
tively. ate-to-severe eczema, steroid-sparing medicat ions 
(such as tacrolimus or p imecrol imus) had been 
^ , . . prescribed in nearly 50%, and many parents would 
Exclusion criteria . , , , , ^^ , 
wait until eczema had worsened or apply G C only as a 
Patients were exc luded if they were not accompanied last resort to avoid the potential side effects of the 
by caregivers or w h e n these caregivers could not drug. "Fears" were interpersonal or bibliophilic and, 
provide reliable information, or if patients suffered to a lesser extent, iatrogenic in nature (Table II). Skin 
from other forms of inf lammatory dermatitis (such as problems (especially skin thinning) and adverse ef-
psoriasis, seborrhoeic dermatit is) . fects on growth and deve lopment (such as poor weight 
gain, reduced intell igence quotient) were the side 
XT , effects of G C use of most concern (Table III). 
Non-eczema controls . • i i ir r i • r , , 
Approximately half of the informants in the moder-
Children with n o history of eczema that were seen at ate-to-severe eczema group had discussed their con-
the clinic for various n o n - e c z e m a t o u s condit ions cerns with doctors. In the 171 informants who 
(such as acne, birth marks and p igmented skin expressed concern about side effects of G C use, 
lesions) during the same period were recruited for doctors (65%), television (52%), newspapers (62%), 
comparison. friends or relatives (57%) were the main sources of 
T h e Clinical Research Ethics C o m m i t t e e of our advice about side effects of G C . T h e Internet was only 
University approved this study. T h e test was used used by 17% of these informants. 
to compare proportions. O d d s ratios (OR) and 95% 
conf idence intervals (CI) were calculated when in- D i s c u s s i o n 
dicated. All comparisons were m a d e two tailed, and p 
values less than 0 .05 were considered to be statisti- Topical G C s are the mainstay of treatment for 
cally significant. inf lammatory skin diseases such as eczema, but their 
use may be associated with local and systemic side 
„ , effects [4], and misunderstandings about their actions Results r^ i A r n 
exist [oj. Apart from anti- inflammatory actions, many 
T w o hundred and twenty-three patients were seen informants believe that G C s kill germs and reduce 
between March and August in 2 0 0 5 . Eighteen cases itch. It is important for physicians to explain to 
(8%) were excluded from analysis because of non- patients and parents the two important facets to 
eczematous dermatitis (e.g. ichthyosis, palmoplantar eczema management , namely, preventive and thera-
dermatitis, keratosis pilaris, psoriasis, urticaria) or peutic measures. Preventive measures refer to proper 
incomplete data as per the exclusion criteria. Twenty- and frequent skin lubrication (emolliation) by topical 
eight patients (14%) suffered from mild disease, and application of moisturizers and bathing [11], which 
137 (67%) of them had moderate-to-severe eczema help reduce itch and the likelihood of flares. When 
according to the N E S S . Forty control cases (including these preventive measures fail to control disease 
acne, warts, nail problems, hair problems, nevus, exacerbation, therapeutic measures such as topical 
vitiligo, pigmentat ion, and haemangioma) were re- G C s , antibiotics and non-steroidal immunomodulat -
cruited (Table I). T h e median age of control cases, ing agents are required to treat skin inflammation. 
mild eczema patients and moderate-to-severe eczema Eczema is an inflammatory condition and G C s are a 
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Table I. Steroidophobia in parents and patients with and without eczema. 
Group A Group Bi Group B2 Yates's corrected p value 
No eczema Mild eczema Moderate-to-severe 
(n =40) (n 二28) eczema (w = 137) P value by x^ A vs B, A vs B2 B, vs B2 
Age of patient < 5 y 8 (20%) 3 (11%) 24 (18%) 0.588 0.505 0.900 0.575 
Male gender 20 (50%) 17 (61%) 69 (50%) 0.590 0.532 0.889 0.429 
Topical GCs prescribed by doctor a 15(38%) 23 (82%) 129 (94%) <0.001 <0.001 <0.001 0.047 
Uses topical GCs regularly 9 (23%) 4 (14%) 56(41%) 0.006 0,593 0.053 0.014 
( > 2 d per week) 
Coexisting conditions that required 8 (20%) 8 (29%) 31(23%) 0.703 0.596 0.892 0.667 
GCs (e.g. asthma, allergic rhinitis) 
Informant thinks GC kills germs 11(28%) 12(43%) 61(45%) 0.153 0.291 0.081 0.963 
Informant thinks GC reduces 15(38%) 16 (57%) 104 (76%) <0.001 0.176 <0.001 0.072 
inflammation 
Informant thinks GC reduces itch 11 (28%) 11 (39%) 68 (50%) 0.040 0.448 0.022 0.429 
"GC fears" 16 (40%) 12(43%) 81(59%) 0.051 0.988 0.062 0.170 
Requests GC-sparing medications b 6 (15%) 10 (36%) 63 (46%) 0.002 0.091 <0.001 0.318 
Applies GCs only as a last resort 5 (13%) 9 (32%) 84 (61%) <0.001 0.096 <0.001 0.009 
to avoid potential side effects 
Waits until eczema gets worse before 2 (5%) 11 (39%) 75 (55%) <0.001 0.001 <0.001 0.199 
applying topical GC 
n.s.: not significant 
"GC fears" broadly defined as concerns expressed by informants about GC use. 
^Mometasone furoate 0.1% (97 of 165 eczema patients) is the most commonly prescribed topical GC, followed by alclometasone 
dipropionate 0.15% (28 of 165 eczema patients) and 1% hydrocortisone (17 of 165 eczema patients). 
b Topical tacrolimus prescribed in one patient with mild eczema but 26 patients with moderate or severe eczema (OR 6.32, 95% CI 0 .85-
130.60, p =0.050 by Fisher's exact test); pimecrolimus prescribed in one patient with mild eczema but 16 patients with moderate or severe 
eczema (OR 3.57, 95% CI 0.46-75.23, p =0.311 by Fisher's exact test). When combined, these calcineurin inhibitors had been prescribed 
significantly more commonly among moderate-to-severe eczema patients (OR 5.75, 95% CI 1.24-36.75, p =0.020). 
f o r m o f a n t i - i n f l a m m a t o r y m e d i c a t i o n . T h u s , pa t i en t s i m p o r t a n t to exp la in that G C s d o n o t have any 
s h o u l d u n d e r s t a n d the t h e r a p e u t i c rat ionale that it is intr ins ic ant i sept i c or a n t i m i c r o b i a l property , 
s ens ib le to u s e G C s d u r i n g a flare w h e n i n f l a m m a t i o n G C fears, b r o a d l y d e f i n e d as c o n c e r n s e x p r e s s e d by 
is present . M o r e t h a n ha l f o f t h e i n f o r m a n t s th ink that i n f o r m a n t s a b o u t G C u s e , w e r e p r e s e n t in 4 0 % of 
G C s kill g e r m s . C o n f u s i o n b e t w e e n the e f f ec t s o f i n f o r m a n t s w i t h n o n - e c z e m a t o u s skin d i sease and 
ant ib io t ics a n d G C s prevai l s a m o n g the C h i n e s e . Very m i l d e c z e m a , c o m p a r e d w i t h near ly 6 0 % in m o d e r a t e 
f e w i n f o r m a n t s u n d e r s t a n d that G C is a c lass o f a m i - or severe d i s ease . T h i s f i n d i n g h igh l ights that c o n -
i n f l a m m a t o r y d r u g , w h e r e a s an t ib io t i c s have b e e n c e r n s a n d fears a b o u t G C s are preva lent , regardless o f 
trans lated e r r o n e o u s l y i n t o C h i n e s e to m e a n ant i - e c z e m a severity. M a n y p a r e n t s w o u l d wait unti l 
i n f l a m m a t o r y ac t ion . A l t h o u g h the u s e o f top ica l G C e c z e m a g o t w o r s e ( 3 2 % m i l d e c z e m a versus 
r e d u c e s e p i d e r m a l i n f l a m m a t i o n a n d m a y indirect ly 6 1 % m o d e r a t e - t o - s e v e r e e c z e m a ) or apply G C s only 
r e d u c e the a m o u n t o f bacter ia in the skin, it is as a last resort ( 3 9 % m i l d e c z e m a versus 5 5 % 
Table II. Nature of concerns about glucocorticoid (GC) use in parents and patients with and without eczema. 
Group A No Group Bj Group B2 Yates's corrected p value 
eczema Mild eczema Moderate-to-severe 
{n =40) {n =28) eczema (« = 137) P value by A vs B, A vs B2 B, vs 63 
Interpersonal (friends' or 9 (23%) 8 (29%) 52 (38%) 0.159 0.776 0.105 0.468 
relatives' opinion) 
Iatrogenic (patients had 2 (5%) 3(11%) 13(9%) 0.629 0.396 0.526 0.737 
experienced adverse effects) 
Bibliophilic (books, 4 (10%) 2 (7%) 20 (15%) 0.476 1.000 0.628 0.375 
magazine, drug formulary) 
Doctor 1 (3%) 0 (0%) 8 (6%) 0.314 1.000 0.686 0.354 
Media (television, 5 (13%) 1(4%) 10(7%) 0.372 0.389 0.334 1.000 
newspaper, radio, pamphlet) 
Miscellaneous (parental, 1 (3%) 2 (7%) 8 (6%) 0.642 0.564 0.686 0.679 
poor growth) 
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Table III. Side effects of glucocorticoid use of most concern to parents and patients with and without eczema. 
Group A No Group B, Mild Group B2 Yates's corrected p value 
eczema eczema Moderate-to-severe 
{n ==40) {n =28) eczema (w 二 137) P value by A vs B, A vs B2 B, vs B2 
Skin thinning 2 (5%) 6 (21%) 39 (28%) 0.008 0.057 0.004 0.597 
Other skin problems " 3 ( 8 % ) 2 ( 7 % ) 15 (11%) 0.717 1.000 0.767 0.740 
Growth and development 2 ( 5 % ) 5 (18%) 45 (33%) 0.001 0.115 <0.001 0.178 
Affects liver/kidney function 0 ( 0 % ) 0 ( 0 % ) 11 (8%) 0.056 NA 0.072 0.214 
Affects immune system 1 (3%) 2 (7%) 6 ( 4 % ) 0.655 0.564 1.000 0.624 
GC resistance 1 (3%) 1(4%) 6 ( 4 % ) 0.861 1.000 1.000 1.000 
GC dependence 2 (5%) 1(4%) 4 ( 3 % ) 0.817 1.000 0.619 1.000 
Increases body hair 0 ( 0 % ) 2 (7%) 6 ( 4 % ) 0.287 0.166 0.339 0.624 
Eye problems (e.g. glaucoma) 1(3%) 0 (0%) 5 (4%) 0.571 1.000 1.000 0.590 
Bone problems (e.g. 4 ( 1 0 % ) 0 ( 0 % ) 6 (4%) 0.151 0.137 0.236 0.591 
osteoporosis, fractures) 
Miscellaneous b 4 (10%) 1(4%) 20(15%) 0.240 0.642 0.628 0.132 
Discussed side effects with 7 (18%) 8 (29%) 73 (53%) <0.001 0.432 <0.001 0.030 
doctor 
^Other skin problems included pigmentation, thickening, atrophy, irritation, texture. 
"^Miscellaneous included influences on sexual characteristics, the endocrine system, respiratory system, circulatory system, health, the 
joints, and as a cause of cancer, obesity, muscle atrophy, etc. 
m o d e r a t e - t o - s e v e r e e c z e m a ) t o avo id their po ten t ia l da te , it a p p e a r s that the I n t e r n e t has n o t b e c o m e a 
s ide e f fec t s . T h i s p r a c t i c e m a y p o t e n t i a l l y e n d in a f r e q u e n t s o u r c e o f a d v i c e in H o n g K o n g . It is 
v i s c o u s cyc l e l e a d i n g to m o r e e x t e n s i v e i n f l a m m a t i o n , i m p o r t a n t t o f i n d o u t the r e a s o n s w h y s o m e parents 
resu l t ing in a m o r e p r o l o n g e d c o u r s e , a larger a m o u n t or pa t i en t s d o n o t d i s c u s s their c o n c e r n s a b o u t 
o f G C u s e , a n d e v e n m o r e p o t e n t G C b e i n g u s e d . In spec i f i c s ide e f f e c t s w i t h their d o c t o r s . Lack of 
pat i ent s w i t h m o d e r a t e - t o - s e v e r e e c z e m a , r e q u e s t s for c o n t i n u i t y , l o n g s c h e d u l e d a p p o i n t m e n t s , t i m e c o n -
s t ero id - spar ing m e d i c a t i o n s ( s u c h as t a c r o l i m u s or straints in c o n s u l t a t i o n , i n t e r r u p t i o n s by a t e l e p h o n e 
p i m e c r o l i m u s ) h a d b e e n m a d e in near ly 5 0 % o f cases , or pager , a n d cul tural insens i t iv i ty c o u l d b e s o m e o f 
W e a t t e m p t to d e f i n e a n d c lass i fy fears b a s e d o n the the barriers that p r e v e n t e f fec t ive c o m m u n i c a t i o n , 
d e f i n i t i o n o f G C " p h o b i a " [ 5 , 6 ] , a n d f o u n d that O u r f i n d i n g s are d i f f e r e n t f r o m the results o f a U K 
"fear" w a s p r e d o m i n a n t l y i n t e r p e r s o n a l a n d rarely s t u d y [7] in that c o n t r o l s w e r e u s e d in o u r s tudy and 
ia trogen ic in n a t u r e ( b e c a u s e t o p i c a l G C has very f e w o n l y pa t i en t s o f C h i n e s e e thn ic i ty w e r e s tud ied . T h e 
s ide e f f ec t s w h e n u s e d appropr ia te ly ) . W e d o n o t use f i n d i n g s in the c o n t r o l p o p u l a t i o n m a y ref lect the 
the t e r m p h o b i a in this s tudy , as it is d i f f i cu l t to d e f i n e b a s e l i n e level o f fears in the c o m m u n i t y against w h i c h 
if a fear or c o n c e r n is truly irrational . B a s e d o n our e c z e m a pa t i en t s m a y b e c o m p a r e d . Sever i ty grading of 
f ind ings , m o r e e f for t s h o u l d b e p l a c e d in pa t i en t e c z e m a w a s a l so c o n s i d e r e d in the analysis . Interest -
e d u c a t i o n a n d e x p l a n a t i o n , e spec ia l l y in the m o d e r - ingly, m a n y o f the G C c o n c e r n s w e r e i n d e p e n d e n t o f 
a t e - to - severe e c z e m a g r o u p . e c z e m a severity (Table III) , re f l ec t ing that they were 
Sk in p r o b l e m s ( e spec ia l l y sk in t h i n n i n g ) a n d a d - n o t necessar i ly rat ional , 
verse e f f ec t s o n g r o w t h a n d d e v e l o p m e n t w e r e the s ide T h i s s t u d y is a c r o s s - s e c t i o n a l analysis , a n d pat terns 
e f fec t s o f G C u s e o f m o s t c o n c e r n . H o w e v e r , w e o f c h a n g e s in G C u s e w e r e n o t eva luated . A l s o , H o n g 
f o u n d that the s p e c t r u m o f c o n c e r n s w a s w i d e K o n g is a relat ively a f f luent a n d m e t r o p o l i t a n city in 
ranging. In a r e c e n t s t u d y c o n c e r n i n g skin t h i n n i n g C h i n a , a n d the s t u d y w a s c o n d u c t e d at a univers i ty 
and G C use in e c z e m a , n o e v i d e n c e of skin a trophy paediatr ic d e r m a t o l o g y c l inic w h e r e m o r e than half o f 
after 2 0 w k of t r e a t m e n t w i t h a o n c e daily p o t e n t our pat i en t s have m o d e r a t e - t o - s e v e r e e c z e m a . T h e 
topica l G C p rep ara t ion w a s f o u n d , s u g g e s t i n g that the results m a y n o t b e genera l i zab le to parents in o ther 
"fear" a b o u t skin t h i n n i n g e x p r e s s e d by parents a n d cit ies o n the m a i n l a n d . F u r t h e r s tud ies at the pr imary 
pat ients m a y b e over e x a g g e r a t e d [ 7 , 1 2 ] . Phys i c ians care level s h o u l d b e u n d e r t a k e n to evaluate the nature 
m u s t q u e s t i o n a n d d i s c u s s t h e s e i s sues a n d c o n c e r n s a n d ex ten t o f G C fears, a n d to c o m p a r e t h e m to this 
in detai l w i t h pa t i en t s a n d their caregivers . O f n o t e , study. 
on ly 530/0 o f i n f o r m a n t s in the m o d e r a t e - t o - s e v e r e T h i s s tudy he lps be t ter u n d e r s t a n d the fears of 
e c z e m a a n d 2 9 % in the m i l d e c z e m a g r o u p h a d parents o f e c z e m a pat i ent s . Fear is soc io -cu l tura l and 
d i s c u s s e d their c o n c e r n s w i t h d o c t o r s . D o c t o r s , te le - m a y vary f r o m c o u n t r y to country . Ins tead of g iv ing 
v i s ion , n e w s p a p e r s , f r i ends or relat ives w e r e the m a i n n o n - s p e c i f i c adv ice or a prescr ip t ion o f topical G C s 
sources o f adv ice a b o u t the s ide e f f ec t s o f G C . T o w i t h o u t a d d r e s s i n g t h e s e fears, it is i m p o r t a n t to tailor 
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Efficacy and tolerability of a Chinese herbal medicine 
concoction for treatment of atopic dermatitis： 
a randomized, double-blind, placebo-controlled study 
K.LE. Hon, T.F. Leung, P.C. Ng, M.C.A. Lam, W.Y.C. Kam, K.Y. Wong, K.C.K. Lee’* Y.T. Sung, K.F. Cheng,t 
T.F. Fok, K.P. Fungt and P.C. Leungj 
Department of Paediatrics, *School of Pharmacy and tInstitute of Chinese Medicine, Chinese University of Hong Kong, Shatin, Hong Kong SAR, China 
Summary 
Correspondence Background There has been considerable interest in traditional Chinese herbal medi -
Dr Kam-Lun Ellis Hon. cine (TCHM) as a treatment for atopic dermatitis (AD). A twice-daily concoct ion 
E-mail: ehon@cuhk.edu.hk； e h � n @ h _ a i l 細 � � ^ ^ ancestral formula containing five herbs has been f o u n d to be beneficial in 
Accepted for publication an open study. 
6 January 2007 Objectives To assess the efficacy and tolerability o f the concoc t ion in children 
w i t h AD. 
Key words Methods Fol lowing a 2 - w e e k run-in period, children w i t h long-standing moderate-
atopk dermatitis, CDLQI (Children's Dermatology to-severe AD were randomized to receive a 1 2 - w e e k treatment w i t h twice-daily 
Life Quality Index), children. SCORED (SCORing l o s i n g o f th ree capsules o f e i ther TCHM or p l acebo . The SCORing of Atop ic Der-
0 丄 2 : c D e ™ _ s ) ’ - _ d Chinese h e - matitis (SCORAD) score. Children's Dermato logy Life Quality Index (CDLQI)’ 
allergic rhinitis score, and requirement for topical corticosteroid and oral anti-
Conflicts of interest histamine were assessed before and at w e e k s 4，8，12 and 16 after treatment. • 
None declared. Adverse events , to lerabi l i ty , h a e m a t o l o g i c a l a n d b i o c h e m i c a l p a r a m e t e r s w e r e • 
moni tored during the study. • 
The study was reg.stered with the Climcal Trial Results Eighty-f ive ch i ld ren w i t h AD w e r e r ec ru i t ed . Over 12 w e e k s , the m e a n • 
Reaistration, Centre for Clinical Trial, Chinese ^ ‘ � • 
u L _ of — Kong — number SCORAD score fell f rom S8.3 to 49 .7 in the TCHM g r o u p (n = 42; P = 0 -003 ) • 
CUHK CCT00084； http://i37.i89.】50.15/ and from 56.9 to 46-9 in the placebo group (n = 43; P = 0 - 0 0 1 ) . However , there 画 
registry/publictriallist.php (accessed 9 March was n o significant difference in the scores at the c o r r e s p o n d i n g t ime points 
2007)]. b e t w e e n the t w o groups. The CDLQI in TCHM-treated patients was significantly 
improved compared w i t h patients receiving placebo at the end o f the 3 - m o n t h 
treatment and 4 weeks after stopping therapy (P = 0 . 0 0 8 and 0 -059 , respectively). 
The total amount o f topical corticosteroid used was also significantly reduced by 
one-third in the TCHM group (P = 0 . 0 2 4 ) . N o serious adverse effects were 
observed be tween the groups. 
Conclusions The TCHM concoct ion is efficacious in improving quality o f life and 
reducing topical corticosteroid use in children wi th moderate-to-severe AD. The 
formulat ion was palatable and wel l tolerated. 
Atopic dermatitis (AD) is a common chronic relapsing disease s t u d y . W e tested the concoction in nine children and 
affecting about 15% of children under the age of 15 years. observed a significant reduction in clinical scores of disease 
As there is no definitive cure for the condition, there has been severity with no apparent adverse effects. The median (range) 
considerable interest in the use of traditional Chinese herbal overall SCORing of Atopic Dermatitis (SCORAD) score before 
medicine (TCHM) as a potential adjunct therapy for AD，’； in and at the end of 3 months was 60.3 (20.0—82.6) and 40.0 
the early 1990s, a decoction was found to be efficacious for (11-4-56-5), respectively (P = 0-008). Significant improve-
treatment of AD in both children^'' and adults^ in the U.K. ments were also noted in the components of the SCORAD 
However, a subsequent randomized control trial (RCT) of the index. The five herbs in the concoction are Flos loniceroe Qinyin-
same decoction in Hong Kong failed to demonstrate any bene- hua), Herba menthae (Bohe), Cortex moutan (Danpi), Rhizoma atractylodis 
ficial effects.9 Recently, a twice-daily concoction containing (Cangzhu) and Cortex phellodendri (Huangbai), and this formulation 
five herbal extracts has been found to be beneficial in an open is based on a widely used ancestral Chinese concoction. We 
© 2007 The Authors 
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demonstrated that there w a s n o cort icosteroid (CS) or CS- packaged and labelled by the Chinese Medic ine Industry 
related c o m p o u n d in this f o r m u l a t i o n . " This RCT a imed to D e v e l o p m e n t Centre, the H o n g Kong Institute o f Vocational 
determine the eff icacy and tolerability o f the TCHM c o n c o c - Education, and fulfi l led the G o o d Manufacturing Practice 
t ion in chi ldren w i t h AD. standard. The c o m p o s i t i o n o f each herb in the formulat ion 
w a s standardized prior to synthesis. The formula consisted o f 
Methods lonicerae (Jinyinhua) 2 g, Herba menthae (Bohe) 1 g, Cortex moutan 
(Danpi) 2 g, Rhizoma atractylodis (Cangzhu) 2 g and Cortex phellodendri 
Participants (Huongbai) 2 g (total 9 g o f raw herbs) . The dosage calculation 
w a s based o n the standard prescription for this concoc t ion in 
The diagnosis o f AD w a s based o n the criteria def ined by TCHM practice for children (7 years o f age or above) and 
Hanif in and Rajka. ‘ ^ Patients aged 5 - 2 1 years w i t h moderate - t e e n a g e r s . T h e dose w a s formulated into standard-weight 
to-severe AD (def ined as an objective SCORAD score > 1 5 ) ” capsules according to established procedures under the super-
m a n a g e d at the paediatric dermato logy outpatient o f a univer- v i s ion o f the Clinical Trials Section o f our ICM. The TCHM 
sity teaching hospital w e r e invited to participate. The SCORAD capsules w e r e tested by our ICM for the presence o f heavy 
is a validated scoring system w h i c h involves assessment o f metals , microbial products and residual pesticides and were 
objective parameters [area (A) and intensity (B) s igns] and f o u n d to be safe. The p lacebo capsules contained three inert 
subjective s y m p t o m s [pruritus and s leep loss (C)] . Patients materials, inc luding capsule shell, corn starch (pharmaceutical 
w e r e exc luded f r o m the study if they suffered from other grade) and caramel ( f o o d grade). Because the preparation was 
inf lammatory dermatoses such as psoriasis, seborrhoeic der- in capsule form, it w a s not necessary to add taste or smell, 
mantis , ichthyosis or overt asthmatic s y m p t o m s o f c o u g h , A series o f assessments w a s i m p l e m e n t e d to assess the qual-
w h e e z e , shortness o f breath or exerc ise - induced bronchospasm ity and validity o f the placebo. Sensory evaluation w i t h refer-
in the preceding 4 w e e k s before recruitment. Furthermore, ence to the techniques used in f o o d science w a s performed, 
patients w e r e not to have received systemic CS, i m m u n o m o d - Panel m e m b e r s w e r e selected for the individual tests w h i c h 
ulating drugs or other preparations o f TCHM 4 w e e k s before inc luded consistency o f packaging and labell ing, consistency 
entering the study. The Clinical Research Ethics Commit tee o f capsule form, and overall di f ference test. The m e m b e r s 
o f the Chinese University o f H o n g Kong approved the study. w e r e randomly divided into t w o groups, TCHM group and 
All parents and patients > 1 5 years o f age provided written placebo group. Us ing visual and tactile observation independ-
i n f o r m e d consent before participation in the study. ently, each m e m b e r assessed the overall characteristics o f the 
given sample , and reported accordingly. They could open up 
D . the capsules to have direct vis ion or smell , but tasting was not 
a l lowed. 
W e def ined the primary o u t c o m e s prospectively as the changes The data were col lected and analysed. The results suggested 
in total SCORAD score and Children's Dermato logy Life Quality that the placebo reached the def ined quality, w h i l e maintain-
Index ( C D L Q i y [ ' 6 at the end o f treatment. The data analysis ing a sensory specification consistent w i t h the herbal capsule. 
w a s carried out us ing an intention-to-treat approach. Based o n The placebo was not considered to exert any beneficial or 
our pilot da ta , 10 the m e a n (SD) o f total SCORAD score in our adverse effects o n AD. Each patient was advised to take three 
AD patients was 55 ( ± 2 0 ) . Forty subjects in each o f the TCHM capsules twice daily for 12 weeks.丨丨 The trial medicat ions 
and placebo arms w o u l d be required to achieve an 80% p o w e r w e r e distributed m o n t h l y to the patients by a research assist-
(P = 0 -20) and an a error o f 0 .05 ( two-ta i led) for detecting a ant. As all patients had moderate- to-severe disease, it was not 
25% difference (1 S-point changes) in m e a n total SCORAD medical ly advisable or ethical to discontinue the patients' rou-
scores b e t w e e n the t w o groups. As the anticipated drop-out tine medicat ions during the trial, w h i c h principally included 
rate was estimated to be 5%, w e aimed to recruit 8 4 children emol l ients , bath oils, soap substitutes, topical CS and oral sys-
in this study. The study was a randomized, double-bl ind, temic antihistamine. They were asked to keep an accurate 
placebo-control led trial in design. The Institute of Chinese diary o f the frequency o f use o f the trial medicat ion and their 
Medic ine (ICM) o f the Chinese University of H o n g Kong alio- routine drugs. The amount o f topical CS use was also w e i g h e d 
cated TCHM or placebo treatment by using a computer- and recorded at the 4 - w e e k l y assessments. 
generated randomizat ion code. The investigators were not 
a l lowed to break the code for any patient until the trial was . ^ 
Assessments 
completed. 
Participants were seen at regular intervals at baseline (visit 1), 
and 4 (visit 2 ) , 8 (visit 3) , 12 (visit 4 ) and 16 (visit 5) weeks 
Treatment 广 . r … 」 .乙 l 
after treatment. The seventy or AD was assessed wi th the 
The trial medicat ions were supplied in containers labelled w i t h SCORAD index at each v i s i t ' b y the principal investigator 
the randomization codes. The drugs were allocated to patients (K.L.E.H.) and the quality o f life questionnaire wi th a valid-
in strict numerical sequence. T C H M ' ° • “ and placebo were pro- ated Chinese translation of the CDLQI by a research assist-
vided in matching capsules. The capsules were manufactured, ant.^"^^^ The CDLQI measures h o w m u c h a skin problem has 
(& 2007 The Authors 
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af fec ted the l i fe o f a pat ient over the p r e c e d i n g 7 days. It c o n - ranks test. All c o m p a r i s o n s w e r e m a d e t w o - t a i l e d , and 
tains 10 q u e s t i o n s relat ing to six categor ies : ( i ) s y m p t o m s and P-values < 0 - 0 5 w e r e c o n s i d e r e d to be statistically s igni f icant . 
f e e l i n g s , ( i i ) dai ly act ivit ies , ( i i i ) l e i sure , ( iv) w o r k and 
s c h o o l , (v) persona l re la t ionsh ips , and (v i ) treatment . A n y ReSUltS 
s y m p t o m s o f c o e x i s t i n g al lergic rhini t i s w e r e quant i f i ed by the 
al lergic r h i n k i s score (ARS), w h i c h evaluates the s y m p t o m s o f Demographics 
s n e e z i n g , w a t e r y r h i n o r r h o e a , nasal c o n g e s t i o n , i t ch ing n o s e , 
i t c h i n g e y e s and e y e w a t e r i n g . ' ^ Figure 1 represents the flow chart o f pat ients g o i n g t h r o u g h 
I n f o r m a t i o n o n adverse event s w a s r e c o r d e d at each visit. d i f f erent phases o f the s tudy. W e s c r e e n e d 9 0 participants 
A n y hosp i ta l i za t ion w a s c o n s i d e r e d as a severe adverse event b e t w e e n February 2 0 0 4 and July 2 0 0 5 . Three w e r e e x c l u d e d 
in the treatment p r o t o c o l . All severe adverse events w e r e because their A D had b e c o m e m i l d at e n r o l m e n t (SCORAD 
inves t iga ted to assess w h e t h e r the event s w e r e direct ly related < 1 5 at visit 1) and t w o r e f u s e d to participate because o f c o n -
to the drugs or u n d e r l y i n g c o n d i t i o n . B l o o d s a m p l e s for c o m - cerns about TCHM use . In total, 8 5 pat ients ( 4 2 TCHM and 
p le te b l o o d counts ; e o s i n o p h i l counts ; total IgE levels; l iver 4 3 p l a c e b o ) part ic ipated in the trial. The cl inical characteristics 
and renal f u n c t i o n w e r e o b t a i n e d b e f o r e treatment (visit 1 ) , o f pat ients b e t w e e n the TCHM and p l a c e b o g r o u p s w e r e s i m i -
and at the e n d o f the 1 2 - w e e k c o u r s e (visit 4 ) . C o u n t i n g and lar (Table 1) . There w a s n o s igni f icant d i f f e r e n c e in SCORAD 
w e i g h i n g o f u n u s e d trial m e d i c a t i o n s and pr imary m e d i c a t i o n s scores , ARS, IgE p e r c e n t a g e and e o s i n o p h i l c o u n t s b e t w e e n 
( topica l CS and a n t i h i s t a m i n e ) w e r e p e r f o r m e d by the research g r o u p s b e f o r e the trial. The pat ients had b e e n treated w i t h 
assistant and s u c h i n f o r m a t i o n w a s b l i n d e d f r o m the principal c o m b i n a t i o n s o f e m o l l i e n t s , m o d e r a t e l y p o t e n t topical cort ico-
invest igator . s teroids ( 9 3 % o f pat ients w e r e o n 0 .1% m o m e t a s o n e furoate 
and 70/0 rece ived n o regular CS) or oral ant ih i s tamines ( 8 6 % 
. . . . . o f pat ients w e r e o n c h l o r p h e n a m i n e and 14% rece ived n o 
Statistical analysis , , 、。 r 。 ^ 」 
regular a n t i h i s t a m i n e ) . S e v e n t y - o n e or 8 5 AD patients had 
Statistical analysis o f the cl inical and laboratory data w a s per- c o e x i s t i n g al lergic rhinit is . 
f o r m e d i n d e p e n d e n t l y by a statistician at the ICM n o t i n v o l v e d 
in the cl inical trial, u s i n g SPSS (vers ion 14 .0 ’ Chicago , IL, _ ^ . , .. 一 6 V 6 Compliance with trial medication • 
U.S.A. ) . C o m p a r i s o n s o f c o n t i n u o u s variables b e t w e e n the • 
TCHM and p l a c e b o g r o u p s w e r e p e r f o r m e d u s i n g Student's C o m p l i a n c e w i t h the trial m e d i c a t i o n s w a s g o o d : 9 3 % o f the • 
t-test or analysis o f covar iance (ANCOVA) w i t h base l ine as a prescr ibed capsules w e r e taken in the TCHM g r o u p and 9 2 % • 
covariate. C o m p a r i s o n s o f categorical data b e t w e e n g r o u p s in the p l a c e b o g r o u p . Four participants ( t w o in the TCHM • 
w e r e assessed by the y^ test or M a n n - W h i t n e y U-test. Changes and t w o in the p l a c e b o g r o u p ) w e r e n o n c o m p l i a n t , de f ined as • 
f r o m base l ine in the s y m p t o m scores w e r e assessed w i t h i n u s i n g < 7 5 % o f prescr ibed m e d i c a t i o n , and t w o patients in 
treatment g r o u p s by paired t-test or W i l c o x o n s i g n e d the p l a c e b o g r o u p w i t h d r e w f r o m the trial. A t eenage girl 
I Assessed for eligibility (n = 90) | 
Excluded (n = 5) 
Not meeting inclusion criteria (n = 3, 
I Enrolment | • SCORAD < 15) 
I Refused to participate (n = 2, 
Randomized concerned about TCHM use) 
Allocated to TCHM (n = 42) V' 1 Allocated to intervention (n = 43) 
Received allocated intervention (n = 42) 1 AHOCa ion J Received allocated intervention (n = 43) 
Lost to follow-up (n = 0) Lost to follow-up (n = 0) 
Non-compliant but intention- [ Follow-up ) Non-compliant but intention-
to-treat analysis (n = 2) to-treat analysis (n=2) 
Analysed {n = 42) [~Analvsis 1 Analysed (n = 43) 
Fig 1. Patient flow chart. TCHM, traditional 
Excluded from analysis (n = 0) ‘ ^ Excluded from analysis (n = 0) 
Chinese herbal medicine. 
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Table 1 Subject baseline characteristics 
120-1 l - ^ T C M 
•~Placebo 
TCHM Placebo P-value 
Subjects enrolled 42 43 HO" • •-
Age (years) 11.7 ± 3 . 8 11.7 ± 3.5 0.932 
Sex 0.920 > 二 - A i 
Female 19 20 O " x X T / \ 
Male 23 23 Q T / “ 
SCORAD score 58.3 ± 15.6 56-9 ± 18.1 0 7 0 3 ^ 9 0 -
CDLQI 1 1 ‘ 0 ± 5 - 1 10-2 ± 5-1 0-504 ^ ” 
Body weight (kg) 38.8 ± 14.8 40-4 ± 17.1 0.649 c 丄 ^ ^ 
Body height (cm) 142.6 ± 18.6 143.4 ± 19.6 0.861 | 8 � - . . 
^ 
TCHM. traditional Chinese herbal medicine; SCORAD, SCORing ^ � 
of Atopic Dermatitis; CDLQI, Children's Dermatology Quality of 丄 
Life. I 6.0 H 1 1 i 1 1 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 
Visit 
refused to take the trial medicat ion and instead used tacroli- L — — 
m u s ointment prescribed by another practitioner and another , ^ ^ , i. . , � � � r ‘ r Fig 3. Improvement irom baseline in mean (standard error) 
boy developed abdominal discomfort after taking the medica- children's Dermatology Quality of Life (CDLQI) scores (P = 0.008 
tion. However , both patients agreed to return monthly for ^nd 0.059 for visits 4 and 5, respectively). TCM, traditional Chinese 
fo l low-up assessment. herbal medicine. 
Eff icacy compared wi th baseline, P = 0-008 compared with placebo) 
but no improvement for placebo-treated patients (Fig. 3). 
Comparing with in group, the mean total SCORAD fell from The duration o f primary CS use in the TCHM group was 
58.3 to 49 .7 (P = 0 -003) in the TCHM group and 56 .9"46 .9 significantly reduced by an average o f 4 days per month corn-
CP = 0 . 0 0 1 ) in the placebo group (Fig. 2) . but there was n o pared with baseline (P = 0 .042 ) ’ whereas topical CS use was 
significant inter-group difference in the scores between the reduced by 1 day in the placebo group (P = 0-289) (Table 2). 
TCHM and placebo groups at the end of treatment (visit 4) . o f 79 patients using 1% mometasone furoate as the primary 
Similarly, there was no significant difference between TCHM topical CS, the amount of use was also significantly reduced in 
and placebo groups in the component SCORAD scores. In con- [he TCHM group (Table 2). However , there was n o significant 
trast, there was more than 30% improvement in CDLQI score difference in the amount of antihistamine use between the 
in the TCHM group at the end of treatment (P = 0-001 t w o groups. 
The addition o f a more potent topical CS and antihistamine 
occurred during fo l low-ups in two and seven patients in the 
65-1 • TCHM, and three and five patients in the placebo group, 
—•— Placebo respectively. Antistaphylococcal antibiotics, including cloxacillin 
and erythromycin were prescribed to 1 6 patients of the TCHM 
60 group and 1 7 patients in the placebo group. 
？i \ Thirty-five participants in the TCHM and 36 in the placebo 
： S 55- f s \ had symptoms of allergic rhinitis. There was no significant 
< \ \ T difference in the total allergic rhinitis scores and the majority 
P \ \ J of allergic rhinitis symptoms between these patients. Only 
^ 50- ^ - 4 — - i the symptom of sneezing improved significantly in the 
i TCHM group from a mean (SD) of 1.5 (0 .9) to 1.1 (1.1) 
^ 丄 (P = 0 -003) . 
45- i r 
Tolerability 
40 n 1 1 1 1 1 
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 The TCHM was generally well tolerated. Table 3 lists the 
I Visit adverse events reported by patients. There was no significant 
‘ ' • difference in the frequency of adverse events reported by par-
Fig 2. Improvement from baseline in mean (standard error) SCORing ticipants. Analysis of b iochemica l data also revealed n o signifi-
of Atopic Dermatitis (SCORAD). TCM, traditional Chinese herbal cant change in the IgE levels, haematological (complete blood 
medicine. counts, eosinophil counts) and biochemical (electrolytes, renal 
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Table 2 Primary topical corticosteroid usage 
Corticosteroid use (days) Using primarily topical mometasone furoate (g) 
TCHM (n = 41) Placebo (n = 43) TCHM (n = 39) Placebo (n = 40) 
Visit mean (SD) mean (SD) P-value' mean (SD) mean (SD) P-value^ 
Month 1 19 (11) 17 (12) 0.631 11.03 (12.91) 11.98 (15-14) 0 7 6 5 
Month 2 16 (12) 16 (12) 0.904 8-17 (10-42) 8.94 (10.95) 0.774 
Month 3 16 (12) 16 (12) 0.964 8.51 (9.68) 11-21 (14-97) 0-288 
Month 4 15 (12) 16 (13) 0 7 0 5 7 . 3 2 ( 8 . 1 3 ) 11-57 (14-81) 0.024 
P-value^ 0-042 0.289 0.020 0-678 
^Compared with placebo; ^compared with baseline. TCHM, traditional Chinese herbal medicine. The placebo-group subjects used more 
mometasone furoate than did the TCHM group at month 4 (P = 0.024). In the TCHM group the use of mometasone furoate was significantly 
decreased after 4 months of treatment (P = 0-020) w h e n compared with baseline. 
Table 3 Adverse events reported by more than one participant a n d sub jec t ive s y m p t o m s in b o t h t he T C H M a n d p l a c e b o 
(number of participants reporting) g r o u p s w e r e dec reased d u r i n g the s t udy p e r i o d , bu t n o statis-
tical d i f f e r e n c e w a s o b s e r v e d b e t w e e n t he t w o g r o u p s . H o w -
TCHM Placebo ever , the d u r a t i o n a n d q u a n t i t y o f p r i m a r y CS ( m o m e t a s o n e 
Events (n 二 42) (n ^ 43) P-value f u r o a t e ) use in the T C H M g r o u p w e r e s igni f icant ly r e d u c e d 
Upper respiratory tract 8 9 0.828 c o m p a r e d w i t h t h o s e of the p l a c e b o g r o u p a n d at basel ine . 
infection T h e resul t sugges t s that t he T C H M m a y possess CS-spar ing 
Diarrhoea 3 0 0 074 ef fec ts 
Abdominal pain 4 2 0 381 As t he t h e r a p e u t i c eff icacy of m a n y T C H M p r e p a r a t i o n s has 
Episodes of asthma 6 3 0-274 1 K) 21 
New rash 8 5 0.342 b e e n p r e v i o u s l y a t t r i bu t ed to CS-con ta in ing i ng red i en t s 
Miscellaneous^ 6 4 0.476 a n d t he r e has b e e n m u c h fear a n d m i s u n d e r s t a n d i n g c o n c e r n - • 
Hospitalization 2 2 0.981 i n g CS use a m o n g p a r e n t s , " it w o u l d be ra t ional to d e v e l o p • 
GP visits'' 21 11 0-020 safe, n o n s t e r o i d - c o n t a i n i n g i m m u n o m o d u l a t i n g f o r m u l a t i o n s • 
Antibiotic for > 3 days 12 6 0-099 that are e f f i cac ious in the t r e a t m e n t of AD. Us ing th in - l aye r • 
Topical/oral corticosteroid 5 1 0.085 c h r o m a t o g r a p h y , i n f r a r e d s p e c t r o p h o t o m e t r y a n d l iqu id c h r o - I 
Away f rom Hong Kong 7 4 0.312 , r , ^ c /-c 1 . j • 
‘ b b m a t o g r a p h y - m a s s s p e c t r o m e t r y , w e r o u n d n o CS or CS-reJated 
^For TCHM: pustules, dizziness, bronchitis, r ingworm, pom- p r e c u r s o r s in th is f o r m u l a t i o n . " W e also f o u n d that the re w a s 
pholyx, pneumonia; for placebo: pustules, appendiectomy, n o c h a n g e in the s e r u m levels of AD-associa led c h e m o k i n e s 
menstrual disturbance, haematuria. bGP visits may include invo lved in the T - h e l p e r 2 p a t h w a y in A D . ' ° A l t h o u g h the 
prescription of various antihistamines, topical steroids, oral exact m e c h a n i s m of ac t ion of o u r T C H M f o r m u l a t i o n is n o t 
antibiotics. Two patients in the TCHM and one patient in the k n o w n , a p r e l i m i n a r y in vitro s t udy d e m o n s t r a t e d that the re 
placebo group had been prescribed a brief course of oral cor- , , � r • i_ i 1 i j ^ t> r r w a s a o s e - a e p e n d e n i supp re s s ion or pe r i phe ra l b lood m o n o -
ticosteroid (3 -5 days) for atopic dermatitis exacerbation by pri-
, Tv^ TTK, J 丄 nuc lea r cell p ro l i f e r a t i on a n d r e d u c t i o n of s e r u m subs tance-P vate practitioners. Six participants m the TCHM group and three ^ 
in the placebo had asthma attacks treated with bronchodilators levels ( u n p u b l i s h e d obse rva t ions ) . H o w e v e r , f u r t h e r invest i -
(none received oral CS). TCHM, traditional Chinese herbal ga t ions are r e q u i r e d to c o n f i r m such effects and to de l inea te 
medicine. the exact b io logica l m e c h a n i s m s of the concoc t i on . 
Adverse effects w e r e relat ively u n c o m m o n and w e r e g e n e r -
ally m i l d and se l f - l imi t ing (Table 3) . T h e r e was n o d i f f e r ence 
a n d liver f u n c t i o n s ) p a r a m e t e r s m o n i t o r e d . All pa t i en t s h a d in haema to log i ca l and b iochemica l p a r a m e t e r s at basel ine a n d 
n o r m a l renal and liver f u n c t i o n f o l l o w i n g TCHM t r ea tmen t . f o l l o w i n g TCHM use. Despi te the c o n c e r n s abou t po ten t ia l 
N o pa t i en t c o m p l a i n e d that the capsule w a s unpa la tab le . hepa t i c and renal toxici ty w i t h TCHM u s e , ^ ' t h e r e w a s 
n o d e r a n g e m e n t of liver and renal f u n c t i o n w i t h i n the 
. 3 m o n t h s of assessment . Unl ike m a n y bi t te r - tas t ing TCHM 
Discussion 
r e m e d i e s , ch i ld ren in this s tudy f o u n d the capsule easy to 
This is the first RCT to d e m o n s t r a t e that TCHM p r e p a r a t i o n s w a l l o w and palatable . 
can i m p r o v e the qual i ty of life in ch i ld ren su f f e r ing m o d e r a t e - The p h e n o m e n o n of p l acebo effects c o m m o n l y f o u n d in 
to-severe AD. W e recen t ly f o u n d in a separate s tudy that the m a n y TCHM s tudies was also p r o m i n e n t in this s tudy. The 
qual i ty of l ife a n d clinical scor ing for AD w e r e t w o d i f f e r en t fact that a pa t ien t w a s involved in the trial and r ev i ewed 
clinical ent i t ies and s h o u l d be evaluated separately. ‘ ^ Total and regular ly cou ld resul t in subjec t ive i m p r o v e m e n t in disease 
objec t ive SCORAD scores , ex ten t of disease, in iens i iy of les ions severity. It has b e e n specula ted that bet ter compl i ance and 
© 2007 The Authors 
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m o t i v a t i o n , w i t h reduc t ion in p s y c h o l o g i c a l stress result ing topical CS use in chi ldren w i t h modera te - to - severe disease, 
f r o m m o r e d i l igent m e d i c a l at tent ion during the trial m a y There is n o d e r a n g e m e n t in haemato log ica l or b iochemica l 
account for the i m p r o v e m e n t in the p l a c e b o group.^ N e v e r - parameters after treatment. This formula t ion can probably be 
theless , our results sugges t that the i m p r o v e m e n t in the pla- u s e d as an adjunct treatment for chi ldren w i t h refractory AD. 
c e b o g r o u p is at the e x p e n s e o f a h igher c o n s u m p t i o n o f 
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IVster Group 2 Eczema IYomi Diagnosis to Treatment 
treated wi th t a c r o l i m u s for 14 d a y s a n d p a l i e n l s g r o u p w a s a l s o s i g n i f i c a n t l y d i f fer - T r e a t m e n t w i th C y A s ign i f i cant ly i n f l u e n c e s 
� u u l l y o b s e r v e d for a 7 d a y s p e r i o d o f ent . ( P c O . O O l ) T h e corre la t i on b e t w e e n the p D C / m D C ratio. Increase o f pDC； in 
f o l l o w - u p . T h e g r o u p B, i n s t e a d , w a s t rea ted F D I wi th sever i iy o f A D w a s s i gn i f i can l . per iphera l b l o o d is a c c o m p a n i e d by the 
w i t h p l a c e b o (vehic le ) . I 'our m a j o r s y m p - (r = 0 . 8 l , P c O . O O ! ) c l in ical efTect a n d m i g h t mirror the d y n a m i c 
t o m s ( e r y i h e m a . o o z i n g , s c a l i n g a n d i i d l i n g ) Conc lus ion: A D is a c o m m o n skin d i s e a s e c h a n g e s o f p D C b e t w e e n sk in a n d per iph-
\vere c o n s i d e r e d as o u t c o m e s d u r i n g the that p l a c e s a large b u r d e n o n p a t i e n t s , their cral b l o o d co inpartrnent , 
dilTerenl p h a s e s o f the s l u d y . fami l i e s , and soc i e ty . W e c a n detec t the 
Results : In g r o u p A . d u r i n g the t r e a t m e n t sever i ty o f A D w a s direct ly re lated to the 
per iod wi th l a c r o l i m u s , w a s o b s e r v e d a h i g h i m p a c t oi" A D o n their parent ' s lives. It 9 0 5 
s ign i f i cant i m p r o v e m e n t in all the f o u r s h o u l d b e s u g g e s t e d thai e d u c a t i o n a n d In vitro i m m u n o m o d u l a t o r y e f f e c t s of a 
c o n s i d e r e d s y m p t o m s . O n the o t h e r h a n d . p s y c h o s o c i a l s u p p o r t for Uirgel ing p a r e n t s n e w l y c o n c o c t e d P e n t a h e r b s f o r m u l a f o r 
n o i m p r o v e m e n t in s y m p t o m s w a s o b s e r v e d a n d careg ivers that m a y d e c r e a s e fumi ly a n d a l l e r g i c i n f l a m m a t i o n 
in the p l a c c b o - t r e a t e d g r o u p B. L o c a l p e r s o n a l b u r d e n a n d i m p r o v e the l o n g - t e r m 丁 Leung\ k Wong,, c Wongl m Lam\ k F » n g � � c Laml 
adverse e v e n t s in I h e l a c r o l i m u s - t r e a t e d phys i ca l o u t c o m e s . p leung^ k Hon^ 
group, such as burning/i tching at the appli- 'Department of Paediatrics, The Chinese University of 
cation sue, were transient and well tolerated. Hong Kong Hong Kong 'Department of Chemical 
Pathology, The Chinese University of Hong Kong, Hong 
N o p a t i e n t s w i t h d r e w b e c a u s e o f b u r n i n g / — Kong, ^institute of Chinese Medicine. The Chinese 
l t d 迎 g P l a s m a c y t o i d a n d m y e l o i d d e n d r i t i c c e l l s Kong, Hon« Kong 
Conclusions: In our study, tacrol imus oint- chi ldren w i t h a top ic dermat i t i s 
m e n t 0 . 1 % a p p e a r e d l o be b o t h e f f e c t i v e B a c k g r o u n d : A t o p i c derm a l it is ( A D ) is a 
and sale in the t reatment o f n icke l sulphate- J Kayserova', R^Horvath^ t Kaima?, a Poiouckova^ m ch ron ic i n f l ammato r y d isorder w i t h skin 
i n d u c e d s t e r o i d r e s i s t a n t A C D . Faculty of Medicine, Charles University Prague, b e i n g m f j l t n U e d b y v a r i o u s i n l l a m m a l o r y 
University Hospital Motol, Department of Immunology, Icukocvtes and clelectivc immunC responses 
Prague, Czech Republic, -University Hospital Motol, 2nd Iq m i c r o b i a l p a l h o g e n s SUCh as S t a p l i y l o -
Faciilty of Medicine, Charles Universitv Praque, . 八 • 」 . 
� ‘ ‘‘ COCCI. O u r g r o u p recent v reported in a 
gQ3 Depaitment OT Immunology, Prague, Czech Republic, to t ' 
Fami l i m act co r r e l a tes w i t h s e v e r i t of "University Hospital Motoi, 2nd Faculty of Medicine, randomised, double-bl ind and placebo-con-
am i y impac co r re ^ s e v e n y o charies university Prague, Department of Paediatric t ro l led t r ia l that the PcntaMcrbs formula 
a top ic de rma t i t i s m ch i l d r en HaematCogy and Oncology, Prague Czech Republic, ^pHP), compns .n . Flos hmcerae. Hcrho 
•Department of Paediatric Surgery, 2nd raculty of ‘ 
H M07.3ffan, Z Pourpak, A Agh細ohammadi, M Medicine, University Hospital Motol, Charles University nienthcie. Cortex niouian. Rhizonw. airacty-
丨，M Gharagozloo M Mom Prague, Prague, Czech Republic lodis and CorteX phclhckncM waS dlicaCiCULS 
Immunology, Asthma & Allergy research Institute, ^ 
Children Medical Center Hospital, Tehran, Islamic 川 t reat ing ch i ld ren w i t h moderatc-to-severe 
Republic of Iran B a c k g r o u n d : Severe Ibrms ot" a t o p i c d e r m a - A D . T h i s s t u d y inves t igated w h e t h e r 
l it is in ch i ldren represent o n e o f the m o s t P H F p o s s e s s e s in viiro irnrnunoir iodulatory 
Background: A t o p i c D e r m a t i t i s ( A D ) is a s er ious al lergic cl inical ent i t ies . S o m e o f act iv i t ies . 
c o m m o n skin d i s o r d e r that a f f e c t s 12'.. l5‘)/o these pa t i en t s require i m m u n o s u p p r e s s i v e M e t h o d s : P H F c a p s u l e s u n d e r w e n t hot -
o f a l l ch i ldren in early c h i l d h o o d . P r e v a l e n c e t r e a t m e n t . D e n d r i t i c cel ls ( D C ) are p r o l e s - water e x t r a c t i o n m e t h o d . Mi iman peripheral 
o f A D is reported to h a v e increased o v e r the s iona l ant igen present ing cel ls crucial for the b l o o d m o n o n u c l e a r cel ls ( P B M C ) were 
three decades . T h e i m p a c t is n o t l imi ted t o in i t ia t ion o f an i m m u n e react ion . T w o major i so la ted fi .om fresh b i i f fy c o a t from b l o o d 
the ch i ld but e x t e n d s to the ent ire fami ly . f o r m s o � D C with the re l evance to the d o n o r s . P H F e x l r a c l w a s tl ien cul tured with 
A l t h o u g h A D is a c h r o n i c sk in d i s e a s e that p a t h o g e n e s i s o f A D . m y e l o i d ( n i D C ) , and s t a p h y l o c o c c a l e n t e r o t o x i n B (SEB; 100 ng, 
can h a v e a m a j o r i m p a c t o n p a r e n t ' s l i fe , its p l a s m a c y t o i d D C s ( p D C ) , m i g h t be dis t in- mL)-ac l ivat . ed P B M C al 37 C and C O 
burden h a s not been well charac ter i zed . T h e g u i s h e d in the peripheral b l o o d . Plcismacy- and the m i t o g e n i c act iv i t ies o f P B M C were 
a i m o f I his s tudy w a s the e v a l u a t i o n o � to id D C s preferent ia l ly i n d u c i n g T h 2 m e a s u r e d i8 h inter by IriUated t h y m i d i n e 
parents w h o had chi idren with A D . i m m u n e r e s p o n s e are o f part icular interest i n c o r p o r a t i o n . D e x a i n e t h a s o n c (！()(J n M ) 
Method: Parents o f 4 0 i n f a n t s a n d ch i ldren in A D . w a s a d d e d lo SF,B-;iclivut,e(i P B M C as 
wi ih A D (based o n H a n i f i n & R a j c a ) less M e t h o d s : m D C a n d p D C were m e a s u r e d by p o s i t i v e contro l s . T h e c y t o t o x i c i t y effecT o f 
than 4 years a n d 40 in Tan is or ch i ldren i l o w c y t o m e t r y as l ineage negat ive , P H F w a s assessed by trypan blue exc lus ion , 
w i t h o u t a n y c h r o n i c d i s ease p a r t i c i p a t e d in C D 4 5 + C l ) l Ic + CI)！23!o, and l ineage � i e - T h e c o n c e n t r a t i o n s o f inf lamirmtory rnedia-
this s tudy ami a p h y s i c i a n HI led F a m i l y g a l i v e , C D 4 5 f C D I l c - C D 1 2 3 h i , respec- lors i n c l u d i n g bra in-der ived n e u r o t r o p h i c 
D e r m a t i t i s Index ( P D I ) q u e s t i o n n a i r e for t ivcly. Six pat i ents with severe A D were factor ( B D N F ) , inter leukin-8 , t h y m u s and 
them via face to face interv iew. A l s o there inc luded in I he study： t w o were treated wi th a c t i v a t i o n - r e g u l a t e d c h e m o k i n e , epithel ial 
w a s a q u e s t i o n a b o u t sever i ty o f A D w h i c h C y c l o s p o r i n A ( C y A ) in the critical per iod neutrophi l ac t iva t ing pept ide , i i i terferon-v 
scored separate ly f r o m n o n e to e x t r e m e l y o f the a g g r a v a t i o n o f A D cl inical c o n d i t i o n . i n d u c i b l e prote in 10, and t u m o u r necros is 
sever A D . (0 4 ) T h e iriean total s core o � Peripheral b l o o d From 10 hea l thy chi ldren, f a c t o r - a in cul ture s u p e r n a t a n t s were iriea-
each q u e s t i o n n a i r e in c a s e s a n d c o n t r o l s o b t a i n e d wi th i n f o r m e d c o n s e n t , served as sured by E L I S A . 
were c o m p a r e d by /-test a n d corre la te c o n t r o l s . Results: T h e o p t i m a l c o n c e n t r a t i o n s o f 
m e t h o d wi th severi ty o f A D . Results: T o t a l n u m b e r o f D C , m D C , p D C P H F f o r use in in vitro e x p e r i m e n t s were 1, 
Results: T h e m e a n d i a g n o s e a g e o f A D w a s a n d p D C / r n D C rat ion did 1.101： dilTer be- iO [ig/rnL a n d 100 n g / m L . in which all 
1.57 土 .53 years (4 m o n t h s to 4 years ) a n d i w e e n A D a n d c o n t r o l s ( F > 0 . 9 9 9 ) . T h e r a p y P B M C cul tures retain > 8 0 % cell viabil i ly , 
the m e a n 士 57 ) s core for F D I w a s with C y A c a u s e d the increase o f ' p D C / m D C O u r results d e m o n s t r a t e d thai the P H F 
13.17. 土 4 . 49 ( R a n g e ^ 3 - 1 9 ) . F o r the c o n - rat io in b o t h treated pat ients f rom 0 . 0 6 to extract: (1) exh ib i ted d o s e - d e p e n d e n t l y (at 
irol g r o u p , the m e a n age ( )1�the ir ch i ldren 0 .45 a n d lYom 0 .57 to 0 .93 , respect ive ly . 1 — lOOOng/mL) s igni l l canl inhibit ion o f 
w a s 2 .68 土 ！.32 years ( R a n g e : 0.5—4) a n d Total n u m b e r o f D C increased in o n e and P B M C pro l i f era t ion u p o n S E B s t imula t ion , 
the m e a n 土 SD s core Cor the F D I w a s decreased in the s e c o n d of. Ihese boys . (2) p o s s e s s e d d o s e - d e p e n d e n t c y t o t o x i c e l -
1.05 土 1.19 ( R a n g e .....  0 - 5 ) . T h e d i f f e r e n c e Conclus ion: D C and their s i i b p o p u l a t i o n s fects o n ac t ivated P B M C . and (?) se lect ively 
b e t w e e n the m e a n o � F D I in c o n t r o l and d o not dilTer b e t w e e n A D and con lro l s . l o w e r e d B D N F p r o d u c t i o n f rom S E B - a c l i -
�.. .2007 The Authors 
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vated P B M C at 0.1 mg/n iL. This Tradit ional ^ poinl up that only pepperminl but not 
Chinese Herbal Medic ine preparation did spearmint was positive at patch test, A 
no I e.xerl any significant inHuence on I he A b s t r a c t w i t h d r a w n . possible explanation lor this finding 
other five cytokines or chernokines that we could be the lower content of menthol in 
have studied. spearmint. 
Conclusions: The cxtract obta ined from our — 
908 
newly concocted P H F is able to inhibit the ^ ^ ^ . , 
. . . , Occupational contact urticaria due to 
prolileralive activities and selectively also , ,„„ , . , — — 一 ~ ~ ~ — “ 
\ ” � i . � , , p e n n y r o y a l {Mentha pulegium) gnq 
B D N F product ion in ShB-s t imula ted 腳 
P B M C (Voni blood donors. These in vitro t^ Perez Caideron\ m Gonzaio Garijo^ B Bartoiome- The fragrance compound geranioi forms 
m i m u n o m o d u h u o r y properties m a v account f j - i a ^ a Lamiiia-Ye^a\ i Moreno-Gaston^ J^onta^ a l l e r g e n s o n air e x p o s u r e . 
r . AT^ ^Allergology, Infanta Cristina University Hospital, Ident i f icat ion and quant if icat ion of 
for the Chnica! benefUs m A D paUenls. Badajoz Spain, ^Laboratory B,a,.Anstegui, 1 . D. o x i d a t i o n p r o d u c t s and e f f ec t on skin 
Bilbao, Spain 
sensitisation 
9 0 6 Background: Mentha pulegium or penny- ^agvair, s Svensson'^ A Borje', A Kariberg ' 
Montelukast treatment in children with royal, is a member of the Lamiaceae family ：；广Un,versi^, Dermatochemistry and Sk,n 
: Allergy, Goteborg, Sweden, Sahlgrenska University 
moderate ly severe atopic dermat i t i s (formerly Lahiateae)； which also includes Hospital, Occupational and Environmental Medicine, 
r … „ „ , Other plants of the same genus as spearmint Goteborg, Sweden 
E Mohammad , A 已ener」 ^ “ ‘ 
'Hamad Med Corp. Peds, Doha. Qatar, ^ Hamad Medical and peppermint, and of different genera as 
Corp., Department of Medical Statistics and thyme, rosemary, basil, and oregano. Fragrances are common causes o「eontaci: 
Epidemiology, Doha, Qatar C a s e repor t : A 25-year-olci w o m a n w o r k i n g allei-gy. G e r a n i o i ( t rans-3 . 7-d imethyl -2 . 6-
as a cook in a restaurant was referred for ocladiene-1 -ol) is an importanl fragrance 
Background: Moderate ly severe comprises several episodes of pruriginous wheal-and- terpcne. It is considered a weak contact 
nearly one-iirth of children with atopic nare eruptions on her hands and forearms allergen and is used ibr screening o � 
dermatitis. within 5—10 m m o!" stripping the leaves of f fragrance allergy a m o n g consecutive dcrma-
Objective: 1 o determine clinical and labora- (he pennyroyal plant, disappearing in 10 litis patients. Analogous ly to olher c o m m o n 
tory el lects o � m o n t e l u k a s t in inoderateiy i 5 m i n when the contact had ceased. The fragrance tcrpenes studied, such as l imonene 
severe atopic dermatitis. patient has been working ai the same place and l inaiool , geranioi has the potential lo 
Methods: Randomized , double blind, place- foj. 5 years. Her symptoms began 2 years autoxidize on air exposure and Ibrrn highly 
bo-conlro!Ied trial with a crossover, wash- ago and were gradually worsening. After the allergenic compounds , The aim of the 
out period from M a y 2002 to February last reaction, she has tolerated the ingestion present study was to investigate the auto-
2006. I he study involved 25 patients, 2 - 1 6 o f recipes including oregano and thyme, and x idai ion of geranioi in room lemperaiure 
years old with dermatitis. Patients received pennyroyal tea. � � ‘ and to determine the sensitizing potency of 
oral montelukast (nine patients. G r o u p B) Methods and results: Skin prick tests with geranioi itself, air-exposed geranioi and its 
or placebo (16 patients. G r o u p A). Patients inhalant and food allergens were negative. oxidat ion products. The oxidation products 
included if > 10% of skin was involved and Total IgE was 45 UI /mL. The patient had were separated by flash chronuitography 
laileci to respond lo 2 weeks convent ional not detectable specific IgE to pennyroyal, and identified using synthesized reference 
treatment. Itching, sleep disturbance, ire- spearmint, peppermint, basil, rosemary, and compounds . Quantif ication of geranioi and 
quency of use of oral anl ih is lamines and oregano. Prick by prick testing with fresh the oxidat ion products in ihe autoxidation 
topical steroids, severity scores were serially pennyroyal leaves gave negative results. We mixture was performed using H F L C - U V 
assessed. In addition, eosinophi l and serum prepared extracts with fresh pennyroyal arid and G C - F I D . The sensitizing potency ol' 
IgE were serially collected. the other plants mentioned above at 2 0 m g / geranioi itself, air-exposed geranioi and its 
Results: Mos t o � p a t i e n t s were between 6 ^ L for piick tests, and at 0.01 arid ().()5% oxidation products was determined using 
and 10 years. Both groups had comparable for paich tests. Prick tests proved negative. the L L N A in mice. The results obtcuncd 
gender distribution. The patients began with Patch tests with pennyroyal and peppenriint show that geranioi is readily auloxidi /ed a I 
montelukast had quite often bronchial vvere positive at 1 5 m m (pruritus, erythema air exposure and that strong sensitizers are 
asthma (55.6%) and allergic rhinitis and papules, lasting 20 rnin), and negative Formed which can greatly iniluence the 
(33.3%) than the patients began witli with the rest of the extracts (which remained sensitizing efiect of geranioi at handling 
Placebo, but less positive family history of negative al 48 and 96 hj. The use lest. and storage, Geranioi fol lows a different 
atopy. While on m o n t e l u k a s t � t h e r e was a peifornied with pennyroyal fresh leaves oxidation pattern compared to liiuilool and 
reduction of mean score for itching in phase clevelopeci immediate pruritus, erythema, l imonene which autoxiciize forming highly 
2 and group A, for sleep disturbance in and papuies on the forearms and hands, allergenic hydroperoxides as primary oxida-
pliase 2. group A, and group B, for improving in 15 min. The IgE reacUvky o � tion products. From geranioi. primarily the 
antihistamines in phase 1 and group B，lor pennyroyal extract was analysed by imniu- non-aUergenic hydrogen peroxide is fbmied 
exient-of-disease in phase i , phase 2, group noblol t ing with the patient's serum, but IgE- together with the ailergenic aldehydes ger-
A and group B，and for severity score in binding proteins were not identified. Prick anial and neral. in addition, small amounts 
phase 2 and blood eosinophil and IgE in (est and open patch lest with men I hoi 1% of a highly allergenic hydroperoxide are 
phase 2. pet proved negative, but a repeated open formed，analogously to the formation o i � t h e 
Conclusion: Montelukast reduccs itching; application test ( R O A T ) was positive at the major linalooi hydroperoxide. The hydro-
sleep disturbance, disease extent and sever- third day. peroxide ibrnied is believed lo be Die major 
ity. blood eosinophil count and serum IgE. Conclusions: We present a case of occupa- contributor to the allergenic activity of air 
tional contact urticaria from pennyroyal, an exposed geranioi, rogelher with the aide-
event no previously described in the medical hydes geranial and neral. The present study 
literature. The clinical history and the results shows that the sensiti/.ing potency o � t h e 
of Ihe tests carried out suggest the diagnosis fragrance compound geranioi increased by 
of nonimmunolog ic contact urticaria. We air exposure, due to formation of contact 
C 2007 The Authors 
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